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Cancer comprises many specific diseases, and it is currently responsible for millions of 
deaths worldwide.1 This broad disease profile is a great challenge for personalized oncology.2 
Critical for the success of cancer therapy is the exploration of improved methodologies for the 
early detection of localized and disseminated tumor cells in patients, where bio-molecular 
imaging has become an indispensable tool.2-3 Being one of many different imaging techniques, 
optical fluorescence imaging has been translated over the years from the bench to clinical 
research, and it is now on the verge of being able to address some of the pressing challenges in 
molecular oncology.3  
Optical imaging can provide real-time, high spatially and temporally resolved detection 
of small cancer foci or establishment of boundaries between malignant and normal tissue during 
surgery, which is the primary treatment modality for most solid tumors.2,4-5 Furthermore, optical 
signals can provide information on tumor metabolism and biochemistry that helps provide an 
understanding of tumors at the molecular level, so as to gain access to the activity of their 
biological processes that may yield the capability to provide personalized “on the spot” 
treatment.3 Thus, advancing development of new optical fluorescent probes for imaging 
techniques has grown exponentially over the years, as these probes continue to revolutionize the 
ability to visualize complex biological processes in living systems.  
Fluorophores have been used in a wide variety of applications, ranging from medical 
diagnostic applications as chemical sensors and molecular probes, to display devices and dye- 
sensitized solar cells.6-7 Although extensive research work has been done on the development of 
molecular imaging probes, their use in the clinical setting is still in its infancy. The number of 
profluorophores that can have their fluorescence signature selectively and quickly altered by the 
presence of a disease-associated enzyme is extremely small, as is the type of disease-associated 
enzyme used for probe activation.8  
The goal of this thesis is development of a group of small molecule-based profluorogenic 
probes and demonstration of their activity with a cancer-associated enzyme, NAD(P)H:quinone 
oxidoreductase-1 (NQO1). This goal was attained by completing several different objectives that 





1.1 Research goals and aims 
An ever-growing area in bio-molecular imaging involves the design of reaction-based, 
small-molecule fluorescent probes that have the capability of real-time interrogation of cellular 
events with a high degree of specificity and selectivity in their native biological environment. 
Such reaction-based fluorescent “smart-probes”9 are especially useful for cancer-related 
cytoreductive surgical interventions to provide real-time information on the tumor cell 
microenvironment. To date, only a small number of clinically approved fluorescent reporters are 
available.10 However, for the most part, these clinically available reporters do not possess the 
ability to have their fluorescent signature selectively revealed in response to a cancer-linked 
trigger or biomarker, leading to poor delineation between normal and diseased cells. In this 
regard, fluorescent probes whose fluorescent reporter signal is turned on by enzyme action hold 
great potential in the identification, enumeration, and study of living cancer cells.4,11-12 
Therefore, the goal of the work presented in this dissertation is envisioned through the 
development of libraries of disease-specific, turn-on fluorescent probes to provide 
detection/identification protocols that could assist in fluorescence-guided surgical resection of 
cancerous tissues.           
 After inception of the tripartite sensor concept in the late 1980s, many groups have 
exploited this idea in the design of prodrugs in cancer therapy.13-16 However, their use in imaging 
probe strategies is still limited.17 The tripartite probe chemistry work presented here involves the 
study of three components, namely trigger, linker, and reporter. As illustrated in Figure 1.1, due 
to their molecular design, the tripartite probes will readily enter the cytosol of cancer cells, where 
rapid NQO1-initiated reduction of the quinone substrate group converts it to an unstable 
intermediate. This is followed by a subsequent self-cleavage of the lactone and linker 
rearrangement to yield an intensely light-emissive fluorescent reporter that will be retained inside 
the cell to provide identification and differentiation of living human tumor cells based on 
intracellular enzyme content.           
 A large part of reporter release kinetics for tripartite probes depends on the electronic and 














Figure 1.1 Schematic representation of activation of a quinone–based tripartite activatable 
“smart probe” inside a cancer cell. 
groups with varying substituents have been studied extensively in the McCarley group, to probe 
their electronic and structural characteristics and their activation by human NQO1 enzyme. A 
main objective of the work presented here involves the study of different linker systems to 
design tripartite probes with rapid reporter release mechanisms. A novel N-methyl-para-amino 
benzyl alcohol (NMPABA) based self-immolative linker system was employed to study the 
kinetics of reporter release from a model probe. The first chapter describes the kinetics of ortho- 
and para- NMPABA based trigger probes, which involves the monitoring of sodium dithionite 
initiated production of 4-nitroaniline reporter groups by UV/visible spectroscopy.    
 Another important aspect in activatable probe design is the achievement of higher signal-
to-background ratios (SBRs). Outcomes of the kinetic studies were beneficial in designing a 
novel imaging probe for NQO1 that was used to complete the second objective. The activatable 
probe presented in the second chapter has two unique fluorescent modulating features to achieve 
higher SBRs. The well-separated absorption/emission between the probe and the reporter, and 
the unique quenching of the probe fluorescence, allowed achieving high SBRs in cellular 
imaging experiments.            
 The use of probe/reporter conjugates with near-infrared excitation and emission energies 
is considered essential for successful in vivo fluorescent imaging experiments. Finally, as for the 
third objective, the imaging probes were designed by incorporating faster eliminating linker 
systems with near-infrared (NIR) fluorophores for future use in routes of in vivo imaging of 
NQO1 enzyme.   
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1.2 Cancer imaging: Lighting up tumor cells 
Intense research on cancer over the years has dramatically increased the public perception 
and clinical knowledge of the causes and biology of cancer, leading to many improved 
preventive and treatment strategies. However, cancer still remains the third leading cause of 
death in the world, behind heart and infectious diseases, signaling the pressing need for effective 
detection and treatment methods.18 In this regard, bio-medical imaging is playing a vital role in 
all aspects of cancer management,19-20 including prediction, screening, staging and metastasis, 
prognosis, therapy planning, and recurrence.21-31 The number of cells contained within the entire 
human body is estimated to be approximately 1014. Because a tumor initially begins with a single 
cell, a detectability of 10-14, an incredibly small number, is needed to trace the origin of a tumor. 
However, the growth of human solid tumors typically displays ‘Gompertzian’ kinetics,32 as 










Figure 1.2 Gompertzian growth curve of a solid tumor and its relationship to cancer 
detection and imaging.32  
Critical to surgical success is the required detection of malignancies at the smallest 
possible number of tumor cells, ideally before occurrence of the angiogenic switch.32 
Unfortunately, the present detection threshold for solid tumors is approximately 109 cells (1 g = 
1 cm3) growing as a single mass, meaning that there are somewhere between zero and 109 
malignant cells in the patient’s body.32 Researchers are hopeful that the advancement of new 
imaging technologies will help mitigate this uncertainty so as to provide improved patient 
outcomes in the near future.  
standpoint, the term remission literally means that there are
somewhere between zero and 109 malignant cells in the patient’s
body (Fig 1). This level of uncertainty is unacceptable to both
patient and caregiver.
The goal of this review is to inform the reader about why current
imaging modalities are generally inadequate for oncology and which
new technologies have the potential to improve patient care.
PRINCIPLES OF MEDICAL IMAGING
Signal-to-Background Ratio
Clinical imaging can be essentially reduced to a simple concept:
the signal-to-background ratio (SBR), which in the case of cancer
imaging is the tumor-to-background ratio. If the goal is to detect or to
image cancer cells in the body, then the signal generated by one or
more contrast mechanisms must be higher than the background
caused by nonspecific signal or nearby normal cells. Even if there is
adequate inherent sensitivity and resolution of an imaging modality to
detect malignant cells, they will be invisible if the background is too
high. To improve the SBR, one of three forms of contrast generation is
used: endogenous contrast, exogenous nontargeted contrast, and ex-
ogenous targeted contrast.
Endogenous and Nontargeted Exogenous
Contrast Agents
Endogenous contrast has undeniable advantages. It doesn’t
require injection of a contrast agent or costly and time-
consuming regulatory approval,4 and it is generally safe. How-
ever, in many clinical situations, endogenous contrast does not
provide adequate sensitivity or specificity for detecting malig-
nant cells and their products.
Nontargeted exogenous contrast, typically in the form of an
extracellular fluid agent, is used routinely in CT and MRI. After intra-
venous injection, nontargeted contrast distributes throughout the ex-
tracellular space and is cleared rapidly by glomerular filtration. This
simple process has been exploited extensively in radiology to
indirectly highlight tumors. Because the effects of nontargeted
contrast agents are indirect and relatively insensitive, a large
number of academic and industrial investigators are developing
agents that target malignant cells or their products directly
(molecular imaging).
Exogenous Targeted Contrast Agents
The development of cancer-specific diagnostic agents is
itself a 3-D problem (Fig 2). The first dimension is affinity (KD),
or more precisely, the ratio of KD to the concentration of target
sites (BMax). The second dimension is biodistribution and clear-
ance, which is a function of the hydrodynamic diameter,
charge-to-mass ratio, and hydrophobicity of the contrast agent.
Hydrodynamic diameter and charge-to-mass ratio are major
determinants of how quickly an agent can extravasate from the
vascular space to the malignant cell and how quickly back-
ground signal can be cleared from the body. As a general rule,
small molecules and peptide ligands (hydrodynamic diame-
ter ! 3 nm) distribute quickly and clear through the kidneys but
require adequate affinity and contact time for effective cancer
imaging. Single-chain (hydrodynamic diameter of approxi-
mately 5 nm) and full-length antibodies (hydrodynamic diam-
eter of approximately 10 nm) fall on a spectrum from
intermediate to poor biodistribution and clearance. Traditional
nanoparticles (" 10 nm) have virtually no clearance from the
body, and even with protective coatings, eventually concentrate
in the reticuloendothelial system. A new study from our labo-
ratory has suggested the criteria (the Choi criteria5) for the
effective use of nanoparticles in vivo. The third dimension is
effect size, which for a diagnostic agent is the SBR and for a
therapeutic agent is cytotoxicity. Optimizing a contrast agent or
radiotracer in all three dimensions is an incredibly difficult task,



















Current Threshold for 
Clinical Detection
Remission
Fig 1. Gompertzian growth curve of a solid tumor and its relationship to cancer
detection and imaging. Number of malignant cells (ordinate) as a function of time
(abscissa). The transition from first lag to log phase of growth, associated with
the transition from diffusion-limited nutrition to neovascularization, is labeled
“angiogenic switch.” Remission is shown as the uncertainty of cell number
ranging from zero to the current clinical threshold for cancer detection (approxi-
























Fig 2. Three-dimensional development of exogenous, targeted diagnostic or
therapeutic agents. Colored box delineates optimal in vivo performance.
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1.3 Bio-molecular imaging modalities in oncology 
 It is often perceived by many that the fate of cancer patients rests upon improved drug 
treatment methods. However, most of the patients with solid tumors have a higher chance of 
survival with surgical intervention. This could be possible only through early stage detection, as 
the successful outcome of surgery decreases significantly with late-stage tumor diagnosis.33 In 
broader terms imaging systems help visualize the expression and activity of particular molecules, 
cells and biological processes.3         
 Many different modalities have been and continue to be developed to image the structure 


























Figure 1.3 Advancement of different molecular imaging technologies used in oncology.3 
modalities used in molecular oncology—X-ray, computed tomography (CT), ultrasound (US), 
magnetic resonance imaging (MRI), single-photon emission computed tomography (SPECT), 
cover systems for the observation of molecular targets at the micro-
scopic and macroscopic levels, as well as non-fluorescence-based optical 
imaging systems.
Fluorescence imaging
Fluorescence illumination and observation has been one of the most 
rapidly adapted imaging technologies, in both medicine and biological 
sciences. Fluorescence has spurred the development of sophisticated 
microscopic, mesoscopic and macroscopic imaging systems, as well 
as miniaturized fibre-optic approaches, imaging probes and genetic 
reporter systems. Fluorescence refers to the property of certain molecules 
to absorb light at a particular wavelength and to emit light of a longer 
wavelength after a brief interval known as the fluorescence lifetime. The 
phenomenon of fluorescence was known by the middle of the nine-
teenth century and was then adapted to fluorescence microscopy in the 
early twentieth century. Medical applications of fluorescence imaging 
date back to 1924, when the autofluorescence of endogenous porphyrins 
was observed in tumours illuminated with ultraviolet light6. In 1942, 
red fluorescence y tumours was observed after intrav nous admin-
istration of porphyrins7, and the first use of fluorescein (which emits 
green light) to improve the detection of brain tumours was reported in 
1948 (ref. 8). Britton Chance and others pioneered the reconstruction of 

















































































Figure 1 | Imaging technologies used in oncology. Many macroscopic imaging 
technologies (shown above the timeline) are in routine clinical use, and 
there have been huge advances in their capabilities to obtain anatomical 
and physiological information since the beginning of the twentieth century. 
Shown are some examples of bones (X-rays), soft tissue (ultrasound, MRI and 
CT rows), three-dimensional organs (CT and MRI rows) and physiological 
imaging (MRI and PET rows). Microscopic and other intravital optical 
techniques (shown below the timeline) have developed over the past decade 
and now allow studies of genetic, molecular and cellular events in vivo. 
Shown are surface-weighted, whole-mouse, two-dimensional tech iques 
(macroscopic reflectance row); tomographic three-dimensional techniques, 
often in combination with other anatomical modalities (tomography 
row); and intravital microscopy techniques (microscopy row). The 
timeline is approximate and is not to scale. BLI, bioluminescence imaging; 
CT, computed tomography; DOT, diffuse optical tomography; FMT, 
fluorescence-mediated tomography; FPT, fluorescence protein tomography; 
FRI, fluorescence reflectance imaging; HR-FRI, high-resolution FRI; 
LN-MRI, lymphotropic nanoparticle-enhanced MRI; MPM, multiphoton 
microscopy; MRI, magnetic resonance imaging; MSCT, multislice CT; 
OCT, optical coherence tomography; OFDI, optical frequency-domain 
imaging; PET, positron-emission tomography. (PET image reproduced, 
with permission, from ref. 4. Diffusion MRI image courtesy of B. Ross and 
A. Rehemtulla, Univ. Michigan Medical School, Ann Arbor. X-ray image 
(left) reproduced, with permission, from ref. 86. Diaphanoscopy image 
reproduced, with permission, from ref. 87. Fibre-optic image reproduced, 
with permission, from ref. 88. BLI image courtesy of K. Shah, Massachusetts 
General Hospital, Harvard Medical School, Boston, Massachusetts. Lifetime 
FRI image courtesy of U. Mahmood and C. Salthouse, Massachusetts 
General Hospital. DOT image reproduced, with permission, from 
ref. 89. FPT image courtesy of G. Zacharakis and V. Ntziachristos, 
Massachusetts General Hospital. FMT–MRI image courtesy of 
J. Chen, Massachusetts General Hospital. Bright-field image (left) 
reproduced, with permission, from ref. 14. Bright-field image (right) 
courtesy of T. Mempel, Massachusetts General Hospital. Epifluorescence 
image courtesy of F. Jaffer, Massachusetts General Hospital. OCT, OFDI 
image reproduced, with permission, from ref. 22. MPM image reproduced, 
with permission, from ref. 51. Microendoscopy image reproduced, with 
permission, from ref. 17.)
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positron emission tomography (PET), and optical imaging—can be grouped according to the: 1) 
type of information obtained (anatomical, physiological, cellular or molecular); 2) resolution 
achieved (macroscopic, mesoscopic or microscopic); and 3) energy used (X-rays, positrons, 
photons, or sound waves) (Figure 1.3).3,35 CT, MRI, PET, and SPECT are used in routine clinical 
practices and for efficacy studies on drugs in clinical trials.3 However, these imaging techniques 
have unique applications, as well as advantages and limitations to each.34 For example, MRI and 
CT techniques rely purely on energy-tissue interactions, whereas PET and SPECT techniques 
depend on the incorporation of reporter probes or contrast agents.36 PET imaging is the most 
widespread imaging technique, and many oncologists make decisions based solely on visual 
analysis of PET images.33,36 However, the risk of radioactivity, low spatial resolution, and 
importantly the high instrumentation cost, somewhat restrict its potential.33 By contrast, optical 
imaging techniques based on fluorescence illumination have gained immense attention in both 
medical and biological sciences; although they are widely used in the traditional laboratory 
setting experimentally, there is clear potential for their translation into the clinic.3 
1.3.1 Fluorescence Imaging: a non-invasive, low-cost alternative 
Fluorescence, a phenomena first discovered by G.G Stokes37 in the middle of the 19th 
century, refers to observation of light emitted by molecules subsequent to their excitation by 
light of a particular energy.38 This inherent feature of many molecules is important in numerous 
scientific and technological disciplines, namely physics, chemistry, materials science, biology, 
and medicine,39-41 out of which medical and biological sciences have rapidly adapted 
fluorescence imaging to a great extent. Observation of autofluorescence from endogenous 
porphyrins in tumors was one of the earliest applications of fluorescence imaging in the medical 
sciences, dating back to 1924.42 Since then, fluorescence imaging has evolved into sophisticated 
microscopic and macroscopic imaging systems that, provide a rapid, non-invasive, and low-cost 
alternative for the current predominant imaging modalities (CT, US, MRI, PET and SPECT), 
thereby showing huge potential in its translation into the clinic. The two main types of 
macroscopic imaging techniques are fluorescence reflectance imaging (FRI) and fluorescence- 
mediated tomography (FMT).43 FRI is used in imaging surface (epithelial) tumors and surgically 
exposed organs so as to yield obtain two-dimensional (planar) images, whereas FMT and 
reconstruction methods provide three-dimensional images for much deeper targets, via the help 
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of sophisticated algorithms.3,43 On the other hand, fluorescence microscopy is a rapidly 
expanding technique that has made it possible to identify cells and cellular components with a 
high degree of selectivity. The two main fluorescence microscopic techniques—multiphoton 
microscopy and laser-scanning confocal microscopy—have been transformed from in vitro cell 
visualization to in vivo imaging. Multiphoton imaging systems can offer hours of imaging with 
high spatial and depth resolutions to yield three-dimensional information, which cannot be 
achieved by confocal microscopy set-ups.3 However, confocal microscopic imaging is still 
widely popular across different disciplines in the biological and medical fields, due to its user-
friendly and low-cost operating procedures. It is also noteworthy to mention awarding of the 
Nobel Prize in chemistry for the year 2014 to Eric Betzig, William E. Moerner, and Stefan W. 
Hell for their involvement in the development of super-resolution fluorescence microscopy,44 
microscopic route to the study of living cells with highest level of molecular detail. 
1.3.2 In vivo near-infrared fluorescence imaging 
 The near-infrared (NIR) region (650–900 nm) of the electromagnetic spectrum offers 
certain advantages for photons to propagate through live tissue much more efficiently than those 












Figure 1.4 A scheme of the in vivo NIR window and the extinction coefficient value of 
water, and oxy- and deoxy-haemoglobin in the visible to near infrared energy range.46 
 
This journal is c The Royal Society of Chemistry 2011 Chem. Soc. Rev., 2011, 40, 4626–4648 4629
produce two 511 keV photons (in opposite directions) that can
be detected with co-incident detectors and because the line of
response can be determined, PET scanners do not require a
collimator, resulting in improved resolution compared with
gamma emitters. Radionuclide cameras are sensitive enough
to detect pico-molar concentrations of radionuclides even deep
in the body. Nuclear imaging is a well-developed area of
medicine, which has evolved over the past fifty years. As a
result, newly developed agents can be readily tested in humans
using a micro-dosing processing. However, given that gamma-
or X-ray exposes the subject to ionizing radiation, radio-
nuclide imaging must always take into consideration radiation
dose based on the radioactivity of the agent and its physical
and biological half life. Thus, an imaging modality with
comparable sensitivity but without ionizing radiation would
be desirable.
Optical imaging relies on photons ranging in wavelength
from the visible to the near infrared (NIR) (500 to 1500 nm
wavelength). Charge Coupled Device (CCD) detectors, which
are used for optical imaging, generally show better sensitivity
for photons at shorter wavelengths. Within this range, NIR
light, r nging from 650 to 800 nm, provides the best visualizati n
of deeper structures, u to several centimeters, from the
surface, as this range is less readily absorbed by living tissue
(Fig. 3). Shorter wavelength photons are limited to imaging
the surface or immediately subsurface phenomena because
of near co plete absorbance of light by oxy- and deoxy-
hemoglobin. Of course, depth of penetrati is partly related
to the strength of the light source, therefore, the signal from
fluorophores with very strong emission can penetrate tissue
more deeply. Numerous visible-to-NIR wavelength emitting
agents are used for optical imaging and such fluorophores can
be detected with pico-molar sensitivity without ionizing
radiation. Optical imaging alone (without exogenous probes)
has been used in clinical practice for detecting blood flow or
blood oxygen concentration in relatively superficial organs
including the breasts, brain, and eyes. Only two optical imaging
reagents; fluorescein and indocyanine green (ICG), have been
approved for use in clinical practice. Small numbers of target
specific fluorescent probes have been introduced for use during
surgery- or endoscopy, but none is in common clinical use.
MR imaging relies on radio waves which have wavelengths
on the order of 1 centimetre. Radiofrequency waves can
penetrate deep into the body. MR imaging generally measures
the magnetic relaxation properties of protons but this requires
excitation by radiofrequency. Paramagnetic metal ions or
nano-sized metal particles are used as contrast agents as they
alter the relaxation rate of adjacent water protons and disrupt
the magnetic field around particles. Detectable relaxation
change can only be achieved when the paramagnetic concen-
tration of the imaging agent is greater than 10 micro-molar
concentration of metal ions or atoms, thus limiting sensitivity.
Radio waves do not expose the subject to ionizing radiation.
With regard to contrast agents, gadolinium chelates and iron
oxide particles have been approved for use in the clinical
practice. However, there is mounting concern regarding the
use of gadolinium contrast agents in patients with renal
impairment due to the risk of nephrogenic systemic sclerosis,
a potentially fatal disorder that results from heavy metal
toxicity of gadolinium ions that are released from chelates.
With this said, MRI signal can be processed in di!erent ways
yielding methods that have a great potential for obtaining
multiplexed information beyond anatomy and without the
need for contrast material.
By keeping these characteristics in mind, appropriate
combinations of two or more signaling moieties, also called
‘‘hybrid imaging’’, can be e!ective in providing more complete
information about a physiologic process. In the next sections,
new molecular probe development, mostly presented as
preclinical examples, is discussed.
B.1.1 Nuclear/optical multi-modality probes. Multimodal
uclear and optical imaging probes are promising agents for
molecular imaging and drug (theranostic) development.37–42
Within this strategy, the role of the radioactive component is
to provide quantitative, whole body data. The radioactive
component provides a continuously emitting signal that can
be utilized to determine probe biodistribution and clearance
and provide physiologic data such as glomerular filtration rate
and probe concentrations in specific sites (such as in a tumor
or organ).43–45 The optical component of the probe provides
the ability to qualitatively visualize target tissue in real time to
assist with interventional, surgical, or endoscopic procedures,
or for specific detection of molecular profiles using multi-color
‘‘always on’’ or tumor-cell specific ‘‘activatable’’ optical
probes (discussed later). These properties make nuclear/optical
probes useful for drug development, physiologic imaging,46
enzyme-specific imaging,37 cardiac imaging, and for e!ective
tumor targeting.38,39,47,48
B.1.1.1 Nuclear/optical dual labeled probes. The use of a
positron emitting isotope as the radioactive component,
provides even better quantitative data for dual nuclear/optical
agents.49 PET has high penetration and sensitivity and is more
quantitative.50,51 With this in mind, several combinations of
PET/optical agents have been developed. For example, an
optical quantum dot (QD) with NIR fluorescence can be
attached to a chelating agent to bind 64Cu for PET imaging,
and to a vascular endothelial growth factor (VEGF) protein
analog for site-specific targeting of the VEGF receptor.
Fig. 3 A schema of the in vivo NIR window and the extinction
coe"cient value of water, oxy- and deoxy-hemoglobin are plotted
















































The NIR wavelength range provides the best visualization of more deeply seated 
tissues—up to several centimeters—from the surface, partly due to the lower absorbance by 
tissues.46 In general, photon absorbance of a particular tissue or organ is the sum of all absorbing 
species present.47 In living, non-pigmented tissue the major absorbers water, lipids, 
oxyhemoglobin and deoxyhemoglobin, show a local minima in the NIR region.46-49 However, in 
a ‘typical’ tissue, having 8% blood volume and 29% lipid content, hemoglobin still accounts for 
39–64% of total absorbance at the NIR wavelengths.49 The photon emitted by a fluorophore is 
also important in in vivo imaging, as the signal from fluorophores with very strong emission can 
penetrate tissue more deeply.   
In addition to tissue absorbance, another drawback for in vivo imaging is tissue 
autofluorescence, which limits the signal-to-background ratio (SBR). The dependence of tissue 
auto fluorescence on excitation light of different wavelengths is depicted in Figure 1.5. As seen 
in Figure 1.5, (b), blue light excitation gives the highest tissue autofluorescence from skin, small 















Figure 1.5 Wavelength–dependent autofluorescence from vital organs and body fluids. (a) 
white light color image of the animal, arrows mark the location of  the gallbladder (GB), small 
intestine (SI) and bladder (Bl); (b) blue/green (460–500 nm/505–560 nm); (c) green/red (525–
555 nm/590–650 nm); and (d) NIR (725–775 nm/790–830 nm).47 
 
common of which are polymethines. One important class
of these molecules is the heptamethine cyanines
(Figure 2a), comprising benzoxazole, benzothiazole,
indolyl, 2-quinoline and 4-quinoline subclasses. Of these,
the indocyanines are the most widely used as they do
not have the aggregation problems associated with the
other subclasses [6]. Peak excitation of this class is at
760–800 nm, and peak emission at 790–830 nm.
In1958, indocyaninegreen(ICG;Cardio-Green;Figure2b)
was submitted for approval to the FDA for use in
indicator-dilution studies in humans. It is one of the least
toxic agents ever administered to humans, with the only
known adverse reaction being rare anaphylaxis. Recently,
several improved heptamethine indocyanines have
become available. For example, Figure 2c shows the
carboxylic acid form of IRDye78 (LI-COR, Lincoln,
NE). This molecule is tetra- rather than di-sulfonated,
which increases aqueous solubility and aqueous quantum
yield (QY), and is available as an N-hydroxysuccinimide
ester derivativ for co alent conjugation t targeting
molecules. Dozens of other heptamethine fluorophores
have been reported [7,8!,9]. Conjugation to the indocya-
nines requires careful handling [10], and a set of robust
methods has recently been published [11!].
Conventional organic fluorophores suffer from significant
limitations. First, and foremost, it is difficult to control
excitation and emission wavelengths. These wavelengths
Box 1 Optimization of parameters for in vivo NIR
fluorescence imaging.
Fluorophore properties Tissue and/or cell targeting
Aqueous solubility Tissue/target refractive indices
Excitation wavelength(s) Rayleigh and Mie scatter of tissue
Extinction coefficient (e) Tissue absorption of excitation light
QY Tissue autofluorescence
Emission wavelength Quenching of fluorophore
Local environment effects
on above
Cellular and sub-cellular diffusion
barriers
Excitation light delivery Signal amplification









Plasma protein binding NIR transmission properties
of opticsVascular perme bility barriers
Filter designBlood clearance
D tector spectral sensitivity
and response
Figure 1




















Wavelength-dependent autofluorescence of vital organs and bodily fluids. (a) Immediately after sacrifice, the viscera of a hairless, athymic
nu/nu mouse were exposed. Tissue autofluorescence was then imaged using three different excitation/emission filter sets: (b) blue/green
(460–500 nm/505–560 nm); (c) green/red (525–555 nm/590–650 nm); and (d) NIR (725–775 nm/790–830 nm). The fluence rate provided by each filter
set was adjusted to 2 mW/c 2. To compensate for differences in emission filter wavele gth width and camera sensitivity, exposure times were
adjusted accordingly. Fluorescence images have identical normalization. For orientation, the white light color image of the animal is shown in (a).
Arrows mark the location of the gallbladder (GB), small intestine (SI) and bladder (Bl).
In vivo near-infrared fluorescence imaging Frangioni 627
www.current-opinion.com Current Opinion in Chemical Biology 2003, 7:626–634
 8 
of the bladder and the gallbladder is reduced significantly. Finally, with an NIR excitation filter 
set (Figure 1.5, (d)), autofluorescence is reduced to a minimum. This feature is important to 
achieve better SBR for most in vivo experiments. 
1.4 Optical molecular imaging 
 The interaction of light with tissue components is the basis of optical bio-imaging 
methods, which have spatial resolutions that span those of sub-cellular microscopy to organ level 
techniques (Figure 1.6).3,50 This photon-component interaction can be based on either 
endogenous or exogenous components that give rise to the observed optical molecular contrast. 
In endogenous contrast methods, inherent morphological differences, such as nuclear size, 
density, and distribution, are utilized to obtain information about the normal and neoplastic tissue 
states. A major challenge with endogenous methods is the nonspecific background contrast; thus 
numerical and analytical models have to be incorporated to achieve successful diagnosis in the 
clinical setting.51 However, one significant benefit with this method is the acquired image does 








Figure 1.6 Five classes of molecular-specific optical contrast agents, from left to right in 
order of increasing size. Relatively small molecules, including glucose and peptides can be 
functionalized with fluorescent dyes. Aptamers can be designed to form activatable ‘‘smart 
probes,’’ with fluorescence being quenched until target binding. Antibody probes are generally 
functionalized with fluorescent dyes in the Fc domain. Targeting molecules can be coupled to 
nanoparticle-based optical reporters, including gold nanoparticles and quantum dots.50 
Nonspecific exogenous contrast agents
Increasing optical contrast with exogenous agents has tradition-
ally relied on nonspecific small molecules to either introduce dis-
tinct absorbing or fluorescent properties, or to induce detectable
changes in native tissue properties. In most instances, these non-
specific agents enhance visualization of alterations in cellular mor-
phology occurring during transformation from normal to precan-
cerous states. A range of vital dyes with absorbing or fluorescent
properties including fluorescein, indocyanine green, cresyl violet
acetate, toluidine blue and Lugol’s iodine are currently used in
clinical screening. These nonspecific dyes can exhibit some degree
of intra- or extracellular localization based on size or charge distri-
bution. Acriflavine is one such agent that binds to nuclear material
and has been used in clinical trials evaluating confocal optical
imaging in several organ sites. In several epithelial tissues, topical
application of acetic acid induces chromatin compaction, allowing
nuclear size, nuclear-to-cytoplasmic ratio and pleomorphism to be
microscopically imaged in situ and provides contrast enhancement
between normal and dysplastic tissue when imaged macroscopi-
cally. These small molecules typically have molecular weights
below 1 kD, allowing efficient delivery either through topical or
intravenous routes. The major limitation of these agents results
from the relatively high level of nonspecific background light,
below which the disease-specific signal component cannot be
detected.
Molecular-specific exogenous contrast agents
Molecular-specific optical imaging using bioluminescent probes
and fluorescent proteins has enabled imaging of reporter gene
expression at macroscopic and microscopic scales, with significant
impact in cell culture and animal studies.9,10 In this review, we
focus on externally administered contrast agents that can in princi-
ple proceed to clinical use. Analogous to many radiolabeled
agents, molecular-specific optical contrast agents comprise an af-
finity ligand targeting a recognized disease biomarker, conjugated
to an optically active reporter. The targeted biomarker may be an
element specifically activated, expressed or upregulated in carci-
nogenesis, or associated with underlying biological processes such
as angiogenesis and metastasis. Cancer biomarkers are continually
being identified by molecular profiling studies and include specific
proteins, cell surface receptors and enzymes. Organic fluoro-
phores, metallic nanoparticles and semiconductor quantum dots
have all been investigated as optical reporters, either involving
direct conjugation to the probe ligand, or indirect binding via a
linker segment. Preparation of the optical reporter may also
include surface fu ctionalization to improve stability, delivery,
retention and specificity. We next discuss some of the current
approaches to contrast agent development, each broadly based
upon probe molecules conjugated to optical reporters, covering
examples spanning a range of physical sizes and molecular
weights as illustrated in Figure 1.
Organic fluorophore reporters
Antibodies, antibody fragments and biologically derived pepti-
des can all act as effective probe species, using the amine, car-
boxyl or thiol functional groups present within the protein struc-
ture for conjugation of an optical reporter (Fig. 1). Hsu et al. tar-
geted the epidermal growth factor receptor (EGFR), a
transmembrane protein found to be overexpressed in many epithe-
lial cancers, by conjugation of an Alexa fluor 660 organic dye to a
monoclonal antibody against EGFR.11 On labeling fresh tissue
biopsies from oral cancer patients with the antibody-dye conju-
gate, confocal microscopy indicated significantly increased fluo-
rescence intensity within the epithelium in samples with dysplasia
and cancer compared with paired normal sites, particularly in the
most superficial region. The use of antibodies as targeting entities
has raised questions concerning immunogenicity and unfavorable
pharmacokinetic properties. These size-related effects have been
circumvented by the use of peptides as probe molecules (Fig. 1),
which can retain a high affinity to the target receptor at a reduced
molecular weight. Ke et al. developed a targeted contrast agent
based upon the EGF peptide and a Cy5.5 organic fluorophore,
demonstrating highly specific labeling in human breast tumor cell
cultures and tumor xenografts.12 Similarly, Becker et al. demon-
strated the efficacy of a peptide-dye conjugate in a mouse xeno-
graft model, incorporating an organic cyanine fluorophore conju-
gated to octreotate, a somatostatin analog.13 Many tumors, includ-
ing gastric and breast carcinomas, overexpress receptors for the
somatostatin peptide, and radiolabeled analogs are currently used
in clinical imaging. Control over structural modifications intro-
duced during the probe-reporter conjugation process is important
in order to preserve the intrinsic specificity and binding affinity of
the probe, as well as to retain solubility. Peptide-based probes are
particularly vulnerable to modification compared with larger anti-
bodies, because the smaller ligands have fewer functional residues
available for involvement at the binding site. For in vivo imaging,
FIGURE 1 – Five classes of molecular-specific optical contrast agent. From left to right in order of increasing size: Small molecules including
glucose and peptides can be functionalized with fluorescent dyes. Aptamers can be designed to form activatable ‘‘smart probes,’’ with fluores-
cence quench d until target binding. Antibody probes are generally functionalized with fluorescent dyes in the Fc domain. Targeting molecules
can be coupled to nanoparticle-based optical reporters, including gold nanoparticles and quantum dots.
1980 PIERCE ET AL.
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Exogenous contrast agents can be of two types, namely nonspecific and molecular 
specific. In general exogenous agents in general rely on absorption or fluorescence properties of 
dyes to provide contrast enhancement between healthy and diseased tissues.50 Molecular-specific 
agents are designed with a known disease biomarker targeting moiety conjugated directly or via 
a linker to an optically active reporter. These biomarkers include cell-specific proteins and 
receptors, and enzymes that get activated, expressed, or upregulated in carcinogenesis-related 
processes. 
1.4.1 Nanomaterial-based imaging 
Many different nanomaterial-based probes have been used in cancer research with great 
success.52-54 An overview of the different types of nanoparticles and the images obtained with 
these nanoparticle-based probes are depicted in Figure 1.7. These nanoparticle-based probes can 
be broadly classified in to two groups: organic species and inorganic nanocrystals (semi-
conducting quantum dots (QDs) and silica nanoparticles).55  Compared to other contrast agents, 
QDs have unique optical and electronic properties, high absorbance cross section, wavelength-








Figure 1.7 Nanomaterial formulations used in imaging and therapy of cancer (non-clinical), 
and associated representative in vivo images for:18 liposomes and micelles (SPECT image 
overlaid with CT);57 polymers and dendrimers (PET image overlaid with CT);58 noble metals 
(near-IR optical imaging);59 semiconductors (fluorescence imaging);60 carbon nanotubes and 
fullerenes (photoacoustic imaging);61 transition metal oxides (MRI);62 metal-organic frameworks 
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is limited to superfi cial sites due to the limited penetration 
depth of light, even in the near infrared range where tissue 
absorbance is minimal. [ 26 ] However, these NPs can also provide 
contrast in X-ray computed tomography (CT) imaging due to 
their high densities as compared to human soft tissue, which 
enables non-invasive, real-time imaging of the vast majority of 
solid tumors. [ 27 ] The high density of the NPs attenuates X-rays 
resulting in high-contrast regions where NPs are present. These 
NPs provide a signifi cant advantage for molecular imaging over 
the commonly used CT contrast agents such as iodine owing to 
their higher X-ray absorption coeffi cient, long circulation time 
in blood, and high surface area for easy attachment of targeting 
and therapeutic agents. [ 28 ] Furthermore, gold NPs can be used 
in photoacoustic imaging where absorbed light causes the NP 
to emit ultrasonic waves through thermo-elastic expansion that 
can be detected by an ultrasound detector. [ 29 ] However, this 
method is still limited to an imaging depth that is penetrable by 
the photons used to excite the NPs. 
 2.3. Semiconductor Materials 
 Semiconductor materials have been widely studied for syn-
thesizing NP cores because of their unique optical proper-
ties that arise from the quantum confi nement of an exciton 
at the nanoscale. [ 30 ] The absorption and emission spectra of a 
semiconductor NP (also known as a quantum dot or QD) are 
size-dependent, and thus the optical spectrum of a QD can be 
fi ne-tuned by altering the size of the NP core. Optical proper-
ties of QDs can also be engineered through controlling their 
shape and surface properties. These QDs show very bright fl uo-
rescence that does not photobleach as organic chromophores 
do, which allows for long-term, repeated imaging. Further-
more, the radiative emission from the QD can be tuned to the 
visual spectrum to allow for intraoperative imaging. However, 
the heavy metals commonly used to synthesize these semicon-
ductor NPs, most commonly cadmium, are highly toxic so their 
use in humans may be limited. Strategies have been developed 
to synthesize cadmium-free quantum dots to improve their 
clinical translation. [ 31 ] In addition, use of these QDs for detec-
tion or diagnosis of cancer is limited to superfi cial sites such 
as skin and esophageal cancers due to the limited penetration 
depth of visible light. Near-infrared-emitting NPs have been 
developed for deeper tissue penetration, but imaging is still 
limited to about 3 cm. [ 32 ] 
 2.4. Carbon Nanotubes and Fullerenes 
 Carbon nanotubes and fullerenes (CNTs) have been investi-
gated for cancer imaging applications. [ 33 ] Both single-walled and 
multi-walled CNTs have a high surface area and internal volume 
for loading of drugs and imaging agents, but alone, CNTs are 
not soluble in most organic or aqueous solutions. Therefore, 
surface modifi cation of CNTs is critical for their use in ther-
anostic applications. [ 34 ] Polyhydroxy fullerene can be detected 
using photoacoustic imaging and used for photothermal abla-
tion therapy after intratumoral injection. [ 35 ] Furthermore, multi-
walled CNTs can be used for photothermal ablation therapy 
owing to their release of vibrational energy upon near-infrared 
light exposure. [ 36 ] However, potential toxicity associated with 
CNTs must be addressed before clinical translation. [ 37 ] 
 2.5. Metal Oxide Nanoparticles 
 Magnetic metal oxide NPs have been very widely studied for use 
as contrast agents in MRI. [ 38 , 39 ] MRI is a powerful tool for med-
ical imaging owing to its virtually unlimited tissue penetration 
depth and thus NPs can be detected anywhere in the body. [ 40 ] 
 Figure  1 .  Typical nanomaterial formulations for imaging and therapy of cancers, their mechanism for imaging, and associated representative images. 
Example images reproduced with permission for: liposomes and micelles (SPECT image overlaid with CT), [ 15 ] copyright 2010, Elsevier; polymers and 
dendrimers (PET image overlaid with CT), [ 275 ] copyright 2009, National Academy of Sciences; noble metals (near-IR optical imaging), [ 276 ] copyright 2011, 
American Chemical Society; semiconductors (fl uorescence imaging), [ 32 ] copyright 2006, Nature Publishing Group; carbon nanotubes and fullerenes 
(photoacoustic imaging); [ 35 ] transiti n metal oxides (MRI), [ 81 ] copyright 2010, American Association for Cancer Research; metal-organic frameworks 
(MRI), [ 51 ] copyright 2009, Nature Publishing Group; and lanthanide series (X-ray radioluminescence imaging). [ 57 ] 
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In conjunction with diagnostic and therapeutic agents, QDs have been used successfully 
in cancer diagnosis and therapy applications with high specificity.65-67 The use of toxic heavy 
metals, e.g., Cd and Se., in the synthesis of QDs limits their potential use in human clinical 
trials.56 However, strategies have been developed either to avoid using toxic metals68-69 or to 
render them biocompatible by covering them with a shell having functionalized (PEG) surface.56 
The surface coatings in QDs help improve blood circulation lifetime as a result of minimized 
protein adsorption, allowing intracellular distribution and cellular uptake.56 Gao et al. were one 
the first to showcase the biocompatibility of QDs in a murine xenograft model, where they used 
a surface functionalized QD (CdSe-ZnS) to target a prostate-specific membrane antigen.65 Also, 
Gao et al. recently demonstrated high tumor uptake with excellent contrast using NIR non-
cadmium QDs coated with mercaptopropionic acid.69 Although these studies showed improved 
outcomes, use of QDs as an exogenous agents so as to make such a predominant technique is 
remain to be seen.  
1.4.2 Antibody-based imaging 
 The high affinity of antibodies toward tumor-specific antigens is the basis for selective 
delivery of diagnostic or imaging probes to cancer sites. The pharmacokinetics profile, bio-
distribution, side effects, and toxicity of some of FDA-approved antibodies are well known, 
enabling the translation of antibody-based imaging techniques into clinics with much ease in 
comparison to others.  
The long plasma half-life of antibodies that result from their increased size and protein 
content (~150 kD) is advantageous, thereby providing higher cancer-specific cell uptake in 
comparison to imaging modes based on nanoparticle and peptide probes, whose relatively fast 
clearance from the body impedes their ability to access and be available at the diseased site.70 In 
addition, a wide variety of imaging probes can be chemically linked to antibodies to yield 
targeted imaging probes for oncology (Figure 1.8). Especially antibody-conjugated fluorophores 
are of great importance in clinical settings, for example indocyanine green (ICG) labeled 
antibodies71-74 have long been used in clinical trials with very limited toxicity in humans.70 
Furthermore, antibody conjugates, such as fluorescein isothiocyanate (FITC)75 and 








Figure 1.8 Modality-specific probes available for antibody labeling for the purpose of cancer 
imaging and localization.70 
In addition, fluorescent antibody conjugates have been designed for more specific tumor 
targets, such as epidermal growth factor receptor (EGFR),78-80 human epidermal growth factor 
receptor-2 (HER-2),76-77 and vascular endothelial growth factor receptor (VEGFR),76-77 for real-
time visualization of tumor cell microenvironment.70,81 However, with all of these advancements 
in antibody-based imaging techniques, their clinical applicability has been limited due to their 
long retention in non-targeted tissues, slow clearance from circulation, and tedious optimization 
refinement of conjugation chemistry for each antibody–species.81 
1.4.3 Peptide-based imaging 
The Peptide-based probe molecules provide favorable pharmacokinetic properties when 
compared to those of antibody-based strategies. In comprison to high-molecular-weight antibody 
conjugates, the much lower molecular weight of peptides leads to high conjugate retention and 
better affinity to tumor target sites. Many tumors have been shown to overexpress receptors for 
somatostatin (SST) or other peptides,82-86 providing strategies for development of peptide-based 
probes for visualizing malignancies. Becker et al. demonstrated that fluorescence- based, SST–
dye conjugates can be used as an alternative to the more conventional radiolabeled SST analogs, 
ielding high sensitivities and low detection limits.87 Further, Ke et al. showed the specificity of 
epidermal growth factor (EGF)-Cy 5.5 fluorescent contrast agent in the detection of EGF 
receptor in human breast cancer xenografts.88  In general, peptide-based probes have fewer 
functional residues available for involvement at tumor receptor sites which limits their wide-
spread use.50   
 
resolution of surgical anatomy. The introduction of optical im-
aging into the operating room, however, is in its early develop-
ment. To date, 5-aminolevulinic acid (5-ALA) for use in malig-
nant glioma surgery is the only agent that has been shown to have
clinical benefit and is approved for fluorescence-guided cancer
resection in Europe. 5-ALA leverages the differential metabolic
activity of brain tumors and is visible in the red region of the
visible spectrum [29]. While the application of 5-ALA has been
shown effective, limitations such as natural autofluorescence of
brain tissue in the deep red region have made adequate contrast a
challenge. Furthermore, because 5-ALA metabolism is a hall-
mark of a limited set of cancer types, it is difficult to extend 5-
ALA beyond malignant gliomas. ICG has shown promise pre-
dominantly in sentinel lymph node mapping and is currently
being studied in liver cancer [30] and breast cancer [31, 32]. The
greatest barrier for broader application of ICG is the lack of
specificity for cancer, since the primary method of preferential
accumulation within the tumor is limited to the enhanced per-
meability and retention (EPR) effect.
Antibody-based optical imaging during surgery confers the
advantage of targeting tumor-specific markers for fluores-
cence. One such approach utilizes antibodies to ligands that
are over-expressed by tumors such as vascular endothelial
growth factor (VEGF). Rapid growth of tumor tissue beyond
1–2 cm in diameter requires signaling for angiogenesis by
way of increased VEGF production. In preclinical studies,
bevacuzimab-IRDye800 administered in a murine subcutane-
ous breast cancer model demonstrated modest fluorescence
within flank tumors [33, 34].
An ther strategy is to employ antibodies to molecular
targets that are resident within the tumor such as epidermal
growth factor receptor (EGFR), human epidermal growth
factor receptor-2 (HER-2), nd vascular endothelial growth
factor receptor (VEGFR). Conjugating a fluorescent dye to a
Fig. 2 Modality-specific probes
available for antibody labeling for
the purpose of cancer imaging
and localization




Radionuclide Half-life Residualizing Radionuclide Half-life Residualizing
89Zr 78.4 h + 111In 67.3 h +
124I 100.3 h ! 131I 192.5 h !
64Cu 12.7 h + 123I 13.2 h !
86Y 14.7 h + 99mTc 6.0 h !
Cancer Metastasis Rev (2014) 33:809–822 811
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1.4.4 Aptamer-based imaging 
 Aptamer-based contrast probes are a another promising avenue in cancer diagnostic and 
imaging applications. Aptamers are single-stranded nucleic acids that are 20–100 bases in 
length89 and can be readily modified at arbitrary positions to form well defined 3-dimentional 
structures,90 capable of binding to their targets with high affinity and specificity.91 Aptamers 
have the ability to bind to almost any molecule of choice, including proteins, phopholipids, 
sugars, and other nucleic acids.89-90 Although similar in nature for their ability to recognize and 
bind to target molecules, aptamers hold several advantages over antibody-targeting probes. For 
aptamers, 1) well-defined structures provide more resistance than antibodies to pH and 
temperature changes, 2) chemical synthesis compared to in vitro or in vivo sytnthesis of 
antibodies, means more economical and scalable production, and 3) smaller size versus 
antibodies can lead to improved tissue penetration and increased systemic clearance. Formulation 
of aptamer-based probes can be achieved in two ways, direct linkage with fluorescent molecules 
or by conjugation with nanoparticle-based probes.92-93 Jung et al. showed an aptamer-conjugated 














Figure 1.9 Epithelial cancer cell imaging via fluorescent polydiacetylene molecular probes 
conjugated to EpCAM aptamer.94 
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bound to epithelial cell adhesion molecule (EpCAM)95-96 protein, a tumor-specific marker  for 
circulating tumor cells.97 Shi and coworkers reported an elegant streategy by the use of 
activatable aptamer probe (AAP) to detect human acute lymphoblastic leukemia cells,98 both in 
buffer and serum.99 Aptamers hold great potential in improving future molecular imaging 
techniques; however, effective clinical translation of aptamer-based contrast agents will require 
the development of new aptamers against biomarkers that have high clinical significance.89 
1.4.5 Fluorescent proteins 
Genetically encoded reporter agents that are derived from fluorescent proteins offer 
another possibility in visulization and tracking of cellular events for real-time extraction of 
molecular information (Figure 1.10).100-101 The advantages of fluorescent protein-based agents 
over organic- based dyes include their ability to be designed to target a variety of biological 















Figure 1.10 Monomeric and tandem dimeric fluorescent proteins derived from Aequorea GFP 
or Discosoma RFP, expressed in bacteria and purified.102  
The green fluorescent protein (GFP)101-103 was one was one of the first fluorescent 
proteins to be used for in vivo imaging.100 A main drawback of GFP is its low emission 
wavelength (∼510 nm), rendering it difficult for clinical in vivo applications. However, work 
when buried inside the intact protein.[52] Theoretical calcu-
lations by Dr. Kim Baldridge at UCSD verified that extension
of the chromophore by two double bonds could account for
the red shift in the excitation and emission spectra.[52] The
tetrameric stoichiometry and chromophore structure were
soon confirmed by independent X-ray crystal structures.[53,54]
The very tight mutual binding of the four subunits severely
hindered the use of DsRed as a fusion tag, because any
protein fusion had to become at least tetrameric. If the fusion
partner engaged in any protein–protein interactions of its
own, massive aggregation and visible precipitation often
resulted. Nevertheless, Robert Campbell succeeded over
many cycles of directed evolution in generating a monomeric
red FP (RFP), which made protein fusions much more
reliable.[55] He, Nathan Shaner, and Lei Wang then engineered
an extensive palette of monomeric FPs whose emission
maxima covered the rest of the visible spectrum out to
648 nm (Figure 12).[56, 57] Other groups have also developed a
multitude of FPs wi h complementary desirable phen types,
including amazing and highly useful photoswitching capabil-
ities,[58] but space does not permit an extensive review here.
4. Examples of Medical and Educational
Significance
One of the most common requests I get is to explain why
GFP and related FPs are significant, preferably in lay terms.
My usual answer has been that their genetically encoded
fluorescent colors can make many key biochemical processes
directly visible inside living cells and organisms. Using
standard molecular biological tricks to connect host cell
genes to FP genes, we can watch when and where those host
cell genes get switched on and off, when the protein products
are born, where they travel, with what other proteins they
interact, and how long they survive. Even when we cannot
directly tag the signals of interest, for example, Ca2+, cAMP,
protease, or kinase activities, we can often engineer FP-based
indicators as in Figure 7 to image those signals indirectly.
These generalized explanations seem too abstract for many
people, who would prefer more specific applications of
relevance to major medical problems. I therefore mention a
few rather arbitrarily chosen examples:
A vaccine against AIDS that would eradicate the disease
from already-infected patients would be extremely desirable.
Tagging of the causative virus with GFP and high-resolution
time-lapse microscopy of infected T cells contacting na!ve
cells shows that the virus can pass directly from one cell to
another through specialized transient adhesions dubbed
virological synapses (Figure 13). If the virus can really
spread between host cells without even transiently exposing
itself to the extracellular milieu where antibodies could
neutralize it, then the task of any postinfection vaccine will be
much harder.
There is much interest in the hypothesis that some of the
pathology in Alzheimer"s disease results from chronic ele-
vations in cytosolic Ca2+ in the affected neurons,[59] but the
evidence has come from neurons in culture rather than intact
animals. The genetic encodability of cameleons has now
enabled imaging of Ca2+ in the brains of normal mice versus
transgenic mice with a model for Alzheimer"s disease.[60] In
normal animals, free Ca2+ in neurons at rest is tightly
regulated around 80 nm, whereas in the disease models,
about 20 % of the dendrites show much higher Ca2+ centered
around 400 nm, particularly in the neighborhood of Alzheim-
er"s plaques (Figure 14). This observation pr vides direct
evidence in vivo for dysregulation of neuronal Ca2+ during
Alzheimer"s disease.
An example of the use of FPs in drug discovery comes
from efforts to find small molecules that inhibit the aggrega-
tion of the Alzheimer"s disease peptide Ab into b-amyloid.
When Ab is fused to the N terminus of GFP, the aggregation
Figure 12. Monomeric and tandem dimeric fluorescent proteins derived from Aequorea GFP or Discosoma RFP, expressed in bacteria, and purified.
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over the years on fluorescent proteins by Tsien (2008, Nobel Prize) and others101,104 showed 
promising outcomes in the design of monomeric fluorescent proteins whose emission maxima 
extend over the visible region,105-106 with the most “red” being 648 nm (Figure 1.10).102-103,107 
Currently much of the work on fluorescent proteins is involved in assessing tumor growth108-109 
and metastasis formation.110-111   
1.4.6 Bioluminescence imaging (BLI) 
Bioluminescence is a natural phenomenon that occurs in numerous organisms that are 
widespread in nature.112 Most notably the flashes of light emitted by the male firefly (Photinus 
pyralis) contains a benzothiazole, generally known as firefly luciferin. This luciferin in the 
presence of luciferin enzyme, produces high intensity light at 562 nm, favorable for 
















Figure 1.11 Schematic representation of major BLI applications. Bioluminescence-based 
assays are currently being applied for (A) detection of biological molecules, (B) gene/protein 
expression and intracellular trafficking, and (C) implanted cell distribution and function.112 
in bioluminescence allows detection of extremely low concentrations of analytes, over 
fluorescent techniques, however, lacks the ability to provide absolute quantification of target 
biological molecules, like ATP and calcium; genetic assays involving
regulation and detection; immunoassays; binding assays; and whole-
cell biosensor assays, among others [38, 39].
One of the first applications of both photoproteins and luciferases,
particularly the Ca2+-sensitive forms derived from coelenterates and
jellyfish, was to measure and monitor calcium ions within various bio-
logical systems, mainly single cells [40, 41]. These pioneering studies
provided the basis for the design and development, only few years
later, of novel methods for incorporating the obelin apoprotein and
mRNA isolated from the hydroid, Obelia, into the cytoplasm of intact
human neutrophils. This approach avoided the consumption of Ca2+-
activated photoproteins during cell activation or injury and provided a
means to monitor protein synthesis in living cells [42].
Subsequent bioluminescent analytical applications included quan-
tifications of ATP [43–45] and both the non-reduced and reduced
forms of nicotinamide adenine dinucleotide (NADH) [46, 47]. Taken
together, these investigations provided the basis for the design and
development of a broad repert ire of reactions in the laboratory set-
ting. These included the forensic luminol test (where traces of blood
at cri e scenes could be detected upon contact with the iron in hae-
moglobin) [48], the cell-surface-localized ATP detection assay [49],
and bioluminescent assays for high-throughput screening (Fig. 3A)
[50].
The GFP, together with other fluorescent proteins with a wide col-
our rang of emis ion (from blue to far-red) and versatile biochemical
and photophysical properties, has also revolutionized the applications
of molecular biology [51]. As a result, over 150 different fluorescent
GFP-like proteins have been described in marine organisms (none in
terrestrial organisms) and divided into seven groups according to
their colour and chromophore structure [52].
For example, it was initially recognized that protein labelling was
feasible by producing chimeric proteins fused to GFP [53, 54] This
use has greatly extended our understanding of protein dynamics,
including protein movements and interactions (Fig. 3B). Subse-
quently, advances in gene technology provided inducible reporters
and viral constitutive reporters that were integrated with GFP in fusion
proteins to study intracellular Ca2+ activity, monitor gene expression
and track cells in intact living organisms [55]. For example, a GFP
labelling system was used to validate the hypothesis that human bone
marrow–derived mesenchymal stem cells (MSC) possessed tropism
for brain tumours, and thus, they could be used as vehicles for deliv-
ering glioma therapies [56]. Novel molecular chimeras have been
recently designed, including GFP or monomeric red fluorescent pro-
tein (mRFP) fused with aequorin, or Vibrio fischeri Y1 yellow fluores-
cence protein fused with bacterial luciferase hydroxyflavin. These
chimeric proteins have yielded improved bioluminescent Ca2+ sensors
for detecting intracellular Ca2+ changes in single cells, like neurons,
zebrafish and mice [57–61]. Recently, the colour palette available with
the Aequorea victoria jellyfish photoproteins (blue to yellow) was
expanded to i clude other mon meric fluorescent proteins (orange to
far-red) derived from non-luminous Anthozoa (corals and sea anemo-
nes). In addition, new optical highlighters and F!orster Resonance
Energy Transfer (FRET) biosensors were developed. Thus, with these
tools, we predict that any biological parameter can be investigated
with an appropriate fluorescent protein–based application [62–64].
The harnessing of animals for research has been crucial for
umerous medical advance ents, including the development of
effective treatments and the understanding of mechanisms involved
in human disorders. Experimental procedures for testing regeneration
in animal models typically require accurate characterization of
implanted cell behaviour and functional benefits, including cell distri-
bution, survival and differentiation status. Many existing analysis
techniques are destructive; this necessitates replicating the




Fig. 3 Schematic representations of major
BLI applications. Bioluminescence-based
assays are being currently applied for (A)
detection of biological molecules, (B)
gene/protein expression and intracellular
trafficking, and (C) implanted cell distribu-
tion and function.
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signal.100 These light-emitting molecules have been used in a wide variety of applications, 
including: immunoassays; binding assays; tracking of cells, in particular dividing cells such as 
tumor cells,113,116 immune cells117 and bacterial cells;118 intracellular assays for monitoring 
biological molecules, like ATP and calcium; and genetic assays involving regulation and 
detection, to name a few.112,119  
1.5 Small-molecule fluorescent probes: promising approach for biomolecular imaging 
A complete understanding of a living system requires methods to probe cells and discrete 
bimolecules within their native biological milieu. Small molecule-based fluorescence imaging 
offers a powerful approach to interrogate biological processes at the molecular level in real time 
with high temporal and spatial resolution.120 The widespread use of confocal, two-photon, and 
epifluorescence microscopy and the development of novel fluorescent imaging probes help 
monitor intra- and extracellular biological events with high selectivity and sensitivity.121 The 
challenge is to design probes that can respond to cellular trigger events in a complex biological 
mixture by utilizing differences in chemical reactivity and levels of overexpression of the target 
analyte.  
1.5.1 Properties of fluorescent probes 
The natural product quinine is believed to be the first reported fluorophore,122 dating back 
to the late 19th century.123 The invention and later commercialization of the fluorometer in the  
1950s led to a huge outburst in fluorescence based bioanalytical techniques, where much of the 
attention has been directed toward the development of novel or improved fluorescent molecules 
with desirable properties for applications in biological environments.124 To date, a vast collection 
of biologically significant small-molecule-based fluorescent probes have been constructed, with 
a set of core scaffolds, mainly spanning the visible region of the electromagnetic spectrum 
(Figure 1.12).123 
The use of fluorescence-based probes for biomaging applications must meet stringent 
requirements.121 For these probes to be successful in biological environments, they should 























Figure 1.12 Plot of fluorophore brightness (ε x Φ) vs the wavelength of maximum absorption 
(λabs) for the major classes of fluorophores. The color of the structure indicates its wavelength of 
maximum emission (λem). For clarity, only the fluorophore moiety of some molecules is 
shown.123 
content and large excess of reactive nucleophilic thiols such as glutathione and cysteine.121 Also, 
it is critical these probes work independently without interacting with endogenous cellular 
processes, and not to produce any toxic byproducts to living systems.121 In addition, the desired 
chemical and photophysical properties of the fluorophores includes: hydrolytic stability; 
lipophilicity in the context of membrane permebility; water solubility; cellular retention; and 
high optical brightness (ε x Φ), which accounts for the efficiency of both light absorption (λabs) 
and the emission (λem) of a particular fluorophore.121 Also, it is preferable to have the excitation  
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and emission profiles in the visible or near-infrared regions, or be amenable to two-photon 
excitation.121 
1.5.2 Modulation of fluorescence 
An important aspect in biomolecular imaging is attainment of a high quality optical 
signal from the target of interest in contrast to the background and other interfering species. 
Modulation of fluorescence mainly through photo-induced electron Transfer (PeT),8,125-126 
Förster resonance energy transfer (FRET),127 and internal charge transfer (ICT)128-132 processes 
help achieve this desired success.133-134 Also, intramolecular cyclization is another rational and 
important strategy to modulate fluorescent properties, especially in xanthene fluorophores such 
as fluorescein and rhodamines.135 In general, these photophysical and chemical mechanisms 
provide fluorescent probes with the ability to show a turn-on or emission increase, or a shift in 
excitation/emission profiles, so as to provide the necessary optical contrast from the background. 
The large number of small-molecule fluorescent probes constructed by these modulating routes 
can be broadly classified into two types: intensity-based and ratiometric probes.120,136 A major 
limitation in intensity-based probes is the inability to account for variabilities in excitation and 
emission efficiency, probe environment, and probe distribution events that are important for 
quantification of the measured fluorescence intensity.130 In contrast, ratiometric imaging is based 
on the measurement of fluorescence emission/excitation intensities at two different wavelengths, 
which allows internal calibration of reacted and unreacted probe to minimize artifacts that may 
arise from environmental factors, therby providing quantitative fluorescence measurements.120  
In general, ICT and FRET are the two most commonly exploited fluorescence modulation 
techniques used in the design of ratiometric fluorescent probes, while PeT and spirocyclization 
mechanisms are used widely in intensity-based probe strategies.  
1.5.2.1    Internal charge transfer (ICT) 
Fluorophores with electron-donating (often an amino group) group conjugated to an 
electron-withdrawing group show very different dipole moments in the ground state and lowest 
energy singlet excited states.137 This difference in dipole moments gives rise to the push-pull 
nature of these fluorophores undergoing ICT from the donor to the acceptor upon excitation of 
light.137-139 Based on the alteration of the asscoiated electronic properties, amine-substituted 
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naphthalimide scaffolds have been widely used in ICT-based fluorophore design strategies, due 
to their change in excitaiton/emission profiles. Some recent examples of ICT-based probe 
development includes, Cu2+ and Hg2+ sensing in aqueous media,140-141 nitoreductase142 and 
hydrogen peroxide130 detection in biological media, mitochondrial hydrogn sulfide imaging,143 
and cancer cell imaging.8,126  
1.5.2.2    Förster resonance energy transfer (FRET) 
FRET is a distance-dependent interaction between the electronically excited states of two 
fluorophores, in which excitation energy is transferred from a donor to an acceptor through long 












Figure 1.13 a) Schematic of the FRET process, and b) Ratiometric fluorescent probes based 
on analyte-induced cleavage of FRET dyads.120 
require the donor emission spectrum to have a favorable overlap with the acceptor absorption 
spectrum, and the highest ocuupied molecular orbital (HOMO) and the lowest unoccupied 
molecular orbital (LUMO) energy levels of the acceptor should be located within those of the 
donor to avoid quenching of the acceptor fluorescence.144 The typical design strategy of FRET 
probes is depicted in Figure 1.13 (b), where in the absence of an analyte, the probe shows the 
emission of the acceptor upon excitation at the donor due to FRET. But in the presence of the 
analyte, FRET is turned off due to the separation of the donor and the acceptor, giving rise to the 
emission of the donor instead of the acceptor. Long et al. synthesized a FRET-based thiol probe 
with a bodipy donor and a rhodamine acceptor to detect free thiols in bological fluids.145 Yuan et 
a) b) 
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al  used the same donor-acceptor dye pair as Long et al, but with a different linker chemistry, and 
they were able to achieve unprecedented selectivity toward aminothiols.146 In different work, 
Yuan and coworkers showed ratiometric imaging of endogenously produced nitric oxide using a 
coumarin-rhodamine donor-acceptor pair.147 However, in this work FRET was achieved through 
a spirocyclic ring opening of the rhodamine dye instead of the commonly employed bond 
breakage for the separation of the donor-acceptor pair.  
1.5.2.3    Photo-induced electron transfer (PeT) 
Intensity-based probes commonly use PeT quenching to control their fluorescent 
properties with regard to analyte detection. In general, a charge transfer complex is formed 
between an electron donor and an electron acceptor, which then returns to the ground state 
without emission of a photon; this is basis for the PeT quenching of the probe. Unlike in 
resonance energy transfer (RET) where a fluorophore is always a donor, the excited fluorophore 
in PeT can be either an electron donor or acceptor. In addition, the direction of the electron 
transfer in the excited state is goverened by the oxidation and reduction potential of the ground 
and excited states of the fluorphore/quencher.39 Thus, the possibility of this electron transfer can 
be predicted from the redox potentials of the fluorophore and the quencher, making PeT a 
favorable choice in designing fluorescence-based probes. Miura et al. reported the first definitive 
evidence of PeT in fluorescein–based probes, to attain efficient fluorescence on/off switching by 
electron transfer from the benzene moiety to the xanthene group, which they termed as acceptor-








Figure 1.14 a) Fluorescein, divided into two parts, composed of the benzene moeity and 
xanthene moeity, and b) rational design strategy for developing novel fluorescent probes based 
on photo-induced electron transfer (PeT); a-PeT and d-PeT refers to acceptor/donor-excited 
PeT–based quenching.134-135  
Optical imaging of tumor sites with rationally
designed ‘activatable’ fluorescence probes
The ability of the unaided human eye to detect small
cancer foci or accurate borders between cancer and nor-
mal tissue during surgery or endoscopy is limited. There-
fore, it is a long-term goal of cancer diagnosis to develop
tumor-imaging techniques that have sufficient specificity
and sensitivity. To achieve this goal, minimizing the
background signal originating from non-target tissues is
critical.
Optical fluorescence molecular imaging has been inves-
tigated as an aid to optically guided surgery and endo-
scopy because of its high sensitivity, low cost, portability,
real-time capabilities, and, importantly, absence of ioniz-
ing radiation. There are two major categories of fluor-
escent probes that have been employed in this setting:
‘always on’ and ‘activatable’. Like other imaging probes
based on other modalities such as PET and MRI, ‘always
on’ fluorescent probes have the disadvantage of high
background signal, which requires considerable time to
clear in order to achieve adequate target to background
ratios (TBRs) (Figure 2a). On the contrary, ‘activatable’
probes themselves have lower background signals, but are
activated upon recognizing cancer specific environments,
hence high TBR imaging of tumor sites can be realized
without washout of probes (Figure 2b). So far, we have
developed several molecular imaging techniques which
enabled highly specific in vivo cancer visualization by
employing a newly designed targeted ‘activatable’ fluor-
escent imaging probe.
Selective molecular imaging of viable cancer
cells with pH-activatable fluorescence probes
Recently, we achieved highly specific in vivo cancer
visualization by employing a newly designed targeted
activatable fluorescent imaging probe. In brief, novel
acidic pH-activatable probes based on the BODIPY
fluorophore were developed using our PeT-based rational
design strategies (Figure 3a, Table 1), and conjugated
them to a cancer-targeting monoclonal antibody. This
agent is activated after endocytotic internalization by
sensing the pH change in the lysosome (Figure 3b). As
proof of concept, ex and in vivo imaging of HER2-positive
lung cancer cells in mice were performed. The probe was
highly specific for tumors with minimal background signal
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Rational design str tegies for developing novel fluorescenc  probes based n photoinduced electron transfer (PeT)-based quenching. (a) Many visible
light-excitable fluorescent molecules can be conceptually divided into two moieties, a fluorophore and an electron donor moiety. (b) Relationships
between the quantum yield of fluorescence and the HOMO energy level of benzoic acid moiety of various fluorescein derivatives. (c) Rational design
strategy for developing novel fluorescence probes. Novel probes could be rationally designed by using specific chemical reactions to target analytes
which meet the criteria that the initial substrate has high HOMO energy and the product has lowered one.
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transfer from the excited fluorophore to the benzene moiety
(donor-excited PeT; d-PeT), i.e., the opposite direction to a-PeT
(Figure 1A). These findings have allowed us to construct another
widely applicable strategy for rational design of a novel class
of functional fluorescence probes. The validity of this approach
was confirmed by applying it to develop a novel fluorescence
probe for reactive peroxometal species with an unique pattern
of sensitivity.
Results and Discussion
Fluorescence Quenching by the Electron-Deficient Ben-
zene Moiety.We recently designed and synthesized dicarboxy-
fluorescein (1a) and its trimethyl ester derivative (1b) mainly
in order to obtain probes with improbed water solubility. Owing
to the presence of electron-withdrawing groups, the electron
densities of the benzene moieties were lowered. According to
our previous studies,8,9 the oxidation potential of the benzene
moiety is the most important factor determining the !fl value
of fluorescein. Therefore, we considered that 1a and 1b should
be highly fluorescent (Figure 2). As anticipated, 1a was highly
fluorescent (!fl ) 0.817), but unexpectedly, the fluorescence
of 1b was significantly quenched (!fl ) 0.001). A similar
phenomenon was also observed in the 6-carboxyfluorescein
derivative (2a, 2c). From the viewpoint of a-PeT, there are some
apparent contradictions in these results.
To understand the mechanism underlying the fluorescence
quenching further, we focused particularly on the reduction
Figure 1. (A) Fluorescein (5a) was divided into two parts, the benzene moiety and xanthene moiety. (B) Schematic molecular orbital diagram of the
fluorescence off/on switch including the PeT process.
Figure 2. Structures and fluorescence properties of carboxyfluorescein
derivatives (1a, 1b, 2a, 2c) measured in phosphate buffer pH 9.
Figure 3. Electrochemical properties of the benzene moiety of carboxy-
fluorescein derivatives (1b, 2c) in aqueous media (V vs SCE).
A R T I C L E S Ueno et al.
14080 J. AM. CHEM. SOC. 9 VOL. 126, NO. 43, 2004
a) b) 
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Later, Ueono et al. used the same fluorescein scaffold to demonstrate PeT through 
electron transfer in the opposite direction, namely from the excited xanthene fluorophore to the 
benzene moiety (donor-excited PeT; d-PeT) to develop probes for the detection of reactive 
oxygen species (ROS).134  
1.6 Applications of small-molecule fluorescent probes 
A plethora of biological imaging applications have used small-molecule fluorescent 
probes as biomolecule labels, enzyme substrates, environmental indicators, and cellular stains, to 

















Figure 1.15 Biological applications of small-molecule fluorophores. A) Site-specific labeling 
of a biomolecule by an orthogonal reaction between two functional groups (red). B) Enzyme 
substrates: (i) enzyme-catalyzed removal of a blocking group (red) elicits a change in 
fluorescence; and (ii) enzyme catalyzes the cleavage of a labeled biomolecule (red) with 
concomitant decrease in FRET. C) Environmental indicators: (i) binding of an analyte (red) 
elicits a change in fluorescence; (ii) protonation of a fluorophore elicits a change in fluorescence. 





1.6.1 Small-molecule-based fluorescent probes used in identification of disease biomarkers 
Reactive–oxygen and nitrogen species (ROS and RNS, respectively) are essential 
elements that serve as signalling species that deliver messages to cellular compartments in 
response to physiological variations; they assist in maintaining normal organ activities.149 
Alteration in ROS and RNS levels are associated with many human health conditions, including 
neurological diseases, artherosclerosis, cancer, and diabetic complications.150 Thus, it is  
important to identify variations of these reliable biomarkers for early identification of disease 
development that may follow.150  
Much work has been done to identify cellular variations in ROS due to singlet oxygen 
(1O2), hydrogen peroxide (H2O2), and hypochlorus acid (HOCl) as well as RNS associated with 
nitric oxide (NO), and peroxynitrite (ONOO-) through small-molecule fluorescent probes with 
high sensitivity and selectivity.121 Chang and coworkers pioneered the hydrogen peroxide-
mediated conversion of arylboronates to phenols for H2O2 detection. Peroxyfluor-1 (PF1), is the 
first fluorescence probe for selective imaging of H2O2 in biological systems, based on a 
xanthenone scaffold they developed.151 Chang and others further explored the boron deprotection 
trigger strategy to develop ratiometric,130 targetable,152-153 trappable,154-155 and in vivo probes156 
that covered the fluorophore emission range from the visible to the near-infrared region.151,157-161 
In addition to the boronate trigger strategy, Nagano and co workers used dicarbonyl cleavage 
reactions to develop the d-PeT modulated fluorescein probe, NBzF, to visualize endogenous 
H2O2 production in macrophages and cancer cells.162 Libby’s group163 and Nagano’s group164 
reported fluorescein- and rhodamine-based fluorescent probes for detection of HClO, while Yang 
and coworkers used a simple and water-soluble p-methoxyphenol derivative to achieve 
colorimetric and fluorometric detection of HOCl in aqueous systems.165 
Nagano and coworkers were the first to use fluorescence based, diaminofluorescein 
(DAF), to assay NO production in living cells.166 This was followed by the development NO 
imaging probes with diaminorhodamines (DARs)167 and diamino probes on Bodipy168 and 
cyanine169 scaffolds. Yang et al. developed HKgreen-1 probe that releases the highly fluorescent 
dichlorofluorescein (DCF) reporter in the presence of peroxynitrite.170 In addition, Sun171 and 
Peng172 used BODIPY- and rhodol-based probes, to image peroxynitrite in living cells.  
Perturbation of cellular thiol homeostasis can reveal insights into several disease 
conditions. Thus, monitoring cellular bio-thiol levels—mainly glutathione (GSH), cysteine 
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(Cys), homocysteine (Hcy), and hydrogen sulfide (H2S)—provides valuable information on 
cellular oxidative stress levels associated with these diseases. A commonly deployed strategy in 
H2S imaging involves the H2S-mediated reductive cleavage of azides to amines.121 Based on this 
azide reduction strategy, the Chang lab developed two Sulfidefluor SF1 and SF2 probes,173 Yu et 
al. reported a ICT-based cyanine,174 and Montoya et al. reported a napthalimide dye175 as H2S 
probes. Both Maeda et al.176 and Wang’s laboratory177 employed the thiol reactivity toward the 
2,4-dinitrobenzenesulfonyl functionality to develop probes for monitoring a wide range of 
biologically relevant thiols.  
Metal ions play important role in all life forms and are responsible for osmotic regulation, 
catalysis, metabolism, and signaling.127 Metals that play a critical role in biology include, the 
highly abundant sodium, potassium, calcium, and magnesium, as well as transition metals 
including iron, zinc, copper, manganese, cobalt, and nickel that are found in trace amounts.127 
Cells tightly regulate these metal pools, as mismanagement can result in several disease 
conditions.178-179 Fluorescent probes help track labile biological metal ion pools to help assess the 
contribution and significance of these metals to healthy and disease states. Chang and coworkers 
developed a BODIPY-based fluorophore CS1,180 and Taki and coworkers made FluTPA2,181 
based on xanthenone scaffold for sensitive detection of ionic copper pools in living cells. Petrat 
et al. used a fluorescein-based Phen Green SK to study labile iron pool in cultured 
hepatocytes.182 Hariyama et al. developed the first Fe2+-selective probe, RhoNox-1, which is 
based on a rhodamine scaffold.183 Many Zn2+ probes have been developed using various 
fluorescent scaffolds, including BODIPY derivatives,184 rhodamine,185-186 coumarin,187 and 
tricarbocyanine.188  
1.7 Small-molecule probes for cancer imaging 
Application of small-molecule-based fluorescence imaging has branched into many areas 
in the biological field, out of which, their involvement in cancer imaging has grown to great 
heights. From early detection and diagnosis tumor sites to surgical removal of diseased tissues, 
small-molecule based fluorescent probes provide great benefits in cancer therapy and 
management. Currently at its developmental stage, fluorescent probes help shine new light on 
tumors thereby improving surgical molecular navigation, to cause a paradigm shift in cancer 
surgery.5  Even with advancement of endoscopic, laproscopic and robotic technologies, surgery 
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in the present day is still largely based on anatomy, traditionally seen by white-light 
illumination.4-5,9 Thus, visual navigation through the surgical field is challenging, as most of the 
tissues in the body appear as various shades of white to pink (nerves, cartilage, muscle, 
connective tissue) or red to deep-red (blood vessels), thereby limiting the accurate identification 
of surgical margins between healthy and diseased tissues.5  
In this regard, fluorescent probes aids in visual enhancement of the surgical field, which 
helps provide better surgical outcomes in comparison to traditional white-light reflectance, 
yielding improved patient outcomes, and decreased operating time and cost.5 Currently, the only 
FDA approved fluorescent probes used to assist intra-oprative resection are indocyanine green 
(ICG)2,189-190 and fluorescein sodium.191 ICG has been used clinically for over 50 years in 
evaluation of liver blood flow, cardiac output, and opthalmic angiography.2 It has a favorable 
uptake in tumor sites, but has a strong biniding tendency to albumin. This albumin binding alters 
the ICG spectra and decreases the quantum yield efficiency from approximately 15% in 
deionized water to 5% in blood.5,192 
1.7.1 Probe design strategies: targeted vs activated 
 The need is great to develop a diverse set of fluorescent probes for in vivo use in cancer 
therapy, in particular fluorescence-guided surgery (FGS).5 Apart from toxicity issues, a major 
impediment in fluorescent probe development is achievement of high signal-to-background ratio 
(SBR) values,32,193 which in the case of FGS is the tumor-to-background ratio (TBR).32,193 
Although cure is the main concern in cancer surgery, preservation of important body 
components, such as blood vessels, and nerves, is considered equally important in achieving 
optimal patient outcome. Thus, the challenge in FGS is to identify positive margins; defined as 
tumor cells being present at the cut edge of the surgical specimen, with high precision and 
accuracy for better prognosis and to help prevent recurrence.5  
The development of fluorescent probes possessing mechanisms capable of overcoming 
the background caused by nonspecific signal or nearby normal cells/tissues could help achieve 
this success. This is possible by either 1) maximizing signal from the target, 2) minimizing signal 
from the background, or 3) doing both.46,194 Inclusion of the above factors in the design process 
has the potential to lead to the development of superior fluorescent probes with high sensitivity, 
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specificity, and TBR values for fluorescence-guided surgical resection of cancerous tissues with 
high figures of merit.  
 Much attention is being paid toward two possible approaches that could help achieve 
high TBRs in fluorescence-guided surgery, 1) targeted “always-on” probes, and 2) activatable 























Figure 1.16 (a) Existing strategies for tumor imaging with MRI, PET, or non-activatable 
‘always on’ fluorescence detection. (b) Novel strategy for selective tumor imaging with 
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Current Opinion in Chemical Biology
(a) Existing strategies for tumor imaging with MRI, PET or non-activatable ‘always on’ fluorescence detection. (b) Novel strategy for selective tumor
imaging with activatable fluorescence probes.
Table 1
Representative rationally designed fluorescence probes based on intramolecular photoinduced electron transfer and spirocycliation




Key reaction with target
molecule
Mechanism Ex/Em (nm) Note Ref.
Singlet oxygen DMAX Fluorescein Endoperoxide formation a-PeTc 492/515 [3]
Nitric oxide DAF Fluorescein Benzotriazole formation a-PeTc 486/513 [4]
DAMBO BODIPY Benzotriazole formation a-PeTc 519/535 pH independency
High sensitivity
[5]
DCl-DACal Calcein Benzotriazole formation a-PeTc 509/531 Cellular retention [6]
hROSa HPF/APF Fluorescein ipso-Substitution a-PeTc 490/515 [7]
HPC/APC Calcein ipso-substitution a-PeTc 494/516 Cellular retention [6]
Peroxynitrite NiSPY BODIPY Nitration a-PeTc/d-PeTd 505/518 pH independency [8]
GSTb DNAT-Me TokyoGreen Substitution of NO2 group d-PeT
d 490/514 [9]
b-Galactosidase TG-bGal TokyoGreen Hydrolysis of b-gal moiety a-PeTc 490/510 [10!]
HMDER-bGal Rhodol Hydrolysis of b-gal moiety Spirocyclization 525/543 Cellular retention [17!]




MMSiR Si-Rhodamine S-Oxygenation Spirocyclization 652/670 pH independency
Near infrared
[16]
Acidic pH DiEtN-BDP BODIPY Protonation to anilines a-PeTc 521/534 Cancer detection [18!!]
g-Glutamyl
transpeptidase
gGlu-HMRG Rhodamine Hydrolysis of glutamyl
moiety
Spirocyclization 501/524 Rapid cancer detection [20!!]
a Highly reactive oxygen species.
b Glutathione S-transferase.
c Acceptor-excited photoinduced electron transfer.
d Donor-excited photoinduced electron transfer.
Current Opinion in Chemical Biology 2012, 16:602–608 www.sciencedirect.com
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conjugated to a tumor-specific targeting moiety that directs the probe into tumor sites away from 
the normal healthy tissues. These types of probes are commonly internalized by cancer cells via 
receptor-mediated endocytosis that helps retain the always on probe inside the cell, thereby 
preventing “bleeding” of fluorescence from diseased cells to normal tissues.195 Because probe 
fluorescence is always on, adequate time has to be allowed for probe clearance from the body 
before imaging, which is necessary to obtain useful TBRs. Furthermore, the always-on probes 
have minimal capability of imaging tumors in kidney, bladder and liver that are along the 
excretory pathway, due to high background fluorescence.195 In contrast, activatable probes 
exhibit minimal fluorescence when they are bound to a quencher, but generate light only upon 
release of the quencher in the malignant tissue, thereby resulting in higher tumor-to-background 
ratios than conventional ‘always-on’ probes. Moreover, unlike ‘always on’ probes there is no 
need to wait for clearance of the probe from the body, but only the need to wait for their 
activation.194  
1.7.2 Enzyme activatable small-molecule-based fluorescent probes 
Enzymes are crucial in catalyzing a variety of biochemical processes that help regulate 
health, and often times disease leads to their deregulation and vice versa. Therefore, the ability to 
track changes in enzyme expression levels provides a good path for disease monitoring. As 
described earlier, enzyme-activatable probes, have opened up a new window for the researcher 
and clinician to follow enzymatic activity in real-time and with greater sensitivity. A common 
strategy in the design of activatable profluorophores involves the incorporation of a peptide 
sequence between the quencher and the fluorohore that can be specifically cleaved by a tumor-
enriched protease, such as cathepsins, caspases, and matrix metalloproteinases.196-201 Other 
commonly studied enzyme targets in fluorescent probe development include γ-
glutamyltranspeptidase (GGT),202-203 aminopeptidase,204 phosphatase,136,205-206 β-
galactosidase,207-208 Hyaluronidase (HAse),209 cytochrome P450,210 β-glucoronidase,211 γ-
glutamylcyclotransferase,212 glutamate carboxypeptidase (PSMA),213 and N-acetyltransferase 
2.214  
As discussed earlier, optical-based cancer imaging will benefit from having high TBRs,  
a possibility with activatable probes, but enzyme activation steps can suffer from being slow 
often being on the hours to days time frame, which decreases their applicability in routine or 
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real-time clinical use.135 Urano and coworkers developed a rhodamine-based probe, gGlu-
HMRG, and demostrated real-time imaging of γ-glutamyltranspeptidase (GGT) enzymatic 
activity associated with human cancer cells. In the presence of membrane bound GGT, the gGlu-
HMRG probe displayed fast activation (within minutes).203 Also, they showed for the first time 
the use of enzyme-activatable probes in topical use by their being spray on GGT-expressing 
tissue surfaces.203 Recently the Hasserodt laboratory reported a novel strategy in activatable 
probe design, where probe activation was achieved through two consecutive enzyme activation 
steps by β-galactosidase and leucine aminopeptidase.215 This type of “dual gating” probe design 
provides highly selective disease recognition when overexpression of one enzyme could be 
characteristic of more than just one disease condition.215 Another less exploited route in the 
design of smart probes involves the incorporation of a trigger/quencher group that is activated 
only in the presence of an overexpressed tumor-associated reductive enzyme (i.e., NAD(P)H: 
quinone oxidoreductase-1).126,216 
1.8 NAD(P)H: quinone oxidoreductase-1 (NQO1)  
In the late 1950s, Earnster and Navazio first isolated from rat liver homogenates and 
characterized the first member of the NQO family, which was later named NQO1 (EC 1.6.99.2); 
DT-diaphorase. The isolation of vitamin K reductase by Martius and coworkers demonstrated its 
structural similarity to NQO1. The NQO gene family has four genetic loci known as NQO1, 
NQO2, NQO3, and NQO4; vertebrates carry the genes for NQO1 and NQO2, a homologous 
NQO3 subfamily is found in eubacteria, and NQO4 subfamily is present in fungi.218 The Amzel 
lab first reported the crystal structure of rat liver NQO1 (Figure 1.17),217 and his group later 
reported the structure of the complex of human NQO1 with duraquinone (DQ), a NQO1 
substrate.219 
 From these structures it was termined that NQO1 is a homodimer of two interlocked 
monomers with a molecular weight of a 60 kDa. Each monomer contains a non-covalently bound 
molecule of flavin adenine dinucleotide (FAD) and has two separate domains: a catalytic domain 
and a smaller C-terminal domain. The catalytic site has three distinct regions; 1) an FAD binding 











Figure 1.17 X-ray crystal structure of human NQO1 dimer (PDB accession code 1d4a). The 
non-covalently bound FAD is shown at both sites.217 
NAD(P)H, and 3) an empty substrate (donor/acceptor) binding site, occupied by the hydride 
donor (NADH or NAD(P)H), or the hydride acceptor substrate.  
1.8.1 Mechanism of NQO1 action on quinones 
 The unique property of NQO1 is its ability to transfer two electrons to a quinone, using 
NAD(P)H as electron donors. The result is a two-electron reduced hydroquinone, in contrast to 
the generation of one-electron reduced highly reactive semiquinone radical, which is formed 
through enzymes such as NADH:cytochrome b reductase, NADPH:cytochrome P450 reductase 











Figure 1.18 a) Quinone reduction pathway by CYP450 and DT-diaphorase.222 b) Ping-pong, 
bi-bi mechanism of NQO1.221 
Fig. 3 Naturally occurring quinones with anticancer properties.
the reduction of quinones, quinone epoxides, aromatic nitro and
nitroso compounds, azo dyes and Cr(VI) compounds. It is closely
related to another flavoenzyme, NRH quinone oxidoreductase 2
(NQO2) that also catalyzes the reductive metabolism of quinones,
although NQO2 is not discussed in detail here.16
NQO1 has long been regarded as a chemoprotective enzyme
catalyzing the reduction and detoxification of exogenous quinones,
although paradoxically, as we have already seen, it is also involved
in the bioactivation of molecules such as MMC into toxic
DNA-damaging agents. It also participates in the metabolism of
endogenous quinones such as ubiquinone, and may be involved in
scavenging superoxide in cells. The enzyme is upregulated in many
tumours, and the recent discovery that it might be involved in
the stabilization of tumour suppressor protein p53 has heightened
interest. Hence the last decade has seen increased focus on this
quinone reductase, discovered 50 years ago, and the enzyme has
been the subject of a number of recent reviews,17–20 including
special issues of Free Radical Biology and Medicine (2000, 29,
201–383) in commemoration of Ernster’s original discovery, and of
Methods in Enzymology (2004, 382, 3–572). Notwithstanding these
excellent review articles, the key features of the enzyme NQO1 are
reiterated herein, although very much from an organic chemist’s
standpoint.
Structure and mechanism
NQO1 has a molecular weight of about 60 kDa, and is a
homo-dimer of two interlocked monomers of 274 amino acids.
Each subunit contains a non-covalently bound molecule of flavin
adenine dinucleotide (FAD), and consists of two domains—
a catalytic domain (residues 1–220) and a smaller C-terminal
domain that forms part of the binding site for the hydrophilic
regions of NAD(P)H.21,22 The fold of the catalytic domain is similar
to that found in other flavoproteins. The structu of the hum n
protein has been solved by X-ray crystallography (Fig. 4).23,24 The
structures of the mouse (86% sequence identity to human) and rat
Fig. 4 X-Ray crystal structure of human NQO1 dimer (PDB accession
code 1d4a). The non-covalently bound FAD is shown at both sites.24
(also 86% sequence identity to human; 94% sequence identity to
mouse) enzymes have also been solved.24,25
The active site of human NQO1 (hNQO1) is located at the
interface of the two monomer units, and is a flexible 360 Å3
pocket lined with aromatic residues. The catalytic site has three
regions: (i) the FAD binding site, (ii) a site near the C-terminus
where the hydrophilic adenine–ribose portion of NAD(P)H binds,
and (iii) the site occupied by the cofactor, the hydride donor
(NADH or NAD(P)H), or the substrate, the hydride acceptor.
The FAD prosthetic group is non-covalently, tightly bound and
does not come off the enzyme readily under native conditions.
The isoalloxazine moiety has extensive contact with the protein;
the hydrophilic rings of the isoalloxazine make hydrogen bonding
interactions with main chain NH groups and side chain hydroxyls
of Thr and Tyr which anchor this side of the flavin in place.
The hydrophobic dimethylbenzene ring of the FAD has the
methyl groups in a hydrophobic pocket, composed of the aliphatic
residues of the second monomer. The ribitol, phosphates and
adenine ring of FAD interact non-covalently with several loops
and helices, anchoring the FAD cofactor to the enzyme. The
structure of the active site containing the bound FAD is shown in
Fig. 5A.
Information on the binding of the cofactor (NADH or
NADPH) comes from the structure of the rat enzyme with bound
NADP+.25 NADP+ has fewer specific interactions with the protein
than does FAD. The nicotinamide ring is in van der Waals contact
with the FAD and with the side chains of aromatic residues, and the
carboxamide makes hydrogen bonds to two tyrosine residues. As
already mentioned, the AMP part of the cofactor interacts mainly
with the C-terminal domain. The binding of substrates to hNQO1
was initially studied with duroquinone (2,3,5,6-tetramethyl-1,4-
benzoquinone).24 The quinone is bound to the active site through
a series of contacts involving the flavin and several hydrophobic
and hydrophilic residues. The substrate is sandwiched between the
five aromatic residues and the central portion of the isoalloxazine
ring of FAD (Fig. 5B). The substrate binding site is highly flexible
and can accommodate a wide range of quinone substrates (q.v.).
The fact that the cofactor and substrate occupy the same site is
consistent with the “ping-pong” mechanism of the enzyme that is
shared with other flavoproteins. In this mechanism, illustrated in
Schemes 1 and 2, NAD(P)H occupies the binding site and transfers

















































Fig. 5 Active site of hNQO1 showing (A) the apo enzyme with the
bound FAD (PDB accession code 1d4a), and (B) the bound substrate
duroquinone (shown in cyan) with the substrate quinone ring stacked
above the isoalloxazine of the FAD (most of the surrounding residues
omitted) (PDB accession code 1dxo).24
its hydride to FAD, the resulting NAD(P)+ leaves the site to be
replaced by the qui o e substrate. Hydride transfer from FADH
esults in reduction of the quin ne, and finally the hydroquinone
departs to restart the catalytic cycle (Scheme 1). The details of the
hydride tra sfer steps re shown in Scheme 2.
Scheme 1 Ping-pong mechanism of NQO1.
There is a high level of conservation between NQO1 and
NQO2, but the NQO2 protein is 43 amino acids shorter. The
overall structures of the enzymes are similar, although NQO2
lacks the C-terminal of hNQO1. Both enzymes bind FAD in
similar ways but NQO2 fails in the binding of NAD(P)H due
to the loss of the C-terminus. Hence NQO2 uniquely uses
dihydronicotinamide riboside (NRH) as a hydride donor as
opposed to NAD(P)H. Nevertheless, in the presence of NRH,
NQO2 is able to catalyze the two-electron reduction of quinones.
Unsurprisingly, due to differences in the protein structure—
the active site of NQO2 is shorter and narrower than that for
NQO1, and therefore suitable substrates have to be relatively
short molecules with flat conformations—the two enzymes have a
different substrate profile. NQO2 is of particular topical interest
with respect to the bioactivation of prodrug CB1954 [5-(aziridin-
1-yl)-2,4-dinitrobenzamide] into a bifunctional alkylating agent.
NQO2, in the presence of the non-biogenic cofactor NRH, can
perform the four-electron reduction of the 4-nitro group in CB1954
some 3000 times more efficiently than hNQO1. The role of NQO2
in bioreduction processes has been covered in recent reviews,26–28
and is not discussed further here.
Physiological role of NQO1
Although originally thought to be involved in mitochondrial
electron transport,15 NQO1 was subsequently shown not to be
a component of the respiratory chain. Likewise, its purported role
in vitamin K1 metabolism was discounted when it was discovered
that the naphthoquinone-based vitamin 3 was not a substrate for
purified rat NQO1. However, the related quinones ubiquinones 1
(Fig. 1) and vitamin E quinone 16 (a-tocopherolquinone) (Fig. 8)
are reduced by the rat enzyme, suggesting a role for NQO1 as
an antioxidant enzyme.20,29 NQO1 is also a phase II detoxifying
enzyme, and protects cells from the damaging effects of reactive
species formed upon metabolism of exogenous quinones.30,31 On
the other hand, NQO1 is also involved in the bioactivation of
anti-tumour quinones such as MMC into cytotoxic species, i.e.
it is also functioning as a toxification enzyme, prompting its
classification as a double-edged sword.29 More recent studies
have suggested that NQO1 can stabilize the tumour suppressor
protein p53 either by inhibiting its degradation, or by a direct
protein–protein interaction.29,32 Finally, it is noted that there are
two well-characterized polymorphisms in NQO1—NQO1*2 and
NQO1*3—both the result of single nucleotide changes. The more
prevalent NQO1*2 polymorphism, the occurrence of which varies
according to ethnic groups with frequencies of up to 22% in
some Asian populations, results in lack of reductase activity. One
possible consequence is that lack of NQO1 activity might increase
the risk of certain types of toxicity. For example, individuals with
the NQO1*2 allele are more susceptible to the toxic effects of
benzene metabolites.33,34
Upregulation and induction of NQO1
NQO1 is expressed at high levels in many solid tumours, and its
presence is readily detected by immunohistochemical staining.35
An example illustrating NQO1 staining in human pancreatic
cancer cells is shown in Fig. 6A. The upregulation or over
expression of the enzyme in tumours compared to surrounding

















































Quinone-containing prodrugs of cytotoxic agents are designed to b selectively activ ted either
by the hypoxic environment of tumor cells or by the two-electron reducing enzyme DT-diaphorase.
Prodrugs that are good substrates of DT-diaphorase will be more cytotoxic under normoxic
conditions but with lower hypoxia selectivity while prodrugs that are good substrates of a one-
electron reductase but poor substrates of DT-diaphorase usually possess good hypoxia selectivity.
It has also been shown that hypoxia selectivity of quinone-containing prodrugs is very sensitive to
structure modification; slight changes on quinone core structure could result in substantial reduction
in hypoxia selectivity.
1. Quinones as Part of Active Drugs
Mitomycin C (MMC, 1) is the earliest clinically used quinone-containing drug recognized as a
bioreductive and hypoxia-selective alkylating agent.30 As the prototype agent in this group, the
mechanism of action of mitomycin C has been extensively investigated and is believed to involve
bioreductive activation as shown in Scheme 2. MMC and its analogues produce their cytotoxicity
through reductive metabolism followed by well-defined fragmentation to bifunctional alkylating
species that crosslink DNA via guanine–guanine in the major groove.31 However this first hypoxia-
targeting prodrug only shows marginal hypoxia selectivity while its N-methyl analogue porfiromycin
(2) shows higher selectivity and has been clinically evaluated as a hypoxia-selective prodrug.32
In addition to reduction by CYP450 reductases, MMC and its analogues are also substrates of
DT-diaphorase33,34 which is widely overexpressed in many types of tumor cells. EO9 (3) and AZQ (4)
are another two principal aziridinylquinones, analogues of MMC developed as hypoxia selective
agents. They are simplified analogues with aziridine attached directly to benzoquinone or indo-
lequinone ring. These two types of quinone compounds were shown to be potent alkylating agents
upon reduction to the corresponding aziridinyl hydroquinone, which effectively increases the pKa of
the aziridine nitrogen for protonation and activation toward nucleophilic attack at physiological
pH values.35
Scheme 1. Quinone reductionpathwayby CYP450sandDT-diaphorase.29
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The catalytic activity of NQO1 follows a ‘ping-pong bi-bi’ mechanism, due to the 
occupancy of the catalytic active site by both cofactor and substrate. In this mechanism, 
NAD(P)H first occupies the active site and transfers its hydride to the N5 of the FAD, and then 
the resulting oxidized cofactor leaves the site to be replaced by quinone substrate. Hydride 
transfer from FADH results in the reduction of the quinone to a hydroquinone, which then 
departs so as to resume the catalytic cycle (Figure 1.18 (b)).   
Further, as depicted in Scheme 1.1, the overall reduction process involves the His 161 
and Tyr 155 residues in the active site. Also, in the final stage of the quinone reduction process, 
hydride transfer first forms ionized hydroquinone intermediate (hydroquinolate), which then 
obtains a proton from bulk water to form the fully reduced hydroquinone species, thereby 



















Scheme 1.1 Mechanism of the two-electron reduction of quinones by NQO1.221 
 
 
Scheme 2 Mechanism of the two-electron reduction of quinones by NQO1.
healthy tissue, as illustrated for non-small cell lung cancer cells in
Fig. 6B,36 may be a result of several factors. Firstly it may give the
tumour cell some sort of advantage to have NQO1 switched on
and expressed. Secondly, NQO1 may be part of a stress response
signalling system and tumour cells may be continually activated
and in a state of “stress”. A further explanation is that NQO1 is
only elevated in solid tumours (not leukaemias), and solid tumours
are most often derived from epithelial cells. Epithelial cells are one
of the cell types that normally contain NQO1 and hence it may
just reflect the cell of origin for the solid tumour.
NQO1 gene expression is regulated by two elements, the
antioxidant response element and the xenobiotic response element
(also known as AhRE since it involves the aromatic hydrocarbon
receptor).29,37 The expression of NQO1 can be induced by a number
of dietary and synthetic agents with a wide range of structural
diversity.38,39 These include 1,2-dithiole-3-thiones such as D3T
and oltipraz; extracts of vegetables such as the flavanol quercetin
and the isothiocyanate sulforaphane; dietary antioxidants such as
tert-butylhydroxy-anisole (BHA); xenobiotics such as aromatic
hydrocarbons, azo dyes, diphenols, and dioxins (Fig. 7). D3T,
isolated from cruciferous vegetables, is a very effective inducer of
phase 2 enzymes such as NQO1 both in vitro and in vivo. The D3T
analogue oltipraz also induces NQO1 activity. Isothiocyanates
are widely distributed in higher plants, especially cruciferous
vegetables, and sulforaphane, found in broccoli, is a very potent
inducer of NQO1. Studies suggest that it might find use as a
chemopreventative agent.40,41
Quinone substrates for NQO1
Although NQO1 can catalyze the two-electron reduction of a
broad range of substrates, as its name implies, its major group of
substrates are quinones. Its role in the metabolism of endogenous
quinones such as the ubiquinones 1 and a-tocopherolquinone 16
has already been discussed, as has the bioactivation of MMC 13.
However, the flexible nature of the active site can accommodate a
wide range of quinone substrates including the natural products
geldanamycin 14 and streptonigrin 15 (Fig. 3), the benzoquinones
AZQ, MeDZQ and RH1 17, the naphthoquinone b-lapachone and
the indolequinone EO9 18 (Fig. 8). The aziridinylbenzoquinones
MeDZQ and RH1 17 are both excellent substrates for hNQO1,
and following reduction are activated into DNA cross-linking
agents; the required ring opening of the aziridines is presumably
easier in the hydroquinone than in the quinone.42 RH1 17 is
in clinical trials. Similarly, the indolequinone diol EO9 18 is
also a potential tri-functional alkylating agent after loss of
water from both the indole 3-carbinyl and vinylogous indole 2-
carbinyl positions, and aziridine ring opening.43 The compound
has recently re-entered phase I clinical trials.44
The mechanism of action of MMC and related mitosenes has
been widely studied, and the role of C-1 and C10 in the alkylation
and cross-linking of DNA, following one- or two-electron reduc-
tion of the quinone, established.10–13,45–47 An accepted mechanism
for the activation of MMC by NQO1 is shown in Scheme 3. Thus
two-electron reduction generates the hydroquinone followed by



















































1.8.2 Role of NQO1 in the cellular environment 
In cells, as determined in studies using rat liver, NQO1 is considered to be mainly 
confined to the cytosol (84% of the total NQO1 amount), and some presence is indicated in 
mitochondria (13%), microsomes (2%), and the Golgi apparatus (1%).224-225 Winski et al.226 
reported the presence of NQO1 in the nucleus determined by immunocytochemical staining; 
however, the mechanism of nuclear localization still remains unclear.227 Also, NQO1 has been 
found to be associated with the mitotic spindle.228 NQO1 is involved in a number of different 
functions (Figure 1.19), which revolve around its ability to reduce a broad spectrum of quinone 
compounds, including simple quinones, quinone-imines, nitro, and azo compounds.229 The 

















Figure 1.19 Proposed role of NQO1 in both chemoprotective/detoxification and 
bioactivation.229 
where dicoumarol is responsible for the inhibition of NQO1 and the menadione leads to the 
formation of superoxides, depletion of intracellular glutathione and nicotinamide nucleotide 
pools, as well as alteration of Ca2+ homeostasis.220 In a biological system products formed by  

















Figure /. Proposed role of NQOI in both chemoprotection/detoxification and bioactivation.
two electron reduction of quinones to hydroquinones, which are more easily excreted or
conjugated and excreted (Fig, !). Two electron reduction removes a reactive
electropbilic quinone from a biological system and bypasses one electron reduction
reactions th t can generate reactive oxygen spec es (Fig. I). However, hydroquinones
are also potentially reactive metabolites and if not conjugated and/or excreted may
undergo bioactivation via autoxidation or, in the case of some antitumor quinones, by
rearrangement reactions (Fig. I). Thus, even from a simple chemical perspective the
overall contribution of NQOI to toxification/detoxification will depend on the
reactivity and properties of the hydroquinone that is generated (Cadenas et al., 1992;
Ross et al.. 1994), However, the possibility that NQOI may function in a broader stress
or adaptive response to potential injury is now receiving more attention, particularly
with respect to antioxidant reactions of NQOI and protein-protein interactions of
NQOI with proteins such as p53 (Fig. 1, discussed below).
An obligate two electron mechanism for the catalytic function of NQOI has been
supported by ESR studies, stop-flow, and steady-state kinetic methods which bave
failed to detect semiquinone radicals during the metabolism of benzoquinone and
naphthoquinone substrates by NQOI (Iyanagi and Yamazaki, 1970; Tedeschi ct al..
1995). Elucidation of the crystal structure of NQOI (Faig et al.. 2000; Li et at.. 1995)
has assisted in elucidating the mechanism of catalysis which has been proposed to
involve a direct hydride transfer mechanism and has been discussed in detail by Amzel
and coworkers (Cavelier and Amzcl, 2001; Faig et al,. 2000; Li et al.. 1995). Two
electron reduction of menadione by NQOI was shown to protect against toxicity in
cultured cell systems (Lind et al,, 1982; Thor et al., 1982) and NQOI has been
implicated in protection against menadione-induced hemolytic anemia (Munday et al.,
1998). NQOi has been suggested as a protective system against benzene-derived
quinones (Moran et al.. 1999; Thomas et al.. 1990) and benzo(a)pyrene 3.6 quinone
induced DNA adduct formation (Joseph and Jaiswal, 1994).
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one-electron reduction (e.g., by NADPH-cytochrome P450) of electrophilic quinones, can 
autooxidize causing oxidative stress; whereas, the two-electron reduction (by NQO1) product 
hydroquinone could be further conjugated and excreted through the kidney, providing 
chemoprotection.220,229 However, if not conjugated, hydroquinones can also undergo 
bioactivation via autoxoidation or, in the case of some antitumor quinones, by rearrangement 
reactions (Figure 1.19). Thus, the overall contribution of NQO1 toxification/detoxification relies 
on the fate of the hydroquinone that is generated. Other cellular functions of NQO1 includes: 1) 
acting as coenzyme Q (ubiquinone) reductases, to protect membrane components of the cell from 
free radical damage, 2) stabilization of p53, a major tumor suppressor gene, 3) induced in 
oxidative stress environment, and scavenge superoxides, among others.230-232  
1.8.3 NQO1 in cancer therapy 
NQO1 is overexpressed in a variety of solid tumors (e.g., non-small cell lung, pancreas, 
breast, ovarian, colon)221,233-234 at levels 2–50 fold greater than in normal tissues, making it a 
prime target for the activation of cancer chemotherapeutic agents.227 A major approach in cancer 
therapy is the design of inert prodrugs, which are converted to an active drug by enzyme action. 
Such methods involve the use of quinone-containing prodrugs with cytotoxic agents that get 
selectively activated either by the hypoxic environment of tumor cells or by the two-electron 
reducing enzyme NQO1.222 Some of the quinone-containing drugs include Mitomycin C (one of 
the earliest clinically used alkylating agents), indolquinone-based E09, and benzoquinone-based 
AZQ.233 Although, weaker compared to quinone reduction, under aerobic conditions NQO1 is 
capable of reducing nitro compounds through 2-, 4-, or 6-electron reductions, to produce nitroso, 
hydroxylamine and fully reduced amine species.220 One specific example for utilization of the 
nitroreductase activity in NQO1, leads to the formation of a cytotoxic antitumor compound in 
rats, namely a nitrophenylaziridine, CB1954.220 The bio-activation of CB1954 by the human 
form of NQO1 is sufficiently slower compared to rat NQO1, decreasing its therapeutic potential 
in humans. However, an isoform of NQO1, namely NQO2, showed dramatic increase in 
cytotoxicity of CB1954 in human cancer cell lines.220 NQO2 differs from NQO1, with its use of 
a smaller dihydronicotinamide riboside (NRH) instead of NAD(P)H as the cofactor and higher 
nitro reductase ability.235-236 Although NQO2 overexpression in cancers is much less defined, 
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efficient reduction of nitro compounds by NQO2 opened up a new area for antitumor prodrug 
design strategies.235  
Another use of NQO1 in cancer therapy involves the development of mechanism-based 
inhibitors. These types of inhibitors provide a novel strategy for treatment of tumors expressing 
NQO1, whereby inhibition of NQO1 leads to the accumulation of intracellular superoxide, which 
is known to cause cell death.237 The anticoagulant dicoumarol is used in NQO1 inhibition assays, 
but is considered as a nonspecific competitive inhibitor of NQO1.237 Further, Cibacron blue, 
chrysin, 7,8-dihydroxyflavone and phenidone, also competitively inhibit NQO1.233 
Indolequinone-based inhibitors have been studied been widley to provide specific and potent 
inhibitors for NQO1. ES936 is one such inhibitor, where reductive activation by NQO1 
generates a reactive iminium ion intermediate, which then alkylates a tyrosine residue at the 
active site of NQO1, inhibiting its quinone reductase activity.237 
1.8.4 NQO1 detection and imaging through profluorogenic substrate probes 
The overexpression of NQO1 in tumors have provided an important biomarker for the 
development of reductively activated prodrugs, antitumor compounds, and liposomal drug 
delivery systems. An avenue that has not been explored to its full potential involves the 
development of profluorogenic substrate probes that can be reductively activated in the presence 
of NQO1 enzyme. Such avenues could be useful in imaging cancer cells that overexpress NQO1, 
ultimately leading to the development of enzyme-activatable profluorogenic probes for 
fluorescence-guided surgical resection of cancerous tissues. Huang et al. reported two different 
NQO1 activatable latent fluorophores BQRh238 and BQc,239 based on the rhodamine 110 and 
coumarin scaffold respectively. However, their intended application was in the development of 
fluorescent-based analyte discrimination through an enzyme-coupled glucose dehydrogenase 
assay system. Recently, William Silvers, one of my former colleagues, was able to develop two 
different turn-on probes for NQO1 detection.126,240 The first probe was not successful in imaging 
applications due to reduction of its reporter form in the cellular environment; however, the 
second probe, Q3NI126 (the first reported NQO1 turn-on probe), was successfully used in the 
detection and imaging of NQO1-positive cancer cell lines with significant figures of merit. A 
main problem associated with Q3NI was its overlapping absorption and emission profile with its 
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free dye counterpart (NI) that gave rise to a low signal-to-background ratio. Also, emission of the 
free reporter (NI) is in the blue region, a limiting factor for potential in vivo use of Q3NI.  
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SUBSTITUENT EFFECT ON NQO1 TRIGGER GROUP AND KINETICS OF  
SELF-IMMOLATION 
2.1 Introduction  
In recent years, there has been a remarkable interest in the development of activatable 
probes that are triggered by endogenous enzymes associated with inflammatory diseases and 
cancers.1 Such systems provide better understanding of cellular processes, in the design of 
prodrug systems, and specifically to design smart optical bio-probes suitable for bio-molecular 
imaging.2 Overexpression of enzymes in certain cancer tissues provides a gateway to develop 
such systems, where NAD(P)H: quinone oxidoreductase-1; a subgroup of reductase enzymes, 
has become of great interest.3  A significant amount of research has been directed towards 
studying the molecular structure and behavior of NQO1 using crystallographic techniques with 
substrates, such as duraquinone (PDB accession code 1DXO) or inhibitors, including dicoumarol 
(PDB accession code 2F1O)4-8 
Research work over the years has shown that the ability of  NQO1 to reduce quinone and 
quinoidal compounds can be used in the development of activatable prodrug9 and antitumor 
compounds.10-11 Although variants of quinone propionic acid trigger groups with mustard9 and 
oxindoles12 moieties have been tested in prodrug therapies, little is known about some simple 
quinones and their reactivity towards human NAD(P)H:quinone oxidoreductase-1 enzyme. Thus, 
it is important to investigate the interaction of different simple quinone trigger groups with 
NQO1, and to understand and seek possibilities of utilizing them in the development of 
endogenously triggered prodrugs, drug delivery vesicles, and imaging agents.  
As generalized in Figure 2.1 the tunability of the quinone trigger groups can be achieved 
with the change of substituents in R1, R2, R3, and R4 positions. A family of tunable quinone 
propionic acid trigger groups were synthesized by two previous colleagues Dr. Nicole M. 
Hollabaugh3 and Dr. Maria F. Mendoza3 in the McCarley group; in the first part of this chapter is 
presented my synthesis of one of those trigger groups, herein denoted as QMeO-COOH. 
 
3This chapter reprinted with permission from Mendoza, M. F.; Hollabaugh, N. M.; Hettiarachchi, 







Figure 2.1 Reduction and cyclization of quinone propionic acid (QPA) trigger groups.3  
Also, the carboxyl functionality of the quinone propionic acid trigger group is important, 
as it can be derivatized to an amide by coupling reactions with free amine groups of lipids, drugs, 
and dyes to develop reductively activated liposomes, prodrugs, and imaging agents. 
Since its introduction by Katzenellenbogen in 1981,13 the tripartite sensor concept has 
provided a new paradigm shift in the design of profluorophores and prodrugs. Tripartite, refers to 
being a three-part compound that includes a trigger, a linker (or a spacer), and a reporter unit 
(Figure 2.2).14 The reporter unit could be any one of the following, namely a lipid (liposomes), a 
drug (prodrug), or a fluorescent dye (profluorophores). In my case and for the work presented 
here, the trigger is an enzymatic substrate, namely a quinone propionic acid, and the reporter 
group is a fluorescent dye separated by a self-immolative linker. As illustrated in Figure 2.2 the 
tripartite probe is stable as long as the enzymatic substrate stays attached. However, chemical or 
enzyme initiated cleavage of the trigger group generates an unstable intermediate that breaks 








Figure 2.2 Conceptual view of a tripartite sensor probe and its mechanism of action.  
  This elegant strategy is a promising approach in the design of biologically–triggered 
activation of pro-fluorogenic probes for high-throughput screening or bio−molecular imaging. In 
the design of such activatable−probes, careful consideration of the linker functionality is 
important in obtaining a faster signal response. A significant amount of research efforts by many 





























of linkers contain a latent nucleophilic group that becomes electron-donating either after a 
chemical or an enzymatic reaction, subsequently initiating an electron-cascade event that causes 
expulsion of the reporter unit.  
Out of the many linker systems studied, para-aminobenzyl alcohol (PABA) has received 
the most attention in developing self-immolative systems.14 However, I found formation of a 
spirolactam16 species hampered the use of PABA spacers in the QPA systems. Thus, a new 
strategy was implemented by methylating the amino functionality of PABA, thereby offering a 







Figure 2.3 Two different self-immolative tripartite probes having quinone trigger,  
N-methyl-p-aminobenzyl alcohol spacer, and nitroaniline reporter groups. 
The second portion of this chapter describes the synthesis and kinetics of two different 
tripartite probes that incorporate this novel NMPABA linker.  
2.2 Experimental 
2.2.1 Synthetic Materials and Methods 
All chemicals were purchased from Sigma-Aldrich or Fisher Scientific and used as 
received. Column chromatography was performed on 50-g SNAP silica columns using a 
Flashmaster Personal from Biotage.  Thin-layer chromatography was performed on aluminum-
backed 60 F254 silica plates from EMD Chemicals Incorporated.  1H and 13C NMR spectra were 
collected in CDCl3, DMSO-d6, or methanol-d4 at room temperature on a Bruker AV-400.  All 
chemical shifts are reported in the standard δ notation of parts per million using tetramethylsilane 
as an internal reference.  Absorption bands in NMR spectra are listed as singlet (s), doublet (d), 
triplet (t), multiplet (m), or two triplets (2t), and coupling constants (J) are reported in hertz (Hz).  
Mass spectral analyses were carried out using an Agilent 6210 ESI-TOF mass spectrometer.  
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Dimethyl nitrophenol (1.00 g, 5.98 mmol) and methanol (4.00 mL) were heated to 65 oC in an oil 
bath. While stirring, 30% aqueous KOH (1.12 mL, 5.98 mmol) was added to the phenolic 
solution at 65 °C and stirring continued for 10 min. Dimethyl sulfate (0.57 mL, 5.98 mmol) was 
added dropwise to the hot phenolate solution over a 10-min period, and vigorous stirring was 
continued for 45 min. The sequential additions of KOH solution and dimethyl sulfate were 
repeated four more times using the same amounts and conditions. After the final addition, the 
mixture was diluted with water (31 mL) and extracted with ether (4 × 8 mL). The combined ether 
extracts were washed with 10% NaOH (3 × 20 mL), 5% HCl (1 × 30 mL), followed by water (1 
× 30 mL), and dried over MgSO4. Removal of solvent with a rotary evaporator provided the 
nitroanisole as a light brown liquid (0.64 g, 59.6%) which was used in the next step without 
further purification. 1H NMR (400 MHz, chloroform-d) δ 7.43 (d, J = 2.2 Hz, 1H), 7.21 (s, 1H), 
3.86 (s, 3H), 2.32 (s, 7H). 
2-Methoxy-3,5-dimethylbenzenamine (2): 
Nitroanisole 1 (3.0 g, 16.56 mmol) in 50 mL of methanol was hydrogenated using a Parr 
apparatus at 2-3 atm, with 10% Pd/C (Dry) as catalyst. Hydrogen uptake ceased after 2.25 h and 
the mixture was filtered by suction to remove catalyst. Solvent removal with a rotary evaporator 
afforded amine as pale yellow liquid (2.28 g, 91%). The amine was used in the next step without 
further purification. 1H NMR (400 MHz, chloroform-d) δ 6.44 (d, 2H), 3.74 (s, 5H), 3.48 (s, 1H), 
2.23 (d, J = 13.9 Hz, 6H). ESI-MS: for C9H13NO: expected m/z = 151.0997 [M + H]+; found m/z 
= 151.0992 [M + H]+; 3.31 ppm error. 
2-Methoxy-3,5-dimethylphenol (3): 
Aniline 2 (1.4534 g, 0.01 mol) was mixed with ice cold water (26 mL) and a solution of conc. 
H2SO4 (2 ml, 0.02 mol) in cold water (10 mL) was added at 0oC with stirring. A solution of 
NaNO2 (0.7 g, 0.01 mol) in cold water (10 mL) was added to the amino solution drop wise at 0 
oC. After the addition was complete, stirring was discontinued, the ice bath removed, and the 
mixture allowed to stand at room temperature for 2 h. The reaction mixture was distilled for 14 
hrs and 450 mL of the distillate was collected. The distillate was extracted with ether (3 x 25 ml), 
the combined ether extracts were washed with 60 mL of saturated NaCl, and dried over MgSO4. 
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Solvent removal with a rotary evaporator afforded the phenol as a yellow-orange oil (1.06 g, 
70%) and was used in the next step without further purification. 1H NMR (400 MHz, 
chloroform-d) δ  2.23 (s, 3H), 2.26 (s, 3H), 3.77 (s, 3H), 5.55 (s, 1H), 6.51 (s, 1H), 6.63 (s, 
1H). ESI-MS: for C9H12O2: expected m/z = 152.0837 [M + H]+; found m/z = 152.0828 [M + H]+; 
5.92 ppm error. 
2-Methoxy-3,5-dimethyl-2,5-cyclohexadiene-1,4-dione (4): 
Crude phenol 3 (313.7 mg, 2 mmol) was dissolved in 6 ml of methanol and the solution was 
placed in a 250 mL round bottom flask. An oxidizing solution was prepared from (1.61 g, 6 
mmol) of potassium nitrosodisulfinate (Fremy's salt), 20 mL of 0.5 M KH2PO4 and 80 mL of 
water. The oxidizing solution was poured into the phenol solution and the resulting dark purple 
solution was stirred at room temperature for 2 h. The mixture was extracted with ether (4 × 20 
mL, 3 × 30 mL), and the combined ether extracts were washed with two 80 mL portions of water 
then dried over MgSO4. Rotary evaporation gave of the crude quinone, and this was purified on a 
25 g/150 mL Flash Si II column using the FlashMaster chromatography system, using ethyl 
acetate/dichloromethane/hexane (1:1:2) to give pure quinone as a yellow-orange solid (182.7 mg, 
55%). 1H NMR (400 MHz, chloroform-d) δ 6.44 (s, 1H), 4.01 (s, 3H), 2.04 (s, 3H), 1.95 (s, 3H). 
ESI-MS: for C9H10O3: expected m/z = 166.0629 [M + H]+; found m/z = 166.0601 [M + H]+; 16.86 
ppm error. 
2-Methoxy-3,5-dimethyl-1,4-benzenediol (5): 
Sodium dithionite (418.25 mg, 2.4 mmol) was dissolved in 6 mL of water and a solution of 
quinone 4 (80 mg, 0.48 mmol) in methanol was added at room temperature with stirring. After 
stirring for 10 min., the mixture was placed in a separatory funnel and extracted with ether (4 × 
5ml). The combined ether extracts were washed with water (1 × 10ml), brine (1 × 10 mL), and 
dried over MgSO4. Solvent removal with a rotary evaporator afforded a quantitative yield of the 
crude hydroquinone and this was purified on a 25 g/150 mL Flash Si II column using the 
FlashMaster chromatography system using ethyl acetate/dichloromethane/hexane (1:1:2) to give 
the pure hydroquinone as a pale yellowish-white solid (367.09 mg, 91%). 1H NMR (400 MHz, 




Methanesulfonic acid (4 mL) was heated to 70 °C in an oil bath and hydroquinone 5 (287.5 mg, 
1.71 mmol) and methyl 3-methyl-2-butenoate (247 µL, 2.02 mmol) were added all at once with 
stirring. Stirring was continued at 70 °C for 2.5 h before the reaction mixture was diluted with 40 
ml of water and extracted with ether (4 × 20 mL). The combined ether extracts were washed with 
40 mL of water, Saturated NaHCO3 (3 × 40 mL), brine (1 × 40 mL), and dried over MgSO4. 
Removal of solvent with a rotary evaporator afforded a red-brown oil which was dissolved in 7 
ml of 5% ethyl acetate in DCM, and was purified on a 25 g/150 mL Flash Si II column using the 
FlashMaster chromatography system using ethyl acetate/dichloromethane (1:20) to remove the 
dark impurity, thereby obtaining the pure lactone as a yellow-tan solid (363.55 mg, 85%). 1H 
NMR (400 MHz, chloroform-d) δ 5.00 (s, 1H), 3.80 (s, 3H), 2.57 (s, 2H), 2.31 (d, J = 12.0 Hz, 
3H), 2.16 (d, J = 8.9 Hz, 3H), 1.45 (s, 6H). 
5-Methoxy-β,β,2,4-tetramethyl-3,6-dioxo-1,4-cyclohexadiene-1-propanoic acid (QMeO-COOH):  
Lactone 6 (68.65 mg, 0.27 mmol) in 2 ml of DMF was added to a stirred solution of pyridinium 
dichromate (464.88 mg, 1.24 mmol) in 7 mL of DMF at room temperature and stirring was 
continued for 4 h. The mixture was diluted to 60 mL with water and extracted with ether (3 × 15 
mL). The combined ether extracts were washed with 30 mL of water followed by saturated 
NaHCO3 (3 × 15 mL). The combined bicarbonate washes were made slightly acidic by the slow 
addition of 30% HCl and the resulting aqueous solution was extracted with ether (4 × 15 mL). 
The combined organic extracts were washed with 25 mL of brine and dried over MgSO4. Solvent 
removal with a rotary evaporator provided a yellow solid which was recrystallized from 20% 
chloroform in hexane to afford the pure quinone acid as small yellow needles (46.7 mg, 65%). 
1H NMR (400 MHz, chloroform-d) δ 3.85 (s, 3H), 3.05 (s, 2H), 2.14 (s, 3H), 1.88 (s, 3H), 1.45 
(s, 6H). 13C NMR (101 MHz, Chloroform-d) δ 188.41, 186.50, 178.45, 158.04, 150.08, 139.84, 
125.40, 59.96, 47.38, 38.36, 29.12, 14.88, 9.01. ESI-MS: for C14H18O5: expected m/z = 266.1154  
[M + H]+; found m/z = 266.1130 [M + H]+; 9.02 ppm error. 
4-(N-Methylamino)benzyl alcohol (8 para): 
To a cold (0 °C) stirred solution of 7 para (10.0 g, 66.1 mmol) in THF (50 mL) was added 1 M 
borane-THF complex in THF (200 mL, 200 mmol), dropwise over a period of 1 h. The solution 
 61 
was stirred for an additional 5 h at ~25 °C and was then cooled to 0 °C. Then 3 M NaOH (60 
mL) was added to the solution to destroy excess hydride and hydrolyze the amine-borane 
complex. The heterogenous mixture was stirred for 12 h at ~25 °C. The aqueous phase was 
saturated with potassium carbonate, and the organic phase was collected. The aqueous phase was 
extracted with Et2O (3 × 50 mL); the combined organic extracts were then dried over anhydrous 
Na2SO4. After filtration, the filtrate was rotoevaporated under reduced pressure. The crude 
product 8 para (7.60 g, 55.5 mmol in 84 % yield) was used in the next step without further 
purification. 1H NMR (400 MHz, methanol-d4) δ 7.22 – 7.01 (m, 2H), 6.69 – 6.48 (m, 2H), 4.44 
(s, 2H), 2.73 (s, 3H). 
4-((tert-butyldimethylsilyloxy)N-methylamino)benzyl alcohol (9 para): 
To a solution of 8-para (5.0 g, 36.45 mmol) in dichloromethane (40 mL) was added tert-
butyldimethylsilyl chloride (5.49 g, 36.45 mmol) and imidazole (2.48 g, 36.45 mmol), The 
mixture was stirred for 1h at room temperature then the reaction mixture was diluted with brine 
solution and then extracted with ethyl acetate (3 × 25 mL). The organic phase was dried over 
anhydrous Na2SO4 and filtered. Solvent was removed using a rotary evaporator leaving a light 
brown color oil (9.34 g, 37.19 mmol) with 98% yield, which was used without further 
purification. 1H-NMR (chloroform-d, 400 MHz) δ 7.18 (d, J = 8.4 Hz, 2H), 6.72 – 6.49 (m, 2H), 
4.66 (s, 2H), 2.85 (s, 3H), 0.96 (s, 9H), 0.11 (s, 6H). 13C-NMR (chloroform-d, 100 MHz) δ 
148.51, 130.16, 127.75, 112.27, 65.14, 30.92. 26.06, 18.49, -5.07 ESI-MS: for C14H25NOSi: 
expected m/z = 252.1778 [M + H]+; found m/z = 252.1800 [M + H]+; 8.7 ppm error. 
3-(3ʹ,6ʹ-Dioxo-1ʹ, 2ʹ,4ʹ-trimethylcyclohexa-1ʹ,4ʹ-dienyl)-3,3-dimethylpropionic acid 4-((tert-
butyldimethylsilyloxy)-N-methylamino)benzyl alcohol amide (10-para): 
3-(3ʹ,6ʹ-Dioxo-2ʹ,4ʹ dioxo-1′, 2′, 4′-trimethylcyclohexa-1′,4ʹ- dienyl)-3,3 dimethylpropionic acid 
Q3 (0.37 g, 1.48 mmol) was dissolved in 50 mL of CH2Cl2, to which was added N-
methylmorpholine (0.45 g, 4.44 mmol). The mixture was cooled to −55 °C. Isobutyl 
chloroformate (0.24 g, 1.78 mmol) was then added, followed by addition of 9-para (1.16 g, 2.28 
mmol) after 10 min. The reaction mixture was stirred for another 5 h. The residue obtained by 
evaporation of the solvent under reduced pressure was dissolved in 50 mL CHCl3. The solution 
was then washed with water (60 mL), 5% HCl (60 mL), 5% NaHCO3 (60 mL), and saturated 
NaCl (60 mL) solutions. The combined organic extracts were dried over anhydrous Na2SO4 and 
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filtered. Solvent was removed using a rotary evaporator, and chromatographed (silica gel, 1:5 
EtOAc/Hex) to provide compound 10-para as a yellow-brown solid (0.29 g, 0.61 mmol) with   
41 % yield. 1H-NMR (chloroform-d, 400 MHz) δ 7.39 (d, J = 8.0 Hz, 2H), 7.19 – 7.11 (m, 2H), 
4.79 (s, 2H), 3.14 (s, 3H), 2.74 (s, 2H), 2.10 (s, 3H), 2.03 – 1.93 (m, 6H), 1.29 (s, 6H), 0.97 (s, 
9H), 0.13 (s, 6H). 13C-NMR (chloroform-d, 100 MHz) δ 191.22, 187.69, 172.14, 154.86, 143.65, 
142.65, 141.18, 137.69, 136.14, 127.27, 64.41, 47.52, 38.06, 37.10, 28.41, 25.95, 18.43, 14.06, 
12.75, 12.11, -5.26. ESI-MS: for C28H41NO4Si: expected m/z = 484.2878 [M + H]+; found m/z = 
484.2873 [M + H]+; 1.0 ppm error. 
3-(3ʹ,6ʹ-Dioxo-1ʹ, 2ʹ,4ʹ-trimethylcyclohexa-1ʹ,4ʹ-dienyl)-3,3-dimethylpropionic acid 4-(N-
methylamino)benzyl alcohol amide (11-para): 
10-para (0.18g, 0.38 mmol) was dissolved in THF (3 mL), to which TBAF (0.6 mL, 1 M in 
THF) was added, and subsequently stirred at room temperature for 2 h. Upon completion of the 
reaction, the solvent was removed and the residue was dissolved in CH2Cl2, washed with brine, 
dried over anhydrous MgSO4, and filtered. Solvent was removed using a rotary evaporator, and 
the crude was chromatographed (silica gel, 5:2 EtOAc/Hex) to provide compound 3 as a yellow 
solid (0.13 g, 0.35 mmol) with 92 % yield. 1H-NMR (methanol-d4, 400 MHz) δ 7.47 (d, J = 7.9 
Hz, 2H), 7.24 (s, 2H), 4.65 (s, 2H), 3.12 (s, 3H), 2.73 (d, J = 5.2 Hz, 2H), 2.07 (s, 3H), 1.96 (d, J 
= 9.7 Hz, 6H), 1.27 (s, 6H). 13C-NMR (methanol-d4, 100 MHz) δ 192.23, 188.76, 174.06, 
156.19, 144.70, 144.06, 143.15, 138.89, 137.60, 129.48, 128.46, 64.53, 39.26, 37.51, 30.90, 
28.90, 14.33, 12.75, 11.97. ESI-MS: for C22H27NO4: expected m/z = 370.2013  [M + H]+; found 
m/z = 370.2001 [M + H]+; 3.24 ppm error. 
12-para: 
para-nitroaniline isocyanate (19.69 mg, 0.12 mmol) was dissolved in dry THF (1 mL). 11-para 
(36.92 mg, 0.1 mmol) and DBTL (6 µL) were added. The reaction was allowed to warm to 45° C 
and was stirred for 6 hours. The reaction was monitored by TLC (EtOAc:Hex 1:1). Upon 
completion of the reaction, the solvent was removed under reduced pressure, and the crude 
product was purified by column chromatography on silica gel (EtOAc:Hex 1:1) to give 12-para 
(22.65 mg, 42%) as a yellow solid. 1H NMR (400 MHz, chloroform-d) δ 8.22 (s, 2H), 7.60 (s, 
2H), 7.47 (s, 2H), 7.35 (s, 1H), 7.21 (s, 2H), 5.27 (s, 2H), 3.15 (s, 3H), 2.75 (d, J = 5.7 Hz, 2H), 
2.10 (s, 3H), 1.96 (d, J = 19.3 Hz, 6H), 1.28 (d, J = 18.9 Hz, 6H). 13C NMR (101 MHz, 
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chloroform-d) δ 191.24, 187.74, 177.27, 172.01, 154.49, 152.56, 144.19, 143.73, 143.20, 137.95, 
136.49, 129.77, 125.75, 125.21, 117.85, 66.83, 47.79, 38.10, 33.65, 31.89, 29.58, 28.55, 24.74, 
22.67, 14.10, 12.70, 12.70, 12.09. 1H NMR (400 MHz, chloroform-d) δ 6.44 (s, 1H), 4.01 (s, 
3H), 2.04 (s, 3H), 1.95 (s, 3H). ESI-MS: for C29H31N3O7: expected m/z = 534.2235 [M + H]+; 
found m/z = 534.2240 [M + H]+ ; 0.93 ppm error. 
Compounds 8-ortho through 12-ortho were synthesized according to the same procedures 
described for 8-para through 12-para. 
2-(N-Methylamino)benzyl alcohol (8-ortho): 1H NMR (400 MHz, chloroform-d) δ 7.30 (td, J = 
7.8, 1.7 Hz, 1H), 7.05 (dd, J = 7.3, 1.6 Hz, 1H), 6.77 – 6.64 (m, 1H), 4.58 (s, 2H), 2.87 (s, 3H). 
13C NMR (101 MHz, chloroform-d) δ 148.50, 129.65, 128.99, 124.57, 116.56, 110.27, 64.36, 
30.40. 
2-((tert-Butyldimethylsilyloxy)-N-methylamino)benzyl alcohol (9-ortho): 1H NMR (400 MHz, 
chloroform-d) δ 7.26 (td, J = 7.9, 1.6 Hz, 1H), 7.12 – 7.01 (m, 1H), 6.75 – 6.62 (m, 2H), 4.72 (s, 
2H), 2.90 (s, 3H), 0.94 (s, 12H), 0.10 (s, 6H). 13C NMR (101 MHz, chloroform-d) δ 148.89, 
129.11, 128.21, 124.86, 116.29, 109.88, 65.49, 30.33, 25.94, 18.28, -5.12. 
 
3-(3ʹ,6ʹ-Dioxo-1ʹ,2ʹ,4ʹ-trimethylcyclohexa-1ʹ,4ʹ-dienyl)-3,3-dimethylpropionic acid 2-((tert-
butyldimethylsilyloxy)-N-methylamino)benzyl alcohol amide (10-ortho): 1H NMR (400 MHz, 
chloroform-d) δ 7.68 – 7.61 (m, 1H), 7.38 (dd, J = 29.9, 7.5, 1.5 Hz, 2H), 7.11 (dd, J = 7.7, 1.4 
Hz, 1H), 4.74 (d, J = 13.8 Hz, 1H), 4.69 – 4.59 (m, 1H), 3.07 (s, 3H), 2.65 (d, J = 17.1 Hz, 1H), 
2.56 (d, J = 17.0 Hz, 1H), 2.10 (s, 3H), 2.02 – 1.92 (m, 6H), 1.28 (d, J = 14.5 Hz, 6H), 0.99 (s, 
12H), 0.14 (s, 6H). 13C NMR (101 MHz, chloroform-d) δ 191.20, 187.72, 172.17, 154.81, 
143.56, 140.42, 137.72, 138.04, 128.65, 128.48, 127.99, 60.86, 47.89, 37.67, 36.17, 28.53, 18.42, 
14.10, 12.76, 12.10, -5.32 
3-(3ʹ,6ʹ-Dioxo-1ʹ,2ʹ,4ʹ-trimethylcyclohexa-1ʹ,4ʹ-dienyl)-3,3-dimethylpropionic acid 4-(N-
methylamino)benzyl alcohol amide (11-ortho): 1H NMR (400 MHz, methanol-d4) δ 7.68 – 7.60 
(m, 1H), 7.44 (dtd, J = 16.9, 7.4, 1.7 Hz, 2H), 7.20 (dd, J = 7.4, 1.6 Hz, 1H), 4.57 (q, J = 13.3 
Hz, 2H), 3.07 (s, 3H), 2.69 (d, J = 17.2 Hz, 1H), 2.59 (d, J = 17.2 Hz, 1H), 2.08 (s, 3H), 2.04 – 
1.93 (m, 6H), 1.28 (d, J = 4.4 Hz, 6H). 13C NMR (101 MHz, methanol-d4) δ 192.24, 188.65, 
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174.09, 156.22, 144.57, 142.26, 39.82, 138.84, 137.37, 130.43, 130.07, 130.00, 129.27, 60.83, 
38.86, 36.97, 28.90, 28.76, 14.40, 12.79, 12.03.  
12-ortho: 1H NMR (400 MHz, chloroform-d) δ 9.00 (s, 1H), 8.23 – 8.12 (m, 2H), 7.73 – 7.55 (m, 
3H), 7.47 (dtd, J = 27.0, 7.5, 1.6 Hz, 2H), 7.26 – 7.13 (m, 1H), 5.48 (d, J = 12.1 Hz, 1H), 4.83 (d, 
J = 12.0 Hz, 1H), 3.18 (s, 3H), 2.21 – 2.06 (m, 3H), 2.00 – 1.91 (m, 6H), 1.53 – 1.37 (m, 3H), 
1.21 (s, 3H). 13C NMR (101 MHz, chloroform-d) δ 192.85, 187.29, 172.61, 155.01, 152.76, 
144.63, 143.40, 142.87, 138.45, 136.23, 132.75, 131.09, 129.05, 125.12, 117.71, 63.72, 47.63, 
37.70, 36.31, 28.74, 27.71, 14.12, 12.79, 12.16.  
2.3 Results   
2.3.1 Synthesis of QMeO-COOH 
QMeO-COOH (Figure 2.4) was synthesized according to Scheme 2.119-20 as a part of an 
on-going project in the McCarley group that involves the development of redox-active trigger 
groups. The first step of the synthesis involves methylation of o-hydroxyl group dimethyl 



































Then the nitro group of 1 was reduced to amine 2 by catalytic hydrogenation using a Parr 
apparatus. The amine of 2 was then converted to phenol 3 by diazotization, followed by 
hydrolysis. Then oxidation of 3 by Fremy’s salt, gave the benzoquinone 4, which was reduced to 
the corresponding hydroquinone 5 using sodium dithionite. The next step involved 1,4-Michael 
addition of methyl 3-methyl-2-butenoate to the hydroquinone 5, giving the lactone 6. Finally the 
PDC oxidation of lactone 6 yielded the target mono-methoxy quinone propionic acid QMeO-
COOH. 
2.3.2. Faster signal relay over self-immolation 
 The tripartite probes (A, B) were designed, such that the nitroaniline reporter groups on 
the benzylic substituents are located at the para and ortho positions of the corresponding methyl 
aniline group. The amide linkage with the quinone propionic acid (QPA) masks the functionality 
of the methyl aniline group. Removal of the QPA group by chemical means resulted in 
disruption of probe molecular structure, so as to cause release of the reporter, para-nitroaniline 
















































1,6-elimination/ para-quinone methide formation
























According to the proposed general mechanism for reporter elimination (Scheme 2.3), 
initial reduction of the quinone to a hydroquinone is followed by the formation of an unstable 
tetrahedral intermediate. This intermediate then collapses to form a lactone and an unmasked 
methyl aniline moiety, thereby triggering the self-immolative process. Disassembly through self-
immolation either by 1,4- or 1,6-elimination results in the release of the nitroaniline reporter 
groups. However, such an elimination process does not lead directly to the release of the   
reporter. Instead it produces an unstable carbamic acid intermediate, which rapidly breaksdown 
to form the free reporter and carbon dioxide at pH = 7.4.21 This dual elimination entropically 
drives the reaction in the forward direction. 
The UV-vis absorbance spectra of the two tripartite probes showed two distinct bands, 
one around 250 nm and another around 327 nm (Figure 2.5). To assess kinetics of 1,6- and 1,4- 
self-immolation, solutions of probes A and B were incubated with two equivalents of a strong 














Figure 2.5 UV-vis absorbance spectra of 40 µM A (1), and 40 µM B (2) upon addition of 
Na2S2O4 (2 eq) in 1:1 DMSO:PBS pH = 7.4 buffer. Solid line – before dithionite addition, and 
dashed – 1 h after dithionite addition. The arrow pointing downwards represents the decrease in 
intensity of the 327 nm band, and the upward arrow represents the increase in intensity of the 




















































The result showed that the band at 327 nm decreased with a concomitant increase of a 
band around 391 nm. The latter corresponds to the release of the nitroaniline group that showed 
gradual increase over the time period studied.  
2.3.3 Kinetics of 1,6- and 1,4- self-immolation routes 
 Upon addition of the reducing agent dithionite, the disappearance of the reactant probes 
A and B (at 327 nm), and the appearance of the product nitroaniline (at 391 nm) were followed 
continuously by UV-vis spectroscopy (Figure 2.6 (a) and (b)). It is important to note that in the 
graphs depicted in Figure 2.6, the extent of the reaction refers to the complete product formation 
(at 327 nm) or the reactant disappearance (at 391 nm) for the maximum time studied. The 
nitroaniline product formation and the para-quinone methide disappearance was observed in 
roughly 1 hour, and it took roughly more than two hours for ortho-quinone disappearance. These 
results indicate that both the rates of the reactant disappearance and the product formation for A 
are faster than that of B.  
2.4 Discussion 
The kinetic experiment revealed vastly different kinetic profiles for compounds A and B 
that have similar electronic arrangement for their self-immolative behavior. As evidenced by the 
UV-vis kinetic data, the 1,6-elimination from A is faster compared to the 1,4-elimination from B 
(Figure 2.6). This is in agreement with some previous work done by other academic groups with 
different self-immolative systems.2,14,22-23 In contrast, Lee et al. reported a more rapid 1,4-
elimination over the more common 1,6-elimination route with hydroxycoumarin based trigger-
linker-reporter conjugates.15  
2.4.1 Kinetic rate equation for the overall rate 
According to the proposed overall mechanism (Scheme 2.4), the initial rate of reduction 
of the tripartite probe activation should be virtually identical for both A and B, because dithionite 
is a strong reducing agent. Previous studies in the McCarley group with a wide range of 
substituted quinone propionic acid groups revealed that dithionite reduction of the quinone 


































Figure 2.6 Plot of extent of reaction vs time a) [R]/[R]0  (Reactant disappearance) and b) 
[P]/[P]∞ (Product formation); c) and d) Plot of ln(extent of reaction) vs time for ortho- (purple) 
and para- (yellow) probes. Also a) and c) represent the reactant disappearance and b) and d) 
represent the product formation. The linear region, showing first-order kinetics, is marked with a 
green box.  
Therefore, it is safe to assume that the initial reduction step has little to no impact on the 
overall rate of the reaction. Further previous work by Johnson et al. demonstrated carbamic 
species of N-arylcarbamates have short lifetimes,21 therefore it is possible that the 
decarboxylation step depicted in Box 2 to have similar rate (k4) for both ortho- and para- 





















Scheme 2.4 Proposed detailed overall reaction steps associated with the 4-nitroaniline 
production from para- (A) and ortho- (B) tripartite probes. Box 1 – possible reaction steps 
involved in the rate determining step (RDS) for Reactant: hydroquinone (R), Tetrahedral 
Intermediate (I), and Products: lactone and linker+nitroaniline species (P%%); inset, simplified 
overall reaction equations. Box 2 – decarboxylation yielding 4-nitroaniline.  
Earlier work by Milstein et al.24 and later by Danforth et al.25 proved that the rate 
determining step in the lactonization reaction is breakdown of the tetrahedral intermediate, and 
that it could be governed by steric factors. According to Scheme 2.4, three steps can be 
influenced by steric factors, namely 1) rate of formation of the tetrahedral intermediate (k1[R]), 
2) rate of collapse of the tetrahedral intermediate (k2[I]), and 3) rate of quinone methide 
formation (k3[P%%]). The obtained crystal structures for 11-para and 11-ortho (Figure 2.7) exhibit 
a difference in the geometry of the two systems. Assuming that the nitroaniline attachment does 
not alter the overall geometry of A and B, attack of O1 to C9 (Figure 2.7) for formation of the 
tetrahedral intermediate is more feasible for the less sterically hindered 11-para over the more  
sterically congested 11-ortho. Winans et al. suggested that the rate of the lactone formation is 
largely governed by the relief of strain of the tetrahedral intermediate.26 If this holds true one 
shall expect that the more strained ortho to collapse faster in comparison to para. Therefore it 





































































Figure 2.7 Single crystal X-ray structures of 11-para and 11-ortho.  
not the collapse of it. Further, it is also important to account for the steric factors involved in the 
rate (k3[P%%]) of the quinone methide formation step, and the UV-vis data does not provide 
adequate information to distinguish the rate-determining step between them.  
Considering that concentration of the tetrahedral intermediate (I) does not build up at 
appreciable amount and is less stable than either of the reactant (R) and products (P) during the 
course of the reaction the concentration of I will be low, consequently I will reach a steady state.  













= k1 R[ ]− k−1 I[ ]
d I[ ]
dt










     
 
 
 However, prior to reaching steady state of [I], rate of reactant disappearance depends on 
both [R] and [I]. But [I] is affected by reactions forming it/removing it. So, it would appear that 
the para species forms product very fast prior to the steady state of [I] being reached, after which 
the rate slows down. Possibly conversion of R to I is initially fast, then the collapse is slow. Also 
for the ortho case, products are formed slowly at first until the steady state of [I] is reached, then 
the rate is faster. Perhaps initial rate reflects tetrahedral intermediate (I) formation, then change 
in rate reflects fast collapse of I. These arguments are in agreement with the sterics of I formation 
(ortho slower vs para). However, it is also important to note that the rate of P% %  formation is 
k2[I]ss, so it is hard to compare para and ortho collapse rates.  
 Interestingly, the plot of the ln(extent of the reaction) vs time exhibited a linear 
dependence on time for the disappearance of the reactant (327 nm band) for both the ortho- and 
para- trigger probes (Figure 2.6 c) for select time periods, denoted by green highlighting. As 
shown in Figure 2.8 the carbamate linkage in the nitroaniline reporter appears to be responsible 
for the chromophore that displays an absorbance band around 327 nm. Further support for this 
comes from the UV-visible spectra of p-nitroacetamide (NIST database)27 species with a 
absorption maxima similar to what I observed for the para species. Therefore the decrease in 
intensity of the 327 nm absorption band (reactant disappearance) could be associated with k1, k2, 
and k3 steps. However, the data obtained is not sufficient to show the chromophore associated 
with linker+nitroaniline conjugate (k3 step) plays a role in the disappearance of the 327 nm 
absorption band. Nevertheless, the linear dependency of the decreasing 327 nm absorption band 
could provide an observed rate constant (Equation 4) to account for the rate change in 1,4- 
(ortho-) and 1,6-elimination (para-) pathways. From Equation (3) at steady state,  












k2 R[ ] = Keqk2 R[ ] Equation (3) 




















Figure 2.8 The absorbance spectra of the para probe A (red), nitroaniline reporter (green), 
and QPA+para-linker (blue) in 1:1 DMSO:PBS pH = 7.4 buffer. 
Therefore, in order to calculate the observed pseudo first-order rate constant (based on 
Equation 4), the slope of the curve marked with a green box in ln (“extent of the reaction”) plot 
(Figure 2.6 c) was used, omitting the time that showed non-linear dependence. The observed rate 
constant (kobs,) for nitroaniline release through 1,6 elimination from para-quinone was found to 
be 0.075 min−1, and for 1,4 elimination from ortho- quinone to be 0.029 min−1 (Figure 2.9). Thus 
a 2.6-fold change in rate provides evidence for the observed faster kinetics for para- over ortho- 
tripartite probe. However, the same trend was not observed in plots Figure 2.6 (b) and (d), 
suggesting mixed kinetics for the nitroaniline formation step.  
Steric analysis based on the single-crystal structures may oversimplify the reasoning for 
these different outcomes, and more work is needed in order to truly understand the kinetics of the 
self-immolative behavior of these probes. For example, geometry optimization with 
computational methods (including solvent parameters) would be useful for better understanding 
the steric factors in aqueous media, or replacing the quinone trigger with a Boc protecting group 
would eliminate the possibility of tetrahedral intermediate formation to give the true kinetics of 
























Figure 2.9 Linear region of the ln(extent of the reaction) vs time plots showing first-order 
kinetics for a) para- and b) ortho-trigger probes.  
the novel NMPABA spacer (with 1,6-elimination pathway) has a favorable rate of elimination 
such that the spacer is appropriate for use in the design of profluorogenic imaging probes. In 
addition the enzyme recognition unit can be separated from a hydrophobic fluorophore to 
achieve improved chemical stability and enzymatic reactivity in the detection and imaging of 
cancer cell lines. The use of this novel self-immolative spacer, in the development of an enzyme- 
activatable probe and its evaluation in cancer cell lines is discussed in the following chapter. 
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DESIGN, SYNTHESIS, AND EVALUATION OF A PET-MODULATED 
NAPHTHALIMIDE-BASED SELF-IMMOLATIVE PROFLUOROPHORE 
3.1 Introduction  
The design and optimization of new enzymatically–triggered, fluorescence–based probes 
specific to biological agents holds great potential in the emerging and promising field of bio-
molecular imaging and bio-marker quantification.1-3 Development of such probes with biological 
activity and signatures will define the borders of diseased and healthy tissue during fluorescence-
assisted surgical resection of cancerous tissues and collection of real-time information on 
diseased tissue cell micro-environment.4-6 To attain this potential, it is necessary to build a 
diverse base of disease–associated, enzyme–activatable probes. 
Development of activatable–probes7-8 with superior signal-to-background-ratios (SBR),7,9 
defined as the amount of signal in the region of interest relative to the amount of signal in a 
neighboring region,10 require either (1) a maximal signal from the target, (2) a minimal signal 
from the background, or (3) a combination of the two. In this regard, triggered-activation of 
imaging probes offers distinct benefits over their “always-on”7,11 counterparts, specifically by 
providing high SBR, which is critical in identifying small cancer foci or creating highly defined 
boundaries that clearly demark the cancer cells from the surrounding normal healthy cells. In this 
route, the probes are designed in such a way that the fluorescence response is switched-on only 
by highly sensitive and selective removal of a fluorescence quencher from the probe by 
triggered-activation to generate a high fluorescent reporter. Since these probes are fluorescently 
quenched (or “off”) at the beginning and retain fluorescence only after activation (or “on”), a 
high SBR can be achieved despite the presence of unactivated probe remaining in circulation. 
This is a clear advantage over the “always-on” probes, whose fast clearance is essential for high 
SBR.  
Numerous imaging probes that exploit targets associated with cancer cells (e.g. pH, pO2, 
oxidation, enzymes) for probe activation have been designed. However, only a small number of  
 
12This chapter reprinted with permission from Hettiarachchi, S.U.; Prasai, B.; McCarley, R.L.; 
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imaging probes have the ability to selectively and rapidly reveal their fluorescence in the 
presence of a cancer-associated enzyme as is the type of disease-associated activating enzymes.12  
To date, only three distinct cancer-linked enzymes have been targeted for unmasking of probe 
fluorescence with improved SBR.6,13-14 Common methods used to quench a probe’s fluorescence 
include: fluorescence resonance energy transfer (FRET), photo-induced electron-transfer (PeT), 
and internal-charge-transfer (ICT), whereby the reporter’s fluorescence is restored by enzyme-
initiated removal of the FRET quencher/donor pair or reaction specific cleavage of the quencher 
(trigger group) from the probe.12 
 NAD(P)H:quinone oxidoreductase-1 (NQO1, DT-diaphorase, EC 1.6.99.2)15-16 is a 
chemoprotective enzyme, and its overexpression (2- to 50-fold greater than normal tissue) is 
found in a wide variety of human tumor cells (e.g., colon, breast, pancreas, non-small cell lung)15 
making it a prime target for the design of bio-activatable profluorophores and prodrugs.17-18 A 
distinct feature of this endogenous, cytosolic cancer-associated enzyme is its ability to catalyze a 
direct two-electron reduction of quinone to hydroquinones. This substrate specificity for 
quinones was utilized in the design of imaging probes for NQO1 detection. This approach to an 
enzyme-specific turn-on fluorescence probe relied on the tuning of a push-pull internal charge–
transfer (ICT)19 within the naphthalimide scaffold to change its emission properties by a redox-
mediated reaction.  
The work here is concerned with the design and synthesis of a molecular probe consisting 
of a trigger recognition unit, a linker and a fluorophore. The probe is efficiently quenched via 
PeT process, by it being bound to an activatable trigger group coupled to the naphthalimide 
through a novel self-immolative linker.20-21 The highly selective and rapid activation of the 
trigger group is achieved by chemical and enzymatic (NQO1-specific) means that result in 
activation of the trigger group’s detachment from the self-immolative linker, with the latter sub-
sequently cleaved from the reporter autonomously, thereby unmasking intense, red-shifted 
fluorescence emission. To achieve this result, I used a trimethyl-locked quinone propionic acid 
trigger group and an N-methyl-p-aminobenzyl alcohol self-immolative linker attached to the 
reporter (Figure 3.1).21-22 Delineated here are the synthesis and characterization of this cloaked 













Figure 3.1 Turn-on of self-immolative profluorophore Q3Nap.12 
3.2 Experimental 
3.2.1 Synthetic material and methods 
All chemicals were purchased from Sigma-Aldrich or Fisher Scientific and used as 
received. Column chromatography was performed on 50-g SNAP silica columns using a 
Flashmaster Personal from Biotage.  Thin layer chromatography was performed on aluminum-
backed 60 F254 silica plates from EMD Chemicals Incorporated.  1H and 13C NMR spectra were 
collected in CDCl3, DMSO-d6, or methanol-d4 at room temperature on a Bruker AV-400.  All 
chemical shifts are reported in the standard δ notation of parts per million using tetramethylsilane 
as an internal reference.  Absorption bands in NMR spectra are listed as singlet (s), doublet (d), 
triplet (t), multiplet (m), or two triplets (2t), and coupling constants (J) are reported in hertz (Hz).  
Mass spectral analyses were carried out using an Agilent 6210 ESI-TOF mass spectrometer.12  
3.2.2 Synthesis 
The general methods for all synthetically derived compounds are shown in Scheme 3.1 
and Scheme 3.2. 3-(3',6'-dioxo-2',4',5'-trimethylcyclohexa-1',4'-diene)-3,3-dimethylpropionic 
acid (Q3PA, 5), 4-(N-methylamino)benzyl alcohol (7), and 4-amino-9-(n-butyl)-1,8-




















































Scheme 3.2 Synthesis of NQO2 cofactor. 
4-Amino-9-(n-butyl)-1,8-naphthalimide (Nap) 
4-Amino-1, 8-naphthalic anhydride (1.14 g, 4.6 mmol) was dissolved in 250 mL ethanol under 
nitrogen atmosphere and brought to reflux. Then butylamine (2.0 mL, 20.23 mmol) was added 
and refluxed for 14hrs. After cooling the solvent was removed under reduced pressure and the 
crude was purified in flash column (20:1 DCM: EtOAc) to get the product as a yellow solid in 
75% Yield. 1H NMR (400 MHz, DMSO-d6) δ 8.61 (d, J = 8.4 Hz, 1H), 8.43 (d, J = 7.3 Hz, 1H), 
8.24 – 8.13 (m, 1H), 7.66 (t, J = 7.9 Hz, 1H), 7.43 (s, 2H), 6.85 (d, J = 8.6 Hz, 1H), 4.01 (t, J = 
7.5 Hz, 2H), 1.58 (p, J = 7.5 Hz, 2H), 1.33 (h, J = 7.7 Hz, 2H), 0.95 – 0.89 (m, 3H). 13C NMR 










































130.14, 131.45, 134.40, 153.14, 163.36, 164.23. ESI-MS: for C16H16 N2O2: expected m/z = 
269.1292 [M+H] +; found m/z = 269.1288 [M+H] +; 1.5 ppm error. 
Q3Nap: 
To a mixture of compound 2 (54 mg, 0.2 mmol) and DMAP (49 mg, 0.4 mmol) in 10 mL 
CH2Cl2 was added a solution of phosgene (15% in toluene, 1.0 mL) at −10 °C. The resulting 
solution was stirred for 3 h maintaining at −10 °C under argon. The excess phosgene was then 
removed by bubbling argon gas for 30 min. To this solution was added the alcohol 3 (221 mg, 
0.6 mmol) and the solution was stirred at 0 °C overnight. The reaction mixture was quenched 
with water (10 mL), and extracted with CH2Cl2 (2×25 mL). The organic phase was dried over 
Na2SO4 and then filtered. Solvent was removed using a rotary evaporator and the crude material 
was chromatographed (silica gel, 5:1 CH2Cl2/EtOAc) to provide Q3Nap as a yellow solid (41.10 
mg, 0.06 mmol, 31 % yield). 1H-NMR (Chloroform-d, 400 MHz) δ 8.63 (t, J = 8.4, 2.2 Hz, 2H), 
8.41 (d, J = 8.3 Hz, 1H), 8.19 (d, J = 8.8 Hz, 1H), 7.78 (t, J = 8.8, 8.2, 2.3 Hz, 1H), 7.57 – 7.48 
(m, 2H), 7.26 (d, J = 7.5 Hz, 2H), 5.35 (s, 2H), 4.22 – 4.07 (m, 2H), 3.17 (s, 3H), 2.77 (s, 2H), 
2.10 (d, J = 2.4 Hz, 3H), 2.07 – 1.94 (m, 6H), 1.78 – 1.65 (m, 2H), 1.44 (q, J = 7.8, 3.7 Hz, 2H), 
1.34 – 1.21 (m, 6H), 0.98 (t, J = 7.4, 2.3 Hz, 3H). 13C-NMR (Chloroform-d, 100 MHz) δ 191.45, 
187.79, 172.1, 164.23, 163.76, 154.66, 153.03, 144.45, 138.71, 136.58, 132.6, 131.42, 130.12, 
129.1, 127.98, 126.87, 125.76, 123.77, 123.05, 118.34, 116.99, 67.3, 47.94, 40.42, 38.23, 37.27, 
30.37, 28.68, 20.54, 14.27, 14.00, 12.89, 12.30. ESI-MS: for C39H41N3O7: expected m/z = 
664.3018 [M + H]+; found m/z = 664.3030 [M + H]+; 1.8 ppm error. 
1-(Carbamoylmethyl)-3-carbamoylpyridinium iodide (13) 
A mixture of nicotinamide (1.0g, 8.2 mmol) and 2-iodoacetamide (1.5g, 8.2 mmol) in DMF was 
stirred at 60 °C for 4 hours. After cooling to room temperature, the mixture was diluted with 
ethyl acetate and stirred for another 30 minutes. Filtration and recrystallization from aqueous 
ethanol afforded colorless crystals. 1H NMR (400 MHz, methanol-d4) δ 9.40 (s, 1H), 9.10 (s, 
2H), 8.37 (s, 1H), 5.72 (s, 2H).24  
1-Carbamoylmethyl-3-carbamoyl-1,4- dihydropyridine (14) 
To a solution of (20 mg) in water (5 mL) was added anhydrous sodium carbonate (50 mg), 
sodium bicarbonate (50 mg), and sodium hydrosulfite (50 mg), and stirred for 30 min at 37 °C. 
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Solvent was evaporated, and the residue obtained was dissolved in methanol. Purification with 
C-18 RP column through a gradient elution (0—50%) AcCN in water afforded. 1H NMR (400 
MHz, methanol-d4) δ 7.05 (s, 1H), 5.94 (s, 1H), 5.04 (s, 1H), 4.06 (s, 1H), 3.16 (s, 2H).24 
3.2.3 Cyclic voltammetry 
Cyclic voltammetry was performed on Q3Nap in 0.1 M (n-butyl)4NClO4/dry acetonitrile 
under anaerobic conditions. A Princeton Applied Research Potentiostat/Galvanostat Model 273A 
was used along with the program Power Suite-2.53. Voltammograms were collected at 0.1 V s−1 
at room temperature after degassing the solution with nitrogen for 20 min. Glassy-carbon 
working (BAS, 3-mm diameter), platinum wire counter, and Ag/AgCl reference (BAS) 
electrodes were used, and the potentials were referenced versus ferrocene/ferrocenium internal 
standard.12 
3.2.4 Enzyme kinetics 
hNQO1. All fluorescence measurements (λex = 432 nm, λem = 540 nm) were obtained at 
room temperature with solutions composed of pH 7.4, 0.1 M PBS/0.1 M KCl/0.007% BSA. 
Solutions of β-nicotinamide adenine dinucleotide, reduced disodium salt (NADH, Sigma-
Aldrich) were made with the PBS buffer so that subsequently prepared solutions possessed a 
final concentration of 1 × 10−4 M β-NADH in each assay. Solutions consisting of 2 × 10−6 to 6 × 
10−5 M Q3Nap were made using the NADH stock. A 40 µg mL-1 stock solution of recombinant 
hNQO1 (Sigma-Aldrich) was prepared using the same buffer as above so as to give 4.0 × 10−5 g 
hNQO1 per assay. Each assay was performed in a quartz fluorescence cuvette containing 1 mL 
Q3Nap solution and initiated by the addition of 1 mL hNQO1 solution.  Measurements were 
collected every 30 s for 10 min.  Fluorescence units were converted to concentration by relating 
the signal increase to a fluorescence signal derived from a known concentration of Nap reporter.  
Plots of velocity versus Q3Nap concentration were used to obtain apparent Km and Vmax values 
from nonlinear least-squares analysis employing algorithms developed by Cleland for 
Michaelis−Menten kinetics.12 
hNQO2. The fluorescence (λex = 432 nm, λem = 540 nm) at room temperature was 
recorded versus time for solutions of 40 µg mL-1 recombinant hNQO2 (Sigma-Aldrich),  
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5 × 10−5 M Q3Nap, and 1 × 10−4 M co-substrate in pH 7.4, 0.1 M PBS/0.1 M KCl/0.007% BSA. 
Co-substrate for hNQO2 was prepared according to Richard J. Knox et al.24 
3.2.5 Cell culture: This work was performed by Bijeta Prasai in the McCarley research group 
HT29 (human colorectal adenocarcinoma), H596 (human non-small cell lung cancer), 
cell culture base media, and fetal bovine serum (FBS) were purchased from American Type Cell 
Culture (ATCC), Manassas, VA. Cell culture was performed as suggested by ATCC. HT29 cells 
were cultured in McCoy’s 5A base medium supplemented with 10% FBS and 100 IU/ml 
penicillin-streptomycin (purchased from Invitrogen). H596 cells were cultured in RPMI-1640 
with 10% FBS and 100 IU/ml penicillin-streptomycin. Cells were incubated at 37 °C in a 
humidified incubator containing 5% wt/vol CO2.  
3.2.6 Cell imaging via scanning laser confocal microscopy and wide-field microscopy 
HT29 and H446 cells were cultured overnight in 22 × 22 mm glass coverslips on a treated 
tissue culture 6-well plate purchased from Fisher Scientific. At that time, old growth medium 
was replaced with 2 mL of fresh medium and then incubated at 37 °C.  Solutions of Q3Nap 
prepared in DMSO were added to each cell line to give 2 × 10−5 M solution of Q3Nap, keeping 
the DMSO concentration at 1% or less.   Cells were incubated with Q3Nap at 37 °C for 30 min 
(HT29) and 2 h (H596).  Cells were then treated with 3.0 × 10−6 M DRAQ5 (nuclear stain 
obtained from Thermo Scientific) for 1 min. Then the medium was removed, and the cells were 
fixed in 2 mL of 4% paraformaldehyde for 15 min with shaking.  After fixing, the cells were 
rinsed with Nanopure water, and the coverslips were mounted to glass slides with Immumount 
(obtained from Fisher Scientific).  Glass slides were left in the dark overnight to allow the 
Immumount to dry.  Confocal images were acquired using a Leica TCS SP2 spectral confocal 
microscope.  For images of cells exposed to Q3Nap, samples were excited using the 458-nm line 
of an Ar/KrAr laser, and the spectral emission was collected between 458 and 514/514 and 680 
nm (Leica DD458/514).  Likewise, cells exposed to DRAQ5 were excited using the 633-nm line 
of a HeNe laser, and the spectral emission was collected between 678 and 773 nm.  All images 
were collected using a pinhole of 3.1 Airy units. Images were frame and line averaged 4 times.  
Image analysis was performed using ImageJ and Leica LAS AF lite software.  Wide-field images 
were acquired using a Leica DM RXA2 fluorescent microscope equipped with a 100x 1.4NA 
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objective lens and a Cooke SensiCam QE.  Slidebook software was used to control the camera 
and microscope as well as image renormalization, deconvolution and scale bar placement.  The 
nucleus was stained with DRAQ5, and a Leica CY5 filter set (λex = 590–650 nm, λem = 663–737 
nm) was used when visualizing this dye.  Cells exposed to Q3Nap were examined using a CFP 
filter set (λex = 426–466 nm, λem = 460–500 nm).  
3.3 Results and Discussion 
3.3.1 Spectroscopic properties of Q3Nap and Nap 
Spectroscopic properties of the probe Q3Nap and the free dye Nap showed striking 
differences in buffered aqueous media (Figure 3.2 (a) and (b)). The probe Q3Nap showed a broad 
absorption band centered around 380 nm with an extinction coefficient (ε = 2.1 x 104  M−1cm−1) 
while Nap reporter had a broad absorption band centered around 432 nm with an extinction 
coefficient (ε = 1.9 x 104  M−1cm−1).  
These differences are attributed to the presence of the quinone propionic acid trigger 
group (Q3PA), as well as the carbamate connection between the N-methyl-p-aminobenzyl 
alcohol, NMPABA, linker, and the naphthalimide fluorophore. The NMPABA linker imparts 
several different inherent properties for the Q3Nap probe system; (1) the self-immolative 
behavior provides a faster signal relay upon a trigger event, (2) the tertiary amide provides 
enhanced environmental stability (prevents the formation of the spirolactam species), (3) the 
aromatic nature and short linker length allow for a high probability of electron transfer that 
yields a favorable ΔGPeT, and 4) forms a carbamate linkage with the Nap dye effecting its ICT 
push-pull properties. The λreport is red shifted roughly 50 nm in comparison to λprobe (432 nm vs 
380 nm), as is λreport vs λprobe (532 nm vs 480 nm), with both observations being in accord with 
the presence of the electron-deficient carbamate in Q3Nap. Another important feature of the 
probe system is the absorptivity of Q3Nap at the maximum absorption wavelength of Nap is ∼5 
times lower than that for Nap reporter. A combination of the aforementioned factors help Q3Nap 




























Figure 3.2 Absorption and emission spectra of 2 × 10−6 M a) Q3Nap  and b) reporter Nap in 
pH 7.40, 0.1 M phosphate buffer; T = 25 °C.12 
a) 
b) 














































































3.3.2 Thermodynamic feasibility of PeT quenching 
In order to assess the thermodynamic feasibility and efficiency of this novel fluorescence 
quenching of Q3Nap by oxidative electron transfer (OeT) and by reductive electron transfer 
(ReT),25  as depicted in Figure 3.3, outcomes from voltammetric measurements of both the 
quinone trigger and the Napbutyl reporter were used in the Rehm-Weller equation to calculate 














Figure 3.3 Cyclic voltammetry of Q3Nap and Q3PA at a 3-mm diameter glassy carbon 
working electrode using 0.1 M tetrabutylammonium perchlorate in acetonitrile; T = 25 °C; Scan 
rate was 0.1 V s−1. 
donor Nap and the potential EA of the quinone propionic acid acceptor of Q3Nap were 
determined to be 1.08 V and −1.05 V respectively. From Figure 3.4 the energy of the first excited 
singlet state (ΔG00) of the Nap reporter, was found to be 3.05 eV; e2/εd which is the Coulombic 
interaction energy of the ion pair, known to be 0.06 eV. From these values, the energy change for 
the OeT quenching, ΔGPeT, is calculated to be −0.98 eV, indicating that electron transfer from the 
excited Nap dye to the electron-poor quinone propionic acid is thermodynamically feasible. 
Similarly, a significantly favorable ΔGPeT of −1.44 eV was computed for the reductive quenching 
and catalyzes the strict two-electron reduction of quinones to
hydroquinones, making this flavoenzyme an ideal target for
prodrug therapies21 and profluorophores.
Herein we report the design, properties, and NQO1-specific
cellular activation of a first-generation, PeT-quenched fluo-
rescence probe. The turn-on sensor probe readily penetrates
the membrane of human cancer cells because it is hydrophobic,
small in molecular weight, and charge neutral. Upon rapid and
preferential, two-electron reduction of the quinone quencher
subunit of the turn-on probe, an intensely light-emissive
reporter results from autonomous removal of the activated
quinone subunit. Efficacious PeT quenching of fluorescence
prior to subunit self-cleavage is ensured by careful selection of
the electronic properties of the naphthalimide reporter and
quinone quencher. The resulting highly fluorescent, cationic
reporter is retained by cells, and it exhibits a strong Stokes shift
between its absorption and fluorescence emission maxima due
to the push!pull internal charge-transfer mechanism associated
with the naphthalimide scaffold. Overall, these probe character-
istics allow for rapid and enhanced signal-to-background
imaging and detection of living cancer cells without the typical
requirement of unactivated probe removal from the environ-
ment. In total, the profluorogenic probe provides for real-time,
highly sensitive, and selective human tumor cell analysis and
differentiation based on NQO1 content.
! RESULTS AND DISCUSSION
Q3NI Probe Fluorescence is Controlled by Photo-
induced Electron Transfer (PeT) Quenching. We designed
the Q 3NI probe to have the fluorescence signal of its
naphthalimide reporter22,23 quenched via oxidative electron-
transfer (OeT) by the covalently attached quinone propionic
acid motif, Figure 1A. It was posited that it would be possible to
achieve this novel mechanism of reporter quenching by
carefully tuning the electronic and optical properties of the
quinone OeT quencher and the naphthalimide reporter NI, due
to extant naphthalimide reporters that are quenched by
reductive electron-transfer (ReT).22 The Rehm!Weller equa-
tion, eq 1,
εΔ = − − Δ −G E E G
e
dPeT D A 00
2
(1)
was used to examine possible quinone propionic acid
quenchers24 and 1,8-naphthalimide reporters as well as linkers
between the OeT quencher and the NI reporter, so as to ensure
that quenching is thermodynamically feasible and efficient.15 In
this equation, ED is the redox potential of the donor and EA that
of the acceptor, ΔG00 is the energy of the first excited singlet
state of the reporter, and e2/!d is the Coulombic interaction
energy of the ion pair, known to be 0.06 eV.15 The energy of
the first excited singlet state of NI was measured to be 3.06
eV.15 From voltammetric measurements, ED of NI was
determined to be 1.74 V, and EA for the quinone propionic
acid group of Q 3NI was found to be !1.01 V (Figure S2).
From these values, the energy change for this OeT process,
ΔGPeT, is calculated to be !0.37 eV, indicating that electron
transfer from the excited dye to the electron-poor quinone is
thermodynamically favorable. The quinone was attached to the
naphthalimide via an N-methylethanolamine linker through a
carbamate to the amine of the naphthalimide ring. This linker
imparts three crucial properties on Q 3NI: the linker is
sufficiently short to allow for a high probability of electron
transfer, the electron-withdrawing carbamate yields a favorable
ΔGPeT, and the presence of the tertiary amide provides
enhanced environmental stability.23,25 As a result, the
fluorescence of Q 3NI in pH 7.4, 0.1 M PBS is effectively
quenched in comparison to that of the free NI reporter, as
not d by their spectra in Figure 1B,C and respectiv
fluorescence quantum yields (Φ) of 0.007 and 0.23 obtained
using quinine sulfate as standard.26 The quantum yield for NI is
superior or comparable to that of other dyes applied to cancer
detection and localization, such as Φ = 0.0028 for indocyanine
green and Φ = 0.21 for Cy5.5 dyes.13,27 The 33-fold
fluorescence enhancement for NI versus Q 3NI and very large
Stokes shift of 116 nm ("max, abs = 374 nm, "max, em = 490 nm)
bode well for use of Q 3NI as a multifunctional turn-on probe
for sensing and imaging applications that utilize reductive
stimuli capable of initiating removal of the reduced quinone
group.28!31
Fluorescence Dequenching of Q3NI is Achieved by
Reduction-Initiated Removal of Quinone. We then wished
to determine if it is possible to produce the NI reporter from
the Q 3NI probe by the expected cyclizative cleavage reaction of
the hydroquinone via the gem-dialkyl effect32 that occurs
subsequent to two-electron reduction of the quinone.28 Thus,
the strong reducing agent sodium dithionite was added to
aqueous solutions of Q 3NI. Under these conditions, it was
found that NI is rapidly released as indicated by the increase in
time-dependent fluorescence intensity (Figure 2) at 470 nm
("ex = 370 nm). To provide proof positive that the increase in
fluorescence for reduced Q 3NI results from cyclizative cleavage
of the hydroquinone reduction product as the lactone, a second
probe (Q 1NI) was synthesized such that the rate of lactone
formation from its hydroquinone form is >103 times slower
than in the case of reduced Q 3NI, due to the lack of the two
methyl groups on the geminal carbon.28 Dithionite reduction of
the Q1 group is known to be as equally fast as the Q3 group.
28
As seen in Figure 2, reduced Q 3NI exhibits exceedingly rapid
NI reporter production in comparison to reduced Q 1NI; at
Figure 1. Schematic representation of the unique utilization of PeT
quenching in the hNQO1 probe Q 3NI and the emission properties
associated with Q 3NI probe and NI: (A) proposed quenching
mechanisms for Q 3NI probe prior to and after chemical/hNQO1-
catalyzed reduction and subsequent production of the fluorescent NI
reporter. Fluorescence spectra and optical images of cuvettes
containing 2.0 ! 10!6 M solutions of (B) Q 3NI probe and (C) NI
reporter in pH 7.4, 0.1 M PBS that result from excitation at "ex = 375
nm (spectra) and "ex = 365 nm (images).
Journal of the American Chemical Society Article
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process (ReT) of the Nap reporter by the reduced quinone (hydroquinone), pointing to its 
















Figure 3.4 Q3Nap absorption (black) and emission (Red) in Acetonitrile solution; T = 25 °C. 
This latter ReT process of quenching the reporter fluorescence by electron rich species 
(e.g. hydroquinone, Figure 3.5) is a common feature with naphthalimide dye. 
 
 
Figure 3.5 Schematic representation of the novel PeT quenching of Q3Nap, proposed 
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3.3.3 Quantum yield  
Fluorescence quantum yield measurements were carried out using dilute dye solutions 
where absorbance was between 0.02-0.08. An amount of 3 mL from these solutions were 
transferred to 1-cm × 1-cm quartz cuvettes and subjected to fluorescence measurements. 
 
         ΦF(X) = (As/Ax) (Fx/Fs) (nx/ns)2 ΦF(S)                                Equation 2     Eq 1  Eq 1 
 
The quantum yields were calculated relative to two different standard solutions, 1) 
coumarin in EtOH (Φ = 0.54)26 for Nap, and 2) quinine sulfate in 1 N H2SO4 (Φ = 0.51)26 for 
Q3Nap using the Equation 2, where Φ F is the fluorescence quantum yield, A is the absorbance at 
the excitation wavelength, F is the area under the corrected emission curve and n is the refractive 
index of the solvents used. Subscripts S and X refer to the standard and the unknown, 
respectively.27 In this equation, absorbance A accounts for the number of absorbed photons and 
area F accounts for the number of emitted photons. Quantum yields for Φ(Q3Nap) and 
Φ(Nap)were obtained in aqueous media under physiological conditions (0.1 M phosphate buffer, 
pH =7.4) and were calculated at 0.002 and 0.19 respectively. This large difference (95-fold 
fluorescence enhancement) in quantum yields is due to photo induced electron transfer (PeT) 
quenching of the naphthalimide reporter by the Q3PA trigger group. To further evaluate this 
outcome, voltammetric measurements were carried out and are described in the next section.  
3.3.4 Reduction-initiated, self-immolative, turn-on response of Q3Nap 
The striking difference in both the absorption (λreportabs  is red shifted roughly 50 nm in 
comparison to λprobeabs , 432 nm vs 380 nm), and the emission (λ
report
emis  vs λ
probe
emis  , 532 nm vs 480 nm), 
prompted the possibility of Q3Nap’s use as a ratiometric probe in these studies. However, the 
large difference in quantum yields of the Q3Nap probe and the Nap reporter did not bode well for 
the ratiometric concept. To test this, Q3Nap was excited at different wavelengths (Figure 3.6): A) 
at the maximum absorbance of Q3Nap, λex =380 nm; B) at the intersection of the two 
absorbances of Q3Nap and Nap λex =400 nm; and C) at the maximum absorbance of the Nap 














































Figure 3.6 Fluorescence turn-on response of 2 µM Q3Nap at with different excitation, (A) λex 
= 380 nm, (B) λex = 400 nm, and (C) λex = 432 nm in pH 7.40, 0.1 M phosphate buffer with 16 
µM sodium dithionite; T = 25 °C. 
 






































































conditions. The outcome of this study revealed that the quenched Q3Nap probe showed minimum 
fluorescence enhancement in A and maximum in C, indicating its true turn-on potential in 
contrast to a ratiometric response.  
The rapid turning on of the reporter Nap by the self-immolative cleavage of the 
NMPABA linker subsequent to the reduction of Q3Nap was next demonstrated. Previous studies 
with dithionite showed that the reduction of the Q3PA moiety is complete within 1 s, and the 
half-life of the lactonization reaction is less than 2 min.28 Thus, sodium dithionite was added to 
aqueous solutions of Q3Nap, and the resulting fluorescence from Nap was used to determine the 

























Figure 3.7 Reduction-stimulated turning-on of Q3Nap to yield Nap reporter. Time-course 
fluorescence (λex = 432 nm, λemis = 540 nm) from 10 µM Q3Nap (pH 7.40, 0.1 M phosphate 
buffer) after reduction by 16 µM sodium dithionite. The inset contains time-dependent spectra of 
2 µM Q3Nap upon reduction; T = 25 °C.12 
 
cytosol of numerous human tumor cells (e.g., colon, breast,
pancreas, and nonsmall cell lung).11 The previously unreported
NQO1-selective, turn-on fluorescence probe 1 relies on tuning
the push!pull internal charge transfer (ICT)14 of the
naphthalimide scaffold via its attachment to the self-immolative
NMPABA linker using an electron-withdrawing carbamate
connection. We show here that upon initiation of trigger group
removal from the tripartite probe, subsequent rapid cleavage of
linker occurs so as to afford reporter 2, which has distinct
spectral properties such that NQO1-positive cancer cells can be
imaged and identified with a positive-to-negative ratio of
"500:1.
As seen in Figure 1, the spectroscopic properties of probe 1
and reporter 2 in buffered aqueous media are strikingly
different, and these differences are attributed to the presence of
the quinone propionic acid trigger group (Q3PA), as well as the
carbamate connection between the N-methyl-p-aminobenzyl
alcohol, NMPABA, linker, and the naphthalimide fluorophore.
The λabs
report is red shifted roughly 50 nm in comparison to λabs
probe
(432 nm vs 380 nm), as is λemis
report vs λemis
probe (532 nm vs 480 nm),
with both observations being in accord with the presence of the
electron-deficient carbamate14 in probe 1. Interestingly, the
absorptivity of probe 1 at the maximum absorption wavelength
of reporter 2 is "5 times lower than that for reporter 2. The
!probe value of 0.002, which is 95 times less than !report = 0.19,9
is due to photoinduced electron transfer (PeT)15 quenching of
the naphthalimide reporter by the Q3PA group. This
conclusion is supported by outcomes based on voltammetric
and spectroscopic data for probe 1, reporter 2, and Q3PA;
9 the
free energy of the PeT process is !0.98 eV, indicating ready
electron transfer from the excited naphthalimide to the
electron-poor Q3PA group of probe 1. In comparison to the
previously reported probe Q3NI,
5 there is a 3-fold-larger change
in fluorescence efficiency for probe 1 upon NQO1 action to
yield the corresponding reporter (!report/!probe), and the
fluorescence energy range of reporter 2 is more attractive for
possible imaging applications.
We next wanted to demonstrate rapid turning on of reporter
2 by the self-immolative cleavage of the NMPABA linker
subsequent to the reduction of probe 1. Dithionite reduction of
the Q3PA m iety is complete within 1 s, and the half-life of the
lactonization reaction is less than 2 min.16 Thus, sodium
dithionite was added to aque us solutions of probe 1, and the
resulting flu r s e ce from reporter 2 was used to termine
the extent of probe 1 conversion to reporter 2 (Figure 2).
Reporter 2 is quickly turned on (t1/2 "6 min) under
physiologically relevant conditions, pointing to the rapid self-
immolative cleavage of the N-methyl-p-aminobenzyl alcohol
and CO2 loss
8 to yield reporter 2; this occurs because of the
electron-rich character of the N-methyl-p-aminobenzyl alcohol
vs that of the more typically encountered p-aminobenzyl
alcohol linker.8,17 Conversion was confirmed by mass
spectrometry analysis of probe 1 solutions treated with
dithionite.9 On the basis of the relatively short time for the
turn-on process, the use of probe 1 should allow for detecting
the presence of NQO1 enzyme activity.
To evaluate the ability of human NAD(P)H:quinone
oxidoreductase-1 (hNQO1) to initiate the decloaking of
probe 1 and reveal free reporter 2 upon Q3PA trigger group
activation, we utilized the fluorescent product formation
technique.18 Under in vitro conditions, solutions of probe 1
(2!60 μM) incubated with hNQO1 (40 μg) and its cofactor
NADH (100 μM) exhibited steady increases in fluorescence,
suggesting a relatively fast rate of reporter 2 production; control
experiments with NADH alone did not yield significant changes
in fluorescence, a result in accord with that previously shown
for the Q3PA trigger group.
10 In addition, the Q3PA trigger
group is stable to reduction/addition reactions in the presence
of glutathione and ascorbate as well as dithiothreitol.5
Scheme 1. Turn-On Self-Immolative Profluorophore 1
Figure 1. Absorbance and emission spectra of 2 μM probe 1 and
reporter 2 in pH 7.40, 0.1 M phosphate buffer. T = 25 °C.
Figure 2. Reduction-stimulated turning on of reporter 2. Time-course
fluorescence (λex = 432 nm, λemis = 540 nm) from 10 μM probe 1 (pH
7.40, 0.1 M phosphate buffer) after reduction by 16 μM sodium
dithionite. The inset contains time-dependent spectra of 2 μM probe 1
upon reduction. T = 25 °C.
Journal of the American Chemical Society Communication
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The Nap reporter is quickly turned on (t1/2∼6 min) under physiologically relevant 
conditions, pointing to the rapid self- immolative cleavage of the N-methyl-p-aminobenzyl 
alcohol and loss of CO2 to yield the Nap reporter. This occurs because of the electron-rich 
character of the N-methyl-p-aminobenzyl alcohol versus that of the more typically encountered 
p-aminobenzyl alcohol linker. The release of the Nap reporter after the initial reduction by 
dithionite was evident by the appearance of an absorption band centered at 432 nm (Figure 3.8), 

























Figure 3.8 Demonstration of the changes in absorption spectra of 2 µM Q3Nap black, before 
and red, after the addition of 16 µM sodium dithionite in pH 7.40, 0.1 M phosphate buffer;  T = 
25 °C. 
This conversion was also confirmed by mass spectrometric analysis of Q3Nap solutions 
treated with dithionite (Figure 3.9). The result clearly show the three products generated; Nap 
reporter, Q3lactone, and the N-methyl-p-aminobenzyl alcohol. 








































Figure 3.9 Positive-ion electrospray mass spectra of Q3Nap (A–before reduction) and after 
reduction (B–with dithionite) to yield Nap, N-methyl-p-aminobenzyl alcohol linker, and the 
lactone. Q3Nap [M+H]+ signal is observed at m/z 664.3012 (expected m/z 664.3018 [M+H]+, 0.9 
ppm error). ✶ Nap [M+H]+ signals observed at m/z 269.1285 and (expected m/z 269.1285 
[M+H]+, 0.0 ppm error). •  Lactone [M+H]+ signals observed at m/z 235.1328 (expected m/z 
235.1329 [M+H]+, 0.4 ppm error).  Linker [M+H]+ signals observed at m/z 138.0913 (expected 
m/z 138.0914 [M+H]+, 0.7 ppm error). 
3.3.5 Q3Nap activation by hNQO1 enzyme 
The fast turn-on response observed in the dithionite–initiated reduction studies, suggests 
that the use of Q3Nap should allow for the detection of NQO1 enzyme activity. To test whether 
human NQO1 can initiate the decloaking of Q3Nap to reveal the free Nap reporter upon 
activation of the quinone trigger group, the formation of the fluorescent product, with different 
concentrations of probe, was monitored over time in the presence of a constant amount of 
enzyme. For quantitative evaluation of Q3 activation by human NQO1, I monitored the 







human NQO1 (4 × 10−5 g) and its cofactor NADH (1 × 10−5 M). The fluorescence intensity was 
converted to concentration of the free Nap reporter, using a calibration curve. Control 
experiments with NADH alone did not yield significant changes in fluorescence, a result in 
accordance with that previously shown for the Q3PA trigger group. From these experiments, the 
initial rate of product formation, V (µmol min−1mg.hNQO1−1), was calculated and plotted as a 








Figure 3.10 Kinetics of human NQO1 (4 ×10−5 g) with Q3Nap (2−60 ×10−6 M) in pH 7.4, 0.1 
M phosphate buffer. Values (n = 3) are the average ±1 sample standard deviation. The curve is 
the best fit to the average data; T = 25 °C. 
Apparent kinetic parameters were then obtained by fitting the data in Figure 3.10 to the 
Michaelis-Menten equation,29 which provides the Michaelis constant (Km) = 10.4 ± 1.0 µM, 
maximum velocity (Vmax) = 0.00225 ± 0.00008 µmol min−1mg.hNQO1−1, catalytic constant (kcat) 
= 0.068 ± 0.002 min−1, and catalytic efficiency (kcat/Km) = 6.52 ± 0.67 ×103 M−1min−1. In 
addition, the Q3PA trigger group is stable to reduction/addition reactions in the presence of 
glutathione and ascorbate as well as dithiothreitol. Also, there is no apparent inhibition of 
hNQO1 activity with the [Q3Nap] values studied. The results indicate that an efficient reporter 
release of the reporter occurs with the interaction between Q3Nap and human NQO1 under 
physiological conditions. However Q3Nap activation by hNQO1 was slow compared to Q3NI,6 a 
previously reported probe in our group. I postulate this is due to the p-aminobenzyl alcohol 
























[Probe 1] × 10-6 M
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linker locking the geometry into one orientation, such that the flexibility the Q3Nap is hindered 
to access the hNQO1 catalytic site. Much faster enzyme kinetics was observed for a different 
probe with a flexible linker, which will be discussed in chapter 4. 
3.3.6 Differentiating and visualizing cancer cells that overexpress hNQO1 
I next sought to apply Q3Nap for fluorescence imaging of various cancer cell lines. 
Specifically, the probes’ ability to differentiate cancer cell lines based on hNQO1 content 
(positive vs negative), by exposing live hNQO1-positive and hNQO1-negative cells to Q3Nap 





















Figure 3.11 Microscopy images of hNQO1-positive HT29 colon (A, B, C) and hNQO1-
negative H596 lung (D, E, F) cancer cells after incubation at 37 °C with 2 × 10−5 M Q3Nap. 
Confocal images in A, B, D, and E; differential interference contrast in C and F. DRAQ5 nuclear 
stain was used for B and E. Scale bar = 20 μm. 
Confocal fluorescence microscopy images of fixed hNQO1-positive colorectal cancer 
cells (HT29) incubated with Q3Nap indicated significant Q3Nap uptake and activation, resulting 
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cells (H596) treated with Q3Nap revealed minimal production of Nap reporter (Figure 3.11). 
These results suggest that Q3Nap is stable in the intracellular environment of NQO1-negative 
cell line, pointing to the fact that the production of the Nap reporter is possible only in the 
presence of hNQO1. In addition similar behavior was observed in another amide-linked 
napthalimide reporter, Q3NI. Wide-field fluorescence micrographs yielded similar results. Upon 
statistical evaluation of the fluorescence intensities in confocal images of hNQO1-positive (35 
samples) and hNQO1-negative (29 samples) cells like those in Figure 3.11, a value of 11 was 
found for the positive-to-negative ratio (Figure 3.12). Similarly, for wide-field fluorescence 
images (33 positive samples/20 negative samples), a PNR of 510 was observed. Thus, the PNR 
value of ∼500 obtained with Q3Nap/Nap is unprecedented in the context of our previous work 
with identical cell lines, and this value can be improved in wide-field measurements by the use 
of a filter set (BCECF) that more completely encompasses the emission profile of Nap. It is 
important to note that this significantly decreased background (negative) signal is achieved via 
several factors, 1) the unique PeT quenching gives rise to an exceedingly large difference in 
fluorescence efficiency between the quenched probe and the free Nap reporter (95-fold increase); 
2) the shift of wavelength to the red by 100 nm in both the energies over which Q3Nap/Nap 
reporter is excited/emits light, and 3) the corresponding lower molar absorptivity of Q3Nap vs 
Nap reporter at the excitation maximum of Nap reporter, in Q3Nap’s design.  
3.3.7 Q3Nap selectivity towards NQO1 over its isoenzyme NQO2  
Human NAD(P)H: quinone oxidoreductase 2 (NQO2, EC 1.10.99.2)30 is a cytosolic 
homodimeric flavoprotein with one FAD prosthetic group per monomer. Like NQO1, NQO2 
also catalyzes a two-electron reductive metabolism of quinones and its derivatives, and has a 
49% identity between their amino acid sequences.31 They both utilizes pyridine nucleotide as 
cofactors; however, NQO2 differs from NQO1 in that it prefers a smaller dihydronicotinamide 
riboside (NRH) as the co-substrate, instead of NAD(P)H. In comparison to NQO1, NQO2 is 
usually expressed at very low levels in human solid tumors, but is expressed at higher levels in 
red blood cells and in leukemias.32 To study the selectivity of Q3Nap probe towards NQO1, 
NQO2 enzyme assay was conducted as described 3.2.4. The Co-substrate 14 was synthesized 
according to a previously reported method, which is known to have greater stability and activity 























Figure 3.12 Integrated intensities for positive and negative NQO1 cell images obtained with 
confocal and widefield microscopy, with average positive and negative values in yellow and the 



















# F intensity 
Data point 
# F intensity 
Data point 
# F intensity 
Data point 
# F intensity 
1 21.5 1 2.1 1 33.7 1 0.000000 
2 26.8 2 3.4 2 39.4 2 0.000000 
3 40.3 3 3.9 3 31.8 3 0.000000 
4 33.1 4 5.1 4 51.0 4 0.004000 
5 16.1 5 4.7 5 48.8 5 0.000000 
6 18.9 6 1.9 6 46.4 6 0.000000 
7 22.2 7 3.5 7 45.8 7 0.000000 
8 44.6 8 2.2 8 35.7 8 0.000056 
9 36.1 9 1.5 9 29.0 9 0.000000 
10 22.2 10 2.6 10 43.2 10 0.000067 
11 36.8 11 6.6 11 45.5 11 0.004000 
12 15.9 12 3.1 12 48.1 12 0.004000 
13 18.6 13 0.8 13 53.4 13 0.865000 
14 21.7 14 -0.1 14 44.7 14 0.015000 
15 16.7 15 2.2 15 54.6 15 0.666000 
16 26.8 16 4.1 19 36.6 16 0.000000 
17 27.4 17 1.6 20 56.5 17 0.000000 
18 29.4 18 2.5 21 44.4 18 0.000000 
19 23.0 19 1.8 22 44.9 19 0.000000 
20 21.2 20 1.7 23 49.6 20 0.000000 
21 40.2 21 1.3 24 49.8 Average 0.077906 
22 36.0 22 1.7 25 39.0 
  23 23.4 23 2.1 26 32.8 
  24 29.0 24 0.2 27 38.8 
  25 28.2 25 3.1 28 14.2 
  26 34.3 26 2.5 29 54.4 
  27 14.8 27 2.6 30 22.2 
  28 24.9 28 2.5 31 24.2 
  29 21.0 29 2.5 32 28.1 
  30 34.5 Average 2.5 33 32.8 
  31 29.4 
  
Average 40.6 
  32 26.2 
  
Wide-field PNR 
  33 30.7 
  
HT29/H596 521.8 
  34 29.6 
      35 35.6 
      Average 27.4 
      Confocal PNR 
      HT29/H596 10.8 
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As shown in Figure 3.13, a fluorescence enhancement, by Q3Nap activation and 
subsequent Nap reporter production, was higher in NQO1 enzyme assay, while NQO2 showed 



















Figure 3.13  Time-dependent fluorescence spectra (λex = 432 nm, λem = 540 nm) of Q3Nap (5 × 
10−5 M) upon exposure to 40 µg human NQO2 (A) in the presence of 100 µM reduced 
nicotinamide co-factor in pH 7.4, 0.1 M PBS/0.1 M KCl/0.007% BSA buffer showing the lack of 
reduction-induced production of Nap, versus Q3Nap activation in the presence of 4 × 10−5 g 
hNQO1 (B) under similar conditions. 
3.4 Conclusions 
I have presented the synthesis, spectroscopic properties and kinetic evaluation of a novel 
self-immolative quenched turn-on fluorescent probe, which features a unique photoinduced 
electron-transfer quenching mechanism, that can be modulated by a reduction initiated removal 
of a cancer-associated-enzyme substrate. Specifically, reduction of the trimethyl quinone 
propionic acid substrate by NADP(H): quinone oxidoreductase triggers the removal of the self-
immolative spacer, which spontaneously falls apart releasing the naphthalimide fluorescent 
reporter possessing a highly intense emission and dramatic change in Stokes shift. I have clearly 
demonstrated that the turning-on of Q3Nap, under physiological solution conditions has a 
sensitive response to human NQO1. This is achieved in a highly selective fashion from dramatic 













fluorescence enhancement of the production of red-shifted Nap reporter, generated only upon 
hNQO1 action on the trigger group of the Q3Nap probe. This was evident by the studies 
conducted with hNQO1-positive HT29 and hNQO1-negative H446 cancer cell lines, resulting in 
Q3Nap activation with unprecedented PNR values.  
The self-immolative linker is important for Q3Nap’s mode of action and for its unique 
spectroscopic properties, mainly providing, 1) a shiftable wavelength, 2) environmental stability, 
3) faster signal relay kinetics and efficient quenching. In addition, the release studies conducted 
with sodium dithionite showed faster Nap production under physiological conditions, but the 
hNQO1 activation of Q3Nap was rather slow, with fairly high binding constants and low 
catalytic turnover numbers. This may be due to the fact that, the rigid self-immolative linker 
locking the geometry of Q3Nap into one position, resulting in a loss of its flexibility when 
binding to the catalytic site of the hNQO1 enzyme. However, with regard to longer-term 
impacts, these types of enzyme-activatable probes, will serve as an important step towards a new 
generation of compounds attractive for use as “intelligent” imaging agents in fluorescence-
assisted studies of cancerous tissues providing real-time information on tumor cell 
microenvironment, and efficacy studies of personalized chemotherapy.10,33 
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DESIGN, SYNTHESIS, AND EVALUATION OF A PROFLUOROGENIC NIR TURN-
ON SUBSTRATE-PROBE FOR DETECTION AND IMAGING OF CANCER CELLS 
4.1 Introduction 
Fluorescence imaging is expected to have a significant impact on future personalized 
oncology, owing to its high temporal and spatial resolution. The design of fluorescence imaging 
probes that can detect chemical or biological analytes with high selectivity and sensitivity is 
especially desired for in vivo imaging. To date, most of the reported probes have been tested for 
in vitro use, and they possess absorption and emission energies in the ultraviolet/visible range, 
which makes them less useful in sensing and imaging targets of interests in living animals. This 
is mainly due to the high absorbance of biomolecules (e.g. water and hemoglobin), scattering 
events, auto-fluorescence of the tissue environment matrix, and limited tissue penetration depths, 
all of which lead to low signal-to-background (SBR) ratios.1-2  
Designing versatile fluorophores that emit in the near-infrared (NIR) region (650–900 
nm) will help mitigate some of these issues.3 NIR fluorescence imaging is advantageous for a 
wide variety of in vivo applications, mainly because of the minimal background interference and 
improved tissue depth penetration.4-5 On the other hand, activatable/turn-on probes6 provide a 
higher SBR ratio than the more conventional “always-on” probes.2 A high SBR is desirable for 
cancer imaging, as it helps to identify diseased tissues from healthy ones, providing real-time 
information on tumor cell microenvironment. It is advantageous to design imaging probes that 
have a built-in mechanism for the controlled switching on of their optical properties in response 
to a user designated reaction or an enzyme-triggered event in cancer cells,7 the latter which is the 
focus of this work. Currently, Förster resonance energy transfer (FRET), photo-induced electron 
transfer (PeT), and internal charge transfer (ICT) approaches provide a gateway to develop turn-
on fluorescent probes.8-10  
To date, only a small number of endogenous, intracellular, distinct cancer-linked 
enzymes have been targeted by a handful of small-molecule, turn-on probes that can be used to 
selectively image cells with improved SBRs.11-12 In this respect, NAD(P)H: quinone 
oxidoreductase-1 (NQO1, DT-diaphorase, EC 1.6.99.2) received great interest as a target in both 
cancer-related prodrug therapies and molecular imaging research. In the previous chapter I have 
shown the synthesis of a unique PeT-quenched probe, Q3Nap,13 and demonstrated its ability to 
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allow imaging of NQO1-positive cancer cell lines, with unprecedented SBRs, but its emission 
lies in the range of 500–550 nm, limiting its applicability for in vivo deep tissue imaging.  
Cyanines, due to their spectroscopic characteristics, have received immense attention in 
the construction of fluorescent labels for NIR imaging.14-15 In general, the excitation and 
emission wavelengths of cyanine dyes are well separated from the shorter wavelength auto-
fluorescence generated from chromophores and macromolecules present in analyte or tissue 
samples. For decades, indocyanine green (ICG) has been used in the clinic as a contrast agent, 
and it is the only FDA-approved imaging agent in humans that emits in the λ > 650 nm energy 
region.4,16-17 However, ICG is an always-on reporter, and its absorption and/or fluorescence 
properties cannot be altered upon specific reaction with biomolecules. This limits the potential 
utility of ICG in development of activatable probes for bimolecular imaging applications.  
However, a novel strategy has recently been reported based on control over the electron 
delocalization through the π-conjugated backbone of a cyanine based fluorophore by trigger 
group cleavage (Figure 4.1).18-19 This trigger group removal and subsequent deprotonation result 
in the formation of the phenolate active donor, which then orients itself to donate the π-electron 



































 Several dyes were synthesized with different acceptor groups and charge states with the 
intention of developing an enzyme-activatable NIR probe (Figure 4.2). Due to its longer NIR 
emission (Figure 4.3), and hydrophilic and zwitterionic charged nature, dye c (Cy) was selected 










Figure 4.2 Series of anionic, cationic, and zwitterionic donor-acceptor dyes with indolium 
and picolinium acceptor groups. 
The designed tripartite probe Q3Cy, consists of a trimethyl-locked quinone propionic acid 
trigger group linked to a fluorescently cloaked heptamethine cyanine fluorophore (Cy) by an 
N,N-dimethylethylenediamine linker (Scheme 4.1). Q3Cy was designed so as to yield minimized 
NIR fluorescence of the Cy reporter by masking the phenolate moiety (donor), resulting in the 











Scheme 4.1 Mechanism of NQO1-enzyme-induced decloaking of Q3Cy to reveal the Cy 
reporter. 
The enzymatically-triggered reductive removal of the quinone head group, followed by 
subsequent cyclization of the linker, is anticipated to result in unmasking of the phenolate 
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π-conjugation between the donor and the acceptor groups so as to offer turn-on NIR 
fluorescence. Furthermore, decloaking of the Cy reporter gives rise to a unique color change, 
making Q3Cy a colorimetric “naked-eye-probe” for NQO1. 
4.2 Experimental 
4.2.1 Synthetic material and methods 
All chemicals were purchased from Sigma-Aldrich or Fisher Scientific and used as 
received. Column chromatography was performed on 50-g SNAP silica columns using a 
Flashmaster Personal from Biotage.  Thin layer chromatography was performed on aluminum-
backed 60 F254 silica plates from EMD Chemicals Incorporated.  1H and 13C NMR spectra were 
collected in CDCl3, DMSO-d6, or methanol-d4 at room temperature on a Bruker AV-400.  All 
chemical shifts are reported in the standard δ notation of parts per million using tetramethylsilane 
as an internal reference.  Absorption bands in NMR spectra are listed as singlet (s), doublet (d), 
triplet (t), multiplet (m), or two triplets (2t), and coupling constants (J) are reported in hertz (Hz).  
Mass spectral analyses were carried out using an Agilent 6210 ESI-TOF mass spectrometer.  






To 2,3,3-trimethylindolenine (500 mg, 3.14 mmol) was added a solution of 1,3-propane sultone 
(422 mg, 3.45 mmol) in 1,2-dichlorobenzene (3 mL). The reaction mixture was stirred at 120 °C 
overnight. The purple precipitate (804 mg, 91%) was collected by filtration, washed with cold 
diethyl ether, and dried in vacuo. 1H NMR (500 MHz, deuterium oxide, d2) δ 7.84 – 7.76 (m, 
1H), 7.75 – 7.66 (m, 1H), 7.64 – 7.54 (m, 2H), 4.70 – 4.52 (m, 2H), 3.08 (t, J = 7.1 Hz, 2H), 2.45 
– 2.28 (m, 2H), 1.53 (s, 6H). ESI-MS: for C14H19NO3S: expected m/z = 282.1159 [M+H]+; found 
















A mixture of 4-picoline (1.36 mL, 14.0 mmol), 1,3-propanesultone (2.60 g, 21.3 mmol) and 1,2-
dichlorobenzene (7 mL) was heated at reflux overnight. The precipitate formed was filtered, and 
washed with acetone, and then recrystallized from EtOH to give compound 16 (2.40 g, 80%) as a 
white solid/powder. 1H NMR (400 MHz, dimethylsulfoxide-d6) δ 8.80 (d, J = 6.6 Hz, 2H), 7.86 
(d, J = 6.3 Hz, 2H), 4.54 (t, J = 7.0 Hz, 2H), 2.49 (s, 3H), 2.29 (t, J = 7.1 Hz, 2H), 2.09 (t, J = 7.0 
Hz, 2H). 13C NMR (101 MHz, chloroform-d) δ 159.31, 144.28, 128.80, 59.24, 47.39, 27.60, 
21.84. ESI-MS: for C9H13NO3S: expected m/z = 216.0689 [M+H]+; found m/z = 216.0692 
[M+H]+; 1.39 ppm error. 




2,3,3-trimethyl-3H-indolenine (2.0 g, 12.5 mmol) and iodoethane (3.3 g, 20.6 mmol) in 60 mL 
toluene were stirred overnight at 100 °C (under N2). After of which, the mixture was filtered, and 
the precipitate was washed with diethyl ether and then dried to afford a pink solid (3.12 g, 79.5 
%). 1H NMR (500 MHz, dimethylsulfoxide-d6) δ 8.03 – 7.93 (m, 1H), 7.90 – 7.82 (m, 1H), 7.68 
– 7.58 (m, 2H), 4.51 (q, J = 7.3 Hz, 2H), 2.85 (s, 3H), 1.54 (s, 6H), 1.45 (t, J = 7.3 Hz, 3H). ESI-





















A mixture of 4-hydrazinobenzene sulfonic acid (60 g, 319 mmol), and 3-methyl-2-butanone (45 
mL, 418 mmol) in glacial acetic acid (300 mL) was heated at 118 oC under a nitrogen 
atmosphere overnight. The crude product was filtered and collected as a pink solid after 
precipitation in ethyl acetate to obtain 18 (65 g, 80%).  
Compound 18 (65 g, 254 mmol) was dissolved in methanol (500 mL). A potassium 
hydroxide solution prepared from potassium hydroxide (17 g, 300 mmol) and 2-propanol (200 
mL) was added into solution of 18 using a dropping funnel for 1 h in a gentle heating condition. 
The crude mixture was filtered, washed with 2-propanol and ethyl acetate, and 19 was collected 
as a brown solid (55 g, 78%). 1H NMR (400 MHz, dimethylsulfoxide-d6) δ 7.64 (s, 1H), 7.56 (d, 
J = 7.8, 2.0 Hz, 1H), 7.34 (d, J = 7.9, 1.9 Hz, 1H), 2.21 (d, J = 1.9 Hz, 3H), 1.25 (d, J = 2.0 Hz, 
6H). ESI-MS: for C11H12KNO3S: expected m/z = 278.0248 [M+H]+; found m/z = 278.0261 
[M+H]+; 4.67 ppm error. 








4-Hydroxyisophtalaldehyde (0.20 mmol), piperidine (0.21 mmol), and picolinium iodide  (0.21 




























atmosphere. After completion, the reaction mixture was concentrated by evaporation under 
reduced pressure. The crude product was further used without purification. ESI-MS: for 
C15H14NO2+: expected m/z = 240.1019 [M]+; found m/z = 240.1019 [M]+; 0.00 ppm error. 
A mixture of crude compound 20 (0.20 mmol), piperidine (0.21 mmol), and indolium 
derivative 15 (0.21 mmol) was dissolved in EtOH 1.5 mL. The reaction mixture was stirred for 1 
h at 80 oC under an Ar atmosphere. After completion, the reaction mixture was concentrated by 
evaporation under reduced pressure. The crude product was diluted with 1:1:0.1 H2O: ACN: 
AcOH, and purified by preparative RP-HPLC (grad. 10%-90 ACN in water, 20 min) to give Dye 
a (67%) as a red solid. 1H NMR (500 MHz, methanol-d4) δ 8.98 (d, J = 2.2 Hz, 1H), 8.87 (d, J = 
16.4 Hz, 1H), 8.67 (d, J = 6.3 Hz, 2H), 8.33 (d, J = 6.7 Hz, 2H), 8.20 – 8.13 (m, 1H), 7.94 (d, J = 
8.9 Hz, 2H), 7.84 – 7.79 (m, 1H), 7.75 (d, J = 8.6, 2.1 Hz, 1H), 7.72 – 7.64 (m, 3H), 7.07 (d, J = 
8.6 Hz, 1H), 5.05 – 4.97 (m, 2H), 4.32 (s, 3H), 3.18 – 3.11 (m, 2H), 2.50 (tt, J = 8.8, 5.3 Hz, 2H), 
1.89 (s, 6H). ESI-MS: for C29H31N2O4S+: expected m/z = 503.1999 [M]+; found m/z = 503.1999 







A mixture of commercially available ethyl-4-hydroxy benzoate (6 mmol) and HMTA (24.8 
mmol) was dissolved in 7 mL of TFA. The reaction was refluxed (95 oC) overnight using a Dean 
Stark system, and cooled to room temperature. 40 mL of water were added and the reaction was 
heated to 80 oC for 2 h. After cooling to room temperature, the product precipitated as a yellow 
solid. 1H NMR (400 MHz, chloroform-d) δ 12.00 (s, 1H), 10.23 (s, 2H), 8.60 (d, J = 1.7 Hz, 2H), 
4.37 (q, J = 7.1 Hz, 2H), 1.57 – 1.04 (m, 3H). ESI-MS: for C11H10O5: expected m/z = 221.0455 


















A mixture of dialdehyde 21 (0.06 mmol), piperidine (0.12 mmol), and picolinium iodide (0.12 
mmol) was dissolved in EtOH. The reaction mixture stirred for 6 h at 80oC under an Ar 
atmosphere. After completion, the reaction mixture was concentrated by evaporation under 
reduced pressure. The crude product was diluted with 1:1:0.1 H2O: ACN: AcOH, and purified by 
preparative RP-HPLC (grad. 10%-90% ACN in water, 20 min) to give Dye b (90%) as a yellow 
solid. 1H NMR (400 MHz, methanol-d4) δ 8.73 (d, J = 6.6 Hz, 4H), 8.43 (s, 2H), 8.18 (d, J = 6.5 
Hz, 4H), 7.53 (d, J = 16.2 Hz, 2H), 4.41 (q, J = 7.1 Hz, 2H), 4.32 (s, 6H), 1.42 (t, J = 7.1 Hz, 
3H). ESI-MS: for C25H26N2O32+: expected m/z = 210.0967 [M]2+; found m/z = 201.0967 [M]2+; 
0.00 ppm error. 






A mixture of 4-hydroxyisopthaldehyde (20 mg, 0.13 mmol), NaOAc (33.9 mg, 0.41 mmol), and 
compound 15 (79 mg, 0.27 mmol) was dissolved in 1 mL Ac2O. The reaction mixture was stirred 
for 30 minutes at 80 oC under an Ar atmosphere. After completion, the reaction mixture was 
concentrated by evaporation under reduced pressure. The acetate derivative was dissolved in 4 
mL MeOH. K2CO3 (cattalytic amount) was added to the suspension, and the reaction mixture 
was stirred at room temperature for 60 min with monitoring by RP-TLC (35% ACN in water, Rf 
= 0.44). After completion, the reaction mixture was diluted with 4 mL H2O, 800 µL AcOH, and 
then chromatographed (C-18 silica, 10%-90% AcCN in H2O) to provide Cy (44 mg, 51%) as a 
red solid. 1H NMR (400 MHz, methanol-d4) δ 9.13 (s, 1H), 8.78 (d, J = 16.4 Hz, 1H), 8.56 (d, J 
= 16.0 Hz, 1H), 8.29 (d, J = 8.9 Hz, 1H), 8.18 (d, J = 16.3 Hz, 1H), 8.00 – 7.86 (m, 3H), 7.84 – 
7.73 (m, 2H), 7.65 (dd, J = 12.7, 10.1, 6.7 Hz, 4H), 7.16 (d, J = 8.9 Hz, 1H), 4.99 (d, J = 21.1, 
8.1 Hz, 4H), 3.11 (dt, J = 12.3, 6.3 Hz, 4H), 2.46 (d, J = 14.2, 7.4, 6.6 Hz, 4H), 1.91 (d, J = 15.1 















137.67, 132.96, 129.61, 129.31, 129.27, 129.14, 127.12, 122.74, 122.66, 122.56, 117.46, 114.73, 
114.42, 112.44, 110.44, 70.06, 52.44, 45.46, 45.10, 29.35, 25.82, 25.61, 24.07, 23.99. ESI-MS: 








The reaction procedure was the same as the Cy synthesis, but with dialdeyde 21 and sulfonated 
indole 15. ESI-MS: for C29H32N2O9S2: expected m/z = 617.1622 [M+H]+; found m/z = 617.1647 
[M+H]+; 4.05 ppm error, and expected m/z = 309.0848 [M+2H]2+; found m/z = 309.0859 






1-Naphthol (1.0 g, 6.9 mmol) was dissolved in 10 mL of TFA. Hexamethylenetetramine (1.94 g, 
13.8 mmol) was added in and the reaction mixture was heated to reflux for 1 h. The reaction was 
allowed to cool to room temperature and 10 mL of 33% H2SO4 was added. The reaction mixture 
was heated to reflux and stirred for an additional 1 h, and then it was poured into water. The 
crude product was extracted twice with EtOAc and then washed with brine. The organic layer 































The crude product was purified by column chromatography on silica gel (EtOAc/ Hex 3:7) to 
afford compound 22 (995 mg, 71%) as a yellow solid. 
Dye e was synthesized following a similar procedure for the synthesis of Dye c, but using 
32. 1H NMR (400 MHz, methanol-d4) δ 9.19 (s, 1H), 8.85 (m, 2H), 8.46 (d, 1H), 8.06 (m, 2H), 
7.76 (m, 2H), 7.64 (m, 3H), 7.48 (m, 4H), 7.21 (m, 1H), 7.01 (m, 1H), 4.76 (s, 4H), 3.15 (s, 4H), 
2.43 (s, 4H), 1.89 (s, 12H). ESI-MS: for C40H42N2O7S2: expected m/z = 727.2506 [M+H]+; found 
m/z = 727.2498  [M+H]+ and expected m/z = 364.1290 [M+2H]2+; found m/z = 364.1293 
[M+2H]2+; 0.82 ppm error. 













Scheme 4.2 Synthesis of Q3Cy. 
Mono-Boc-N-N-dimethyl-ehtylendiamine (23):  
N,N-Dimethyl-ethylendiamine (10 g, 113 mmol) was dissolved in DCM (120 mL), and the 
solution was cooled by ice water. Di-tert-butylcarbonate (8.3 g, 38 mmol) in DCM (60 mL) was 
added dropwise at 0 oC. After the addition ended the reaction was allowed to warm to room 
temperature and was stirred overnight. The solvent was then removed under reduced pressure 
and the crude mixture was dissolved in EtOAc and was washed with brine. The organic solution 












































provide compound 23 as a pale yellowish oil (6.5 g, 34.5 mmol) with 91% yield. 1H NMR (400 
MHz, chloroform-d) δ 3.30 (t, J = 6.9 Hz, 2H), 2.84 (s, 3H), 2.69 (t, J = 6.6 Hz, 2H), 2.41 (s, 
3H), 1.42 (s, 9H), 1.39 – 1.31 (m, 1H). ESI-MS: for C9H20N2O2: expected m/z = 189.1598 
[M+H]+; found m/z = 189.1590 [M+H]+; 4.23 ppm error. 
Q3PA-diamine-BOC (24): 
Compound 23 (2.0 g, 10.6 mmol) was dissolved in a solution of Et3N (5 mL) in 10 mL of DMF. 
In a separate flask, EDCI (4.134 g, 21.2 mmol) and HOBT (2.862 g, 21.2 mmol) were introduced 
to a solution of Q3PA acid (2.65 g, 10.6 mmol) in 15 mL of DMF and subsequently stirred for  
1 h. Resulting mixture was then added dropwise to the mono BOC-protected amine solution at 
room temperature and then stirred overnight under N2. The solution was diluted with ethyl 
acetate washed with water, and then dried with MgSO4, with subsequent solvent removal 
by evaporation under reduced pressure. The crude material was purified by flash 
chromatography using a gradient Hex:EtOAc, 7:1 to Hex:EtOAc, 3:2 (Rf =0.44) to afford the 
desired compound 24 as an oil (2.88 g, 6.8 mmol, 65%). 1H NMR (400 MHz, chloroform-d) δ 
3.40–3.04 (m, 4H), 2.91–2.61 (m, 8H), 1.95 (d, J = 3.1 Hz, 3H), 1.75 (d, J = 9.8 Hz, 6H), 1.41–
1.14 (m, 15H). ESI-MS: for C23H36N2O5: expected m/z = 421.2697 [M+H]+; found m/z = 
421.2704 [M+H]+; 1.66 ppm error. 
Q3PA-diamine-TFA salt (25): 
A solution of 24 (2.8, 6.8 mmol) and trifluoroacetic acid (10 mL) in 20 mL of CH2Cl2 was stirred 
for 2 h. The solution was evaporated under reduced pressure.  The crude material was used in the 
next step without further purification. 1H NMR (400 MHz, chloroform-d) δ 3.49 (s, 2H), 2.97 (t, 
J = 27.4 Hz, 7H), 2.59 (s, 3H), 2.05 (s, 3H), 1.83 (d, J = 18.7 Hz, 6H), 1.34 (s, 6H). ESI-MS: for 
C18H29N2O3+: expected m/z = 321.2173 [M]+; found m/z = 321.2185 [M]+; 3.73 ppm error. 
Compound 26: 
A phosgene solution (15% in toluene, 5 mL) was cooled to 0 °C (under N2). To this was added 
dropwise a mixture of 25 (1.31 g, 4.08 mmol), triethylamine (0.650 mL, 4.63 mmol) in dry 
toluene (5 mL). The reaction was stirred at 0 °C for 30 min then at room temperature overnight. 
The suspension was filtered off and the solvent removed under reduced pressure to yield 
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activated 25, that was used in the next step without further purification. 4-
hydroxyisophtalaldehyde (118 mg, 0.79 mmol) was dissolved in anhydrous pyridine (3 mL), and 
activated 20 (257.1mg, 0.7 mmol) was added. The reaction was stirred at room temperature 
overnight and monitored by TLC. Upon completion, the solution was diluted with ethyl acetate 
and washed with 1 N HCl. The combined organic layer was dried over MgSO4 and filtered. 
Solvent was removed under reduced pressure, and the residue was chromatographed (silica gel, 
30-70% EtOAc in Hexane) to provide compound 26 as a yellow solid with 61% yield. 1H NMR 
(400 MHz, chloroform-d) δ 10.18 (s, 1H), 10.03 (s, 1H), 8.35 (d, J = 2.6 Hz, 1H), 8.12 (d, J = 8.5 
Hz, 1H), 7.47 (qd, J = 14.2, 13.3, 8.1 Hz, 1H), 3.61 – 3.38 (m, 4H), 3.18 – 2.96 (m, 8H), 2.10 (t, 
J = 3.6 Hz, 3H), 1.95 – 1.84 (m, 6H), 1.40 (d, J = 3.1 Hz, 6H). ESI-MS: for C27H32N2O7: 
expected m/z = 497.2283 [M+H]+; found m/z = 497.2282 [M+H]+; 0.20 ppm error. 
Q3Cy probe: 
A mixture of Compound 26 (41 mg, 0.08 mmol), NaOAc (14.6 mg, 0.18 mmol), and compound 
15 (50.57 mg, 0.18 mmol) was dissolved in 2 mL Ac2O. The reaction mixture was stirred for 30 
minutes at 80 oC under an N2 atmosphere, and the reaction was monitored by RP-TLC (50% 
ACN in water, Rf = 0.38). After completion of the reaction, the solvent was removed under 
reduced pressure, and the residue was diluted with 3 mL H2O, 3 mL ACN, 300 mL of AcOH and 
this was chromatographed (C-18 silica, gradient of 10%-90% AcCN in H2O) to provide Q3Cy 
(49 mg, 0.04 mmol) in 60% yield. 1H NMR (500 MHz, chloroform-d) δ 9.34 (d, J = 7.0 Hz, 1H), 
8.57 – 8.16 (m, 5H), 7.90 – 7.72 (m, 2H), 7.62 – 7.39 (m, 7H), 5.23 – 4.97 (m, 4H), 3.65 – 3.42 
(m, 4H), 3.20 (s, 1H), 3.11 – 2.99 (m, 7H), 2.90 – 2.78 (m, 4H), 2.41 (d, J = 11.1 Hz, 4H), 2.13 – 
2.07 (m, 3H), 1.89 (d, J = 3.0 Hz, 6H), 1.83 (d, J = 5.5 Hz, 6H), 1.78 – 1.69 (m, 6H), 1.40 (d, J = 
3.9 Hz, 6H). 13C NMR (101 MHz, chloroform-d) δ 191.08, 187.67, 182.95, 181.79, 172.73, 
154.62, 154.50, 152.87, 146.61, 144.18, 143.34, 143.06, 140.47, 140.38, 138.17, 138.08, 136.59, 
132.74, 130.50, 130.15, 129.70, 127.36, 124.25, 122.89, 122.62, 154.44, 114.91, 114.30, 52.89, 
52.30, 47.54, 47.21, 46.79, 46.46, 46.21, 45.00, 37.56, 36.63, 36.21, 36.03, 35.77, 35.25, 33.71, 
28.66, 27.03, 26.85, 25.33, 20.83, 14.35, 12.73, 12.12. ESI-MS: for C55H66N4O11S2: expected m/z 
= 1023.4243 [M+H]+; found m/z = 1023.4232 [M+H]+; ppm error, and expected m/z = 512.2158 
[M+2H]+2; found m/z = 512.2162 [M+2H]+2; 0.78 ppm error. 
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4.2.5 Enzyme kinetics  
hNQO1. All fluorescence measurements (λex = 590 nm, λem = 690 nm) were obtained at 
room temperature with solutions composed of pH 7.4, 0.1 M PBS/0.1 M KCl/0.007% BSA. 
Solutions of β-nicotinamide adenine dinucleotide, reduced disodium salt (NADH, Sigma-
Aldrich) were made with the PBS buffer so that subsequently prepared solutions possessed a 
final concentration of 1 × 10−4 M β-NADH in each assay. Solutions consisting of 2 × 10−6 to  
5 × 10−5 M Q3Cy were made using the NADH stock. A 5 µg mL-1 stock solution of recombinant 
hNQO1 (Sigma-Aldrich) was prepared using the same buffer as above so as to give 2.5 × 10−6 g 
hNQO1 per assay. Each assay was performed in a quartz fluorescence cuvette containing 0.75 
mL Q3Cy solution and was initiated by the addition of 0.75 mL hNQO1 solution.  Measurements 
were collected every 30 s for 10 min.  Fluorescence units were converted to concentration by 
relating the signal increase to a fluorescence signal derived from a known concentration of Cy 
reporter.  Plots of velocity versus Q3Cy concentration were used to obtain apparent Km and Vmax 
values from nonlinear least-squares analysis employing algorithms developed by Cleland for 
Michaelis−Menten kinetics.21 
4.2.6 Quantum yield 
Fluorescence quantum yield measurements were carried out using dilute dye solutions 
where absorbance was kept between 0.02–0.08. An amount of 1.5 mL from these solutions was 
transferred to 1-cm × 1-cm quartz cuvettes and subjected to fluorescence measurements. 
ΦF(X) = (As/Ax) (Fx/Fs) (nx/ns)2 ΦF(S)    Equation 1 
 
The quantum yield of Cy were calculated relative to CY 5.5 (Φ = 0.23)22 using Equation 
1, where Φ F is the fluorescence quantum yield, A is the absorbance at the excitation wavelength, 
F is the area under the corrected emission curve, and n is the refractive index of the solvents 
used. Subscripts S and X refer to the standard and the unknown, respectively. In this equation, 
absorbance A accounts for the number of absorbed photons, and the area F accounts for the 
number of emitted photons. The quantum yield of Φ(Q3Cy) was obtained in aqueous media (0.1 
M phosphate buffer, pH =7.4) and was calculated to be 0.06. 
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4.3 Results and Discussion 





























Figure 4.3 Normalized absorption (dashed), emission (solid) spectra of the donor-acceptor 
dye series (a–e), in pH 7.4, 0.1 M phosphate buffer. T = 25 °C. 






















































































































































































































































































According to a published procedure by Shabat et al. I synthesized a series of dyes (a–e) 
comprising anionic, cationic and zwitterionic charged dyes.18-19,23 Dyes were constructed using 
three different dialdehyde species (4-hydroxyisophtalaldehyde, 21, 22) by condensing them with 
different picolinium and indolinium acceptor groups.19 As depicted in Figure 4.1, initial 
deprotonation of the phenol results in a phenolate donor, which donates its electrons to the 
conjugated acceptor groups. This generates a resonance species that has an extended π-
conjugated backbone, resulting in increased emission wavelengths in the NIR region. Dye e 
showed the furthest NIR emission at around 715 nm, while b and d showed the lowest NIR 
emission around 625 nm (Figure 4.3). However, Dye c was selected as a potential candidate for 
further studies in developing a probe for NQO1, due to its large Stokes shift, increased water 
solubility, brightness (εΦ), and neutral zwitterionic charge state. 
4.3.2 Spectroscopic properties of Q3Cy probe and Cy reporter 
Q3Cy was synthesized using a four-step synthetic route outlined in Scheme 4.2. The 
trimethyl quinone propionic (Q3PA) acid was first coupled to a Boc-protected dimethylethylene 
diamine (2) linker, followed by Boc deprotection to yield 25 as the ammonium TFA salt. 4-
hydroxyisophtalaldehyde was then coupled to 25, and subsequent condensation with two 
equivalents of indolium sulfonate groups (15) gave Q3Cy in good yields. The indolium-3-propyl-
sulfonate groups provided good water solubility and also prevented aggregation, both properties 
being desirable for biological applications of Q3Cy.   
The spectroscopic properties (Figure 4.4) of Q3Cy and Cy showed striking difference in 
buffered aqueous media, with Q3Cy having its maximum absorption centered at 391 nm with an 
extinction coefficient, ε,  of 1.09 × 104  M−1cm−1, while Cy has two absorption bands, with one 
centered at 477 nm (ε = 2.98 × 104 M−1cm−1) and the other at 590 nm (ε  = 3.30 × 104  M−1cm−1). 
Importantly, the absorbance spectra of the Q3Cy probe and the Cy reporter showed two unique 
features important for the development of activatable probes. Firstly, as depicted in Figure 4.4, 
Q3Cy shows minimal absorption both in the red ( = 590 nm) and the orange ( = 477 nm) 
region where Cy has its maximum absorbance values; this is a desirable spectroscopic feature for 
development of “turn-on” probes. Secondly, the good overlap in absorbance of Q3Cy and Cy in 


















Figure 4.4 The absorbance properties of the Q3Cy probe and the Cy reporter color coded 
according to the different regions: red and orange, minimum absorption of Q3Cy and maximum 
absorption of Cy; green, overlap region. Absorbance recorded in pH = 7.4, 0.1 M PBS;  
T = 25 °C.  
Therefore, in order to assess the emission properties in the red, orange, and green regions, 













Figure 4.5 The fluorescence emission of, a) Q3Cy, and b) Cy at different excitation 
wavelengths. Red, λex = 590 nm; orange, λex = 470 nm; and green, λex = 440 nm. All performed 









































































































































































The Q3Cy probe has its maximum emission in the green region, but showed minimum 
emission in the red and orange regions. On the other hand, Cy showed its maximum emission 
signal in the red region, and showed decreasing emission intensity in orange and green regions 
respectively. 
4.3.3 Q3Cy as a “turn-on” probe 
Aqueous solutions of Q3Cy probe were virtually non-fluorescent at the maximum 
excitation wavelength of the Cy reporter, as noted by a weak emission band at 690 nm. However, 
the Cy reporter has a very significant emission at 690 nm (Figure 4.6). This large ∼125-fold 
difference in fluorescence is desirable for developing a turn-on response, as this is particularly 



















Figure 4.6  Left, emission spectra of 2.5 × 10−5 M solutions of Q3Cy (yellow) and Cy (blue), 
Right, red excitation region where the solutions were excited (λex = 590 nm). Both experiments 
were carried out in pH 7.40, 0.1 M PBS; T = 25 °C.  
of using Q3Cy as a “turn-on” probe for NQO1. The sequence of events that leads to the release of 
the free Cy reporter is illustrated in Scheme 4.3. The initial reduction (step i) of Q3Cy forms a 
hydroquinone species, which then through collapse of a tetrahedral intermediate yields a stable 
lactone (step ii). In the subsequent step, the dimethyl aminoethylenediamine linker is removed to 
form a stable cyclized urea together with the free Cy reporter (step iii).  

















































Scheme 4.3 Schematic representation of a series of reactions after NQO1 activation of Q3Cy 
probe, resulting in the release of the free Cy reporter.  
Therefore, in order to demonstrate this behavior, buffered solutions (pH = 7.4) of Q3Cy 
containing NADH (100 µM) were incubated with human NQO1 (2.5 µg), and the enzymatic 
reaction was monitored through fluorescence spectroscopy. As expected, interaction of Q3Cy 
with NQO1 as noted in emission spectra obtained by 590 nm excitation (λex), leads to 
fluorescence spectra with a turn-on peak centered around 690 nm in the near-infrared region; the 














Figure 4.7 Human NQO1 enzyme-initiated switching on of Cy reporter. Left: wavelength 
scan of 1.5-mL solution of 2.5 × 10−5 M Q3Cy and 2.5 µg of hNQO1 in pH 7.40, 0.1 M PBS. 
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4.3.4 Stability and enzymatic reactivity of Q3Cy 
 High stability and faster kinetics in aqueous media are important factors in the design of 
imaging probes for use in biological milieu. Thus, aqueous solutions of Q3Cy in the presence and 
in the absence of NQO1 enzyme were excited at 590 nm, and the emission was observed at 690 
nm to study the release of the Cy reporter. As depicted in Figure 4.8 (red line) Q3Cy  
 












Figure 4.8 Time-course fluorescence of 1.5-mL solution of 2.5 × 10−5 M Q3Cy and 2.5 µg of 
NQO1 in pH 7.40, 0.1 M PBS Q3Cy (λex = 590 nm, λem  = 690 nm, black). Red line shows the 
stability of Q3Cy in the absence of NQO1 under same solution conditions; T = 25 °C.  
showed excellent stability in the absence of NQO1 enzyme in aqueous PBS media for the 
intended time frame for the fluorescence measurements. Importantly Q3Cy exhibited fast 
activation (Figure 4.8, black line) in the presence of human NQO1, revealing the maximum Cy 
release in ∼40 minutes. As demonstrated in the previous chapter for Q3Nap, NQO1 activity 
towards the Q3Cy probe was measured through the formation of fluorescent Cy reporter, with 
different concentrations of the Q3Cy probe (2−50 × 10−6 M) in the presence of fixed amount of  
NQO1 enzyme (2.5 µg/mL). The fluorescence intensity at 690 nm was measured and converted 
to concentrations of free Cy reporter using a calibration curve. From these experiments, the 
initial rate of product formation, V (µmol min−1mg.hNQO1−1), was calculated and plotted as a 
function of Q3Cy concentration (Figure 4.9). Apparent kinetic parameters were then obtained by 











Q3Cy + NQO1 
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fitting the data in Figure 4.9 to the Michaelis-Menten equation, which provides the Michaelis 
constant (Km) = 2.19 µM, maximum velocity (Vmax) = 0.13 µmol min−1mg.hNQO1−1, catalytic 


















Figure 4.9 Kinetics of human NQO1 (2.5 µg/mL) with Q3Cy (2−50 ×10−6 M) in pH 7.4, 0.1 
M phosphate buffered saline. Values (n = 3) are the average ±1 sample standard deviation. The 
curve is the best fit to the average data. T = 25 °C.  
 These results provided evidence for the NQO1–initiated enzymatic reduction of the Q3Cy 
probe under physiological conditions that results in efficient release of the Cy reporter, and it is 
clear this activation is faster compared to the Q3Nap activation described in the previous chapter. 
The use of a more flexible N,N-dimethyl amino linker (compare to the more rigid p-aminobenzyl 
alcohol linker used in Q3Nap), and the use of negatively charged sulphonate groups allowed the 
Q3Cy probe to have a favorable geometry and interactions at the active site of the NQO1 
enzyme, thus providing faster activation kinetics compared Q3Nap. However, molecular 
modeling and molecular docking studies are needed to provide a definitive answer for this 
behavior.   


























4.3.5    Q3Cy as a “naked-eye” colorimetric probe 
An important feature I observed in fluorescence turn-on emission experiments is the 
change in solution color, initially being yellow, and after completion of the reaction the solution 
became blue; the latter is the characteristic color for aqueous Cy reporter. This prompted the 
possibility of Q3Cy use as a colorimetric probe in NQO1 identification. To test this, the 
absorbance profile of the NQO1 reduction of Q3Cy substrate was carried out, using similar 
solution conditions to those in the fluorescence measurements. As expected, the enzymatic 
reaction led to a change in the color of the solution from yellow (Q3Cy) to deep blue (Cy), 
indicating production of the Cy reporter. Furthermore, the change in color also makes Q3Cy a 
potential candidate for future ex vivo tissue imaging studies and quantification assays for NQO1 
biomarker. Isosulphan blue is an absorbance–based imaging agent used in identification of tumor 
sentinel nodes in lymphatic systems;24 however, such agents require high dye concentrations, 
limiting their applicability in routine clinical applications. Interestingly, as the Q3Cy probe 
absorbance around 390 nm decreased, two new absorption bands started to appear around 470 















Figure 4.10 Colorimetric response of Q3Cy probe in the presence of human NQO1. Left, 
absorbance profile; and right, change in color from yellow to deep blue for a solution of 2.5 × 
10−5 M Q3Cy and 2.5 µg/mL of hNQO1 in pH 7.4, 0.1 M PBS; T = 25 °C.  
observation of an isosbestic point is indicative of a ratiometric response and provided a new 
route to study Q3Cy probe activation by NQO1 enzyme. 
 


























































4.3.6 Q3Cy as a “ratiometric” probe 
 To study the ratiometric response of the probe, a solution of Q3Cy (25 µM) and NQO1 
(2.5 µg/mL) in PBS (pH = 7.4) with NADH (100 µM) was excited at 440 nm. Similar to the 
absorbance measurements, an emission band corresponding to the probe at 515 nm decreased in 
intensity, and concomitantly two new emission bands started to appear around 550 nm and 690 













Figure 4.11 NQO1 enzyme-initiated ratiometric response with the Q3Cy probe, Left: 
wavelength-scan of 1.5-mL solution of 2.5 × 10−5 M Q3Cy and 2.5 µg of hNQO1 in pH 7.40,  
0.1 M PBS; Right: green excitation region where the solutions were excited (λex = 440 nm);  
T = 25 °C. 
the excitation energy being closer to the  band than the more red-shifted  band, the 
former showed higher emission intensity around 550 nm in comparison to the near-infrared band 
centered around 690 nm. However both emission bands showed increase in intensity with time 
indicating release of the Cy reporter.  
To examine the possibility of quantitative analysis of NQO1 activity, I conducted 
experiments of concentration-dependent monitoring of enzymatic reaction with aqueous 
solutions of Q3Cy. In the assay shown in Figure 4.12, the Q3Cy probe concentration (25 µM) was 




































































Figure 4.12 Graphs a–g represent the ratiometric response of 25 µM Q3Cy with 100 µM 
NADH in the presence of different concentrations of NQO1 enzyme (0.5, 1, 2.5, 5, 10, 15, 20 
µg/mL) in pH 7.4, 0.1 M PBS. The arrows indicate the signal response, decreasing (515 nm, 
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fluorescence intensity was measured with time. As shown in Figure 4.12 the fluorescence 
intensity at 515 nm decreases, and the two Cy bands at 550 nm and 690 nm increase with 
increasing NQO1 concentration. To further evaluate this ratiometric response, the dependency of 
the corresponding peak intensity ratios (I550/I515) was plotted against the NQO1 concentrations, 

















Figure 4.13 Dependence of the emission intensity ratios (I550/I515) of Q3Cy (25 µM) on the 
concentration of NQO1 enzyme (0.5–20 µg/mL), in pH = 7.4, 0.1 M PBS, λex = 440 nm;  
T = 25 °C.  
            However, the ratiometric fluorescent plot (I550/I515) versus time showed a linear 
relationship with high correlation coefficients (Figure 4.14). This type of a ratiometric 
fluorescent response is particularly important In the development of NQO1 enzyme 
quantification assays. This is because Q3Cy employs simultaneous readings of three fluorescent 
signal intensities in the presence of NQO1, which helps account for the reacted and unreacted, 



















Figure 4.14 Time–dependent ratiometric fluorescence response (I550/I515) of Q3Cy (25 µM) for 
different concentrations of NQO1 enzyme (0.5–20 µg/mL), in pH = 7.4, 0.1 M PBS. λex = 440 
nm; T = 25 °C.  
4.3.7    Q3Cy for in vitro and in vivo imaging of cancer cells that overexpress NQO1  
 The lack of switching on of the dormant fluorescence in the absence of the enzyme, the 
large difference (∼100 nm) between the absorption and the emission of the Cy reporter, and the 
near-infrared emission range of reporter bodes well for providing high signal-to-background 
ratios for in vivo imaging experiments with Q3Cy probe. It is also noteworthy to mention that the 
unique feature of the Q3Cy probe having “turn-on” and “ratiometric” responses is unprecedented 
in the context of the previous work in the McCarley group. Recently, Kobayashi et al. reported a 
bacteriochlorin-based dye that has two different excitation wavelengths so as to image peritoneal 
ovarian cancer implants both at the surface (green light excitation), and at shallow depths (red 
light excitation) in the abdominal cavity with high sensitivity and specificity.25 This type of a 
two-mode response is beneficial in diagnosing both surface level and more deeply seated 
diseased tissues. Another important feature of the Q3Cy probe is its high water solubility, which 
is beneficial for in vivo imaging experiments. The colorimetric nature of Q3Cy could be useful 
for ex vivo tissue staining experiments for studying the presence or the absence of NQO1.  
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The fast activation, hydrolytic stability, and multi-mode (ratiometric, turn-on, 
colorimetric) response of the Q3Cy probe is quite promising for use in cancer cell imaging. The 
Q3Cy was designed as a neutral zwitterionic probe to promote good cell penetration. However, 
preliminary studies performed by one of my colleague Bijeta Prasai, using NQO1-positive 
colorectal cancer cell line (HT29) showed unexpectedly low probe uptake, thus offering low 
















Figure 4.15 Microscopy images of live hNQO1-positive HT29 colon cancer cells: control 
experiment without the presence of Q3Cy (a, b, c), and after incubation at 37 °C with 5 × 10−5 M 
Q3Cy (d, e, f). Confocal images in a and d; differential interference contrast in b and e; and 
overlay image c and f. For images of cells exposed to Q3Cy samples were excited using a 633 nm 
line of a HeNe laser, and the spectral emissions were collected between 655 and 735 nm. Scale 
bar = 20 μm. 
Although there is precedence for cellular penetration of sulfonate containing zwitterionic 
dyes (e.g., Cy 5 and ATTO655 used in cellular protein imaging),26-27 the negatively charged 
sulfonate groups could hinder the membrane permeability of Q3Cy. Also, it is of common 
practice to protect negatively charged phenoxyl and carboxyl groups (e.g. coumarins, resorufin, 
fluorescein) as cleavable phenolates and carboxyesters to enhance cellular delivery, such 
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methods are not useful for protection of sulfonate groups.28-31 The Ting lab at Massachusetts 
Institute of Technology demonstrated a facile route for ester protection of sulfonated 
fluorophores for intracellular protein imaging.32 Inspired by their idea, The McCarley group is 
currently in the process of synthesizing a protected Q3Cy probe for better cellular delivery. Also 
I believe that once the probe gets inside cells, the esterases commonly found in the cell will 
cleave the sulfonate-protecting groups, yielding Q3Cy for the activation by the NQO1 enzyme 














Scheme 4.4 A new route for cellular delivery of Q3Cy, by protection of sulfonate groups as 
esterase-cleavable acetoxy esters, and probe activation in cellular media. 
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SUMMARY, CONCLUSIONS, AND OUTLOOK: A NEW GENERATION OF 
HEPTAMETHINE CYANINE-BASED PROFLUOROPHORES 
5.1 Summary and Conclusions 
The overall goal of this research was the design, synthesis and evaluation of 
fluorescence-based activatable probes for detection and identification of human cancer enzyme 
NQO1 with high signal-to-background ratios. The outcomes of the work presented in this 
dissertation are innovative upon examination of previous work done in McCarley research lab 
and other groups on enzyme activatable probes, as the outcomes provide important contributions 
to the development of such fluorescence-based activatable probes for future in vivo imaging 
experiments.  
In the second chapter I have shown the synthesis of two different tripartite probes (ortho- 
and para-) composed of a trimethyl-locked quinone propionic acid (QPA) trigger group, an N-
methylaminobenzyl alcohol linker, and 4-nitroaniline reporter, and I demonstrated their self-
immolative behavior. The dithionite-initiated reduction of the quinone trigger group and 
subsequent linker decomposition resulted in the release of 4-nitroaniline reporter. The reactant 
probes disappearance (327 nm) and the product nitroaniline formation (391 nm) were monitored 
by UV/visible spectroscopy, and it was concluded that 1,6-para elimination was comparatively 
faster than 1,4-ortho elimination under the conditions here. Thus, the 1,6-para elimination route 
was selected in the design of a NQO1-activatable probe.  
In the third chapter, I have presented the synthesis and properties of a novel turn-on 
probe, Q3Nap (Figure 5.1), and its biological evaluation in detecting the cancer-associated 
enzyme NQO1. Q3Nap consists of a QPA trigger group linked to a fluorescently masked 
naphthalimide by N-methyl-p-aminobenzyl alcohol, NMPABA, so as to establish an electron-
withdrawing carbamate connection. This changed the electron density around the naphthalimide 
scaffold so as to modulate the fluorescence properties of the Q3Nap probe through a push-pull 
internal charge transfer (ICT) mechanism. This fluorescence modulation is reflected in the 
spectroscopic measurements, as the free Nap reporter showed a red shift of roughly 50 nm in 
both absorbance and emission spectra vs those of the Q3Nap probe. Interestingly, due to a unique 
photo-induced electron transfer quenching mechanism, Q3Nap showed a very weak emission 
band having a low quantum yield of 0.002. The PeT based quenching is supported by outcomes 
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based on voltammetric measurements performed on Q3Nap, where a favorable free energy 
change for both the oxidative electron transfer (OeT, −0.98 eV) and the reductive electron 
transfer (ReT, −1.44 eV) was obtained. The free naphthalimide reporter exhibited a high 
quantum yield of 0.19, thereby showing an intense emission intensity change for dithionite- 
initiated switching on of the cloaked Q3Nap probe.  This turn-on response was rapid, and a 
maximum Nap release was observed in roughly ∼15 min under physiologically relevant 
conditions, pointing to the rapid self-immolative cleavage of the N-methyl-p-aminobenzyl 
alcohol linker. Also this conversion was confirmed by mass spectrometry analysis of Q3Nap 
solutions treated with dithionite, where I observed all three products, namely, lactone, benzyl 
alcohol linker, and naphthalimide fluorophore; this provides further evidence for the proposed 
mechanism of Q3Nap activation. In addition the rate of Nap release is comparable with what I 

















Figure 5.1 Synthesized and proposed NQO1 activatable small-molecule profluorogenic 
probes. The color of the structure indicates the maximum emission wavelength of the 





Under in vitro conditions, buffered solutions (pH = 7.4, 0.1 M PBS) of Q3Nap (2−60 µM) 
incubated with hNQO1 (40 µg) and its cofactor NADH (100 µM) exhibited a steady increase in 
fluorescence, pointing to a relatively fast rate of Nap production; control experiments with 
NADH alone did not yield significant changes in fluorescence suggesting high stability of Q3Nap 
in aqueous media. Furthermore, I was able to demonstrate high selectivity of Q3Naps toward 
NQO1 over its isoenzyme NQO2 by performing in vitro enzyme kinetic experiments that 
revealed ineffective reporter release over time. Bijeta Prasai one my colleagues in the McCarley 
group, performed cell assays to investigate the possibility of Q3Naps use in differentiating types 
of cancer cells based on NQO1 content (positive vs negative). Confocal fluorescence images 
exhibited high Q3Nap probe uptake and its activation in hNQO1-positive HT29 cancer cells, 
while minimum signal was observed in hNQO1-negative H596 cells, leading to a highly 
selective differentiation between the two cancer cell lines. Importantly, statistical analysis of 
confocal cell images for positive and negative cancer cells resulted in a very high positive-to-
negative ratio (PNR, ∼500), an unprecedented number in the context of previous work in the 
litreature. However, Q3Nap displayed slower enzymatic activation is noted by its high Km = 10.4 
µM and low Vmax = 0.00225 µmol min−1mghNQO1−1 in comparison to a previously synthesized 
naphthalimide based probe, Q3NI.1 Even though the self-immolative N-methyl-p-aminobenzyl 
alcohol linker provided faster elimination kinetics via quinone methide formation, it appears to 
conformationally lock the molecule, which prevent favorable binding at the active site of the 
NQO1 enzyme.  
In order to achieve fast enzymatic activation, I have synthesized a second probe Q3Cy, 
comprised of the quinone trigger group, an N,N-dimethylethylenediamine linker, and a cyanine- 
based, near-infrared fluorophore (Figure 5.1). The cyanine fluorophore used had a large Stokes 
shift of ∼100 nm and has an excitation maximum of 590 nm with a corresponding emission 
maximum at 690 nm. Similar to the Nap fluorophore described earlier, the cyanine fluorophore 
has modulated fluorescence based on internal charge transfer mechanism. However, unlike 
Q3Nap, attachment of the QPA ethylenediamine linker to the cyanine fluorophore did not quench 
the fluorescence of the Q3Cy probe; instead Q3Cy exhibited an absorption and a relatively 
intense emission around 390 nm and 515 nm, respectively. Importantly, the sulfonated groups of 
the cyanine scaffold provided better water solubility, allowing all the kinetic experiments to be 
performed in aqueous media without using any organic cosolvents. Even though the probe was 
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not quenched, it did not show any emission upon excitation at the maximum absorption 
wavelengths (470 nm and 590 nm) of the free Cy reporter, allowing Q3Cy to behave as a turn-on 
probe in the presence of NQO1 enzyme. This type of probe quenching and enzyme-initiated 
fluorescence turn-on in the near-infrared region is beneficial for providing higher signal-to-
background ratios for in vivo imaging applications. Also, the flexible ethylene diamine linker 
resulted in faster enzyme kinetics (Vmax = 0.1303 µmol min−1mg.hNQO1−1) and better binding 
affinity (Km = 2.19 µM) at the NQO1 active site in comparison to Q3Nap.  
Interestingly, the enzymatic activation of Q3Cy resulted in a rapid color change from 
yellow to blue, and a ratiometric absorbance profile was observed that had a clear isosbestic 
point around 440 nm. Another unique and important feature of the Q3Cy probe was its 
ratiometric emission profile, which upon excitation at 440 nm showed an isoemission point 
around 540 nm. This type of ratiometric activity is particularly useful in enzyme quantification 
assays for providing highly sensitive and quantitative responses depending on enzyme 
concentration. Q3Cy was designed as a zwitterionic species to bear an overall neutral charge in 
the molecule so as to provide better cellular permeability for identification of intracellular NQO1 
enzyme content. However, preliminary studies with HT29 cell lines did not show appreciable 
Q3Cy uptake, possibly due to presence of sulfonate groups in the probe molecule. Currently, 
protection of the sulfonate groups by acetoxy-esters is underway. I believe that this derivatization 
will offer enough hydrophobicity by masking the negative charges of the sulfonate groups so as 
to provide efficient cellular uptake. Once onside the cell the esterase-labile sulfonate protecting 
groups will be cleaved off, to yield a trappable negatively charged Cy reporter that can be 
activated by NQO1 inside the cell. 
5.2 Outlook 
5.2.1 New generation of NIR activatable probes based on heptamathine cyanine scaffold 
In a parallel project, I was interested in developing imaging probes with a heptamethine 
cyanine scaffold that have long excitation/emission wavelengths in the NIR region. 
Heptamethines are good candidates for fluorescent reporter labeling techniques, because the 
meso-position in their conjugated polymethine chain can be easily occupied by various 
nucleophiles (Figure 5.2).2  
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The heptamethine conjugates are widely used in protein labeling agents as “always-on” 
probes and show minimal change in their spectral properties. In addition, a much smaller singlet 
excitation energy, ΔE00 in the Rehm-Weller equation has hampered their potential use as tunable 






Figure 5.2 New generation of heptamethine-based dyes by amine substitution: a) chloro- 
substituted, and b) methylamine-substituted heptamethine fluorophores. 
  However, Peng et al. demonstrated displacement of Cl in the polymethine linker by 
amine substitution could significantly alter the spectral properties of the heptamethine scaffold.2-3 










Figure 5.3 Mechanism of enzymatic activation of a first-generation, heptamethine-based 
Q3TCy probe. 
  This idea will be utilized in the design of a new generation of fluorescent probes for 
NQO1 detection. Q3TCy has been designed such that the quinone propionic acid trigger group is 
directly coupled to the TCy reporter, thereby affording three different outcomes: 1) the 
carbamate linkage between the TCy and quinone propionic trigger group attenuates the electron 
density on the amine, thus shifting the absorption maximum to a longer wavelength; 2) it is 























the indocyanine moiety to the quinone trigger group; and 3) fast enzyme kinetics will occur upon 
removal of the eliminating/cyclizative attachments (Figure 5.3). According to the proposed 
enzymatic activation depicted in Figure 5.3, the reduction of the quinone trigger group followed 
by the lactone formation directly yields the free TCy reporter, bypassing the linker self-
immolation/cyclization step that was required for the previous two probes, Q3Nap and Q3Cy 
respectively. The synthesis of the Q3TCy probe is still under investigation, and I was able to 
synthesize the free TCy reporter; and its spectroscopic properties are depicted in Figure 5.4. 
Aqueous solutions (1% DMSO as cosolvent) of TCy displayed a broad absorption band centered 













Figure 5.4 Normalized absorbance and emission of TCy reporter in 1% DMSO, pH = 7.4, 
0.1 M phosphate buffer. T = 25 °C. 
  The large Stokes shift (>120 nm) and the near-infrared emission of TCy are two 
important features desirable for design of imaging probes for in vivo imaging applications. In 
preliminary cellular imaging experiments (performed by Bijeta Prasai), efficient uptake of the 
free TCy reporter in NQO1-positive HT-29 cells was observed (Figure 5.5). This proves that the 
overall positive charge delocalized through the cyanine backbone does not affect the 
permeability of TCy through the cell membrane. Therefore, I believe that because Q3TCy is 
expected to have the same delocalized positive charge, it could also enter the cell as efficiently as 
the free TCy reporter. It is important to note that the initial coupling reaction of Q3PA and TCy 
performed with EDCI/pyridine resulted trace amounts (characterized through ESI-MS) of the 
 138 
Q3TCy probe, and currently, the synthesis of Q3TCy with different coupling conditions is in 
progress.  
 







Figure 5.5 Preliminary microscopy images of hNQO1-positive HT29 colon cancer cells after 
incubation at 37 °C with 2.5 × 10−5 M TCy reporter: a) confocal image, b) differential interface 
contrast, c) overlay. Scale bar = 20 μm. 
 Water solubility is an important requirement for in vivo imaging applications of the 
Q3TCy probe, thereby minimizing aggregation for desirable high emission intensities. 
Incorporation of either sulfonate or carboxylic acid groups in the heptamethine scaffold could 
provide better water solubility; however, this could also lead to decreased cell permeability due 
to the overall negative charge associated with such functionalizations. Possible future Q3TCy 









Figure 5.6 Possible future target probes for NQO1 imaging based on the heptamethine 
scaffold. a) carboxyl and b) sufonate protection with esterase-cleavable acetoxy and sulfonate 
ester functional groups. 
  These carboxy- and sulfonate-protected probes do not yield altered overall net charge, 























probe is expected to be hydrolyzed by intracellular esterases, and then upon interaction with the 
NQO1, enzyme the free negatively charged reporter is released for accumulation inside the cell.  
 Taken together, the work presented in my dissertation provides design concepts for the 
development of a new generation of enzyme-activatable, fluorescence-based substrate probes for 
imaging applications with high signal-to-background ratios. With a better understanding of the 
enzymatic activity and improvement of the fluorescent properties these types of imaging probes 
in hand, has great potential to translate their use into clinical applications in the future. 
5.3 Experimental 



















Scheme 5.1 Synthesis of Q3TCy probe and TCy reporter. 
Compound 27 
A solution of 40 mL of N,N-dimethylformamide in 40 mL dichloromethane was cooled to −6 oC,  
and phosphorus oxychloride (37 mL) was added dropwise with stirring, followed by 
cyclohexanone (10.0 g, 0.10 mol). The mixture was refluxed for 3 h. After cooling, the solution 
was poured onto 200 g of ice and allowed to stand overnight. 27 was collected as a yellow solid 
(8.04 g, 46.5 %). ESI-MS: for C8H9ClO2: expected m/z = 173.0364 [M+H]+; found m/z = 
































Under the nitrogen atmosphere, to a three-neck flask containing compound 27 (11.23 g, 36 
mmol) in 70 ml acetic anhydride, sodium acetate (2.95 g, 36 mmol) was added. The solution was 
heated to 70 oC for 1 h. After of which, the reaction solution was poured to potassium iodide 
aqueous solution, stirred. The generated mixture was filtered, and the precipitate was washed 
thoroughly with diethyl ether. 28 was obtained as green solid was obtained (7.88 g, 68.6 %). 1H 
NMR (400 MHz, chloroform-d) δ 8.37 (d, J = 14.1 Hz, 2H), 7.48 – 7.35 (m, 4H), 7.30 – 7.18 (m, 
4H), 6.23 (d, J = 14.1 Hz, 2H), 4.27 (q, J = 7.2 Hz, 4H), 2.77 (t, J = 6.1 Hz, 4H), 2.00 (m, 2H), 
1.74 (s, 12H), 1.48 (t, J = 7.2 Hz, 6H). 13C NMR (101 MHz, chloroform-d) δ 171.98, 150.71, 
144.58, 141.86, 141.26, 128.97, 127.59, 125.44, 122.41, 110.83, 101.14, 49.46, 40.22, 28.18, 
26.92, 20.81, 12.60. ESI-MS: for C34H40ClN2+: expected m/z = 511.2875 [M]+; found m/z = 
511.2871 [M]+; 0.78 ppm error. 
TCy 
Methylamine (2M in methanol; 34 mL, 0.4 mmol) was added to compound 28 (58.3 mg, 0.1 
mmol) dissolved in anhydrous DMF (10 mL). The reaction mixture was stirred at 85 oC for 3 h 
under N2. The solvent was removed under reduced pressure and the crude product was purified 
by column chromatography on silica gel (DCM:MeOH 100:0 to 100:1) to afford TCy as a glossy 
blue solid (54.8 mg, 95 %). 1H NMR (400 MHz, methanol-d4) δ 7.70 (d, J = 12.9 Hz, 2H), 7.41–
7.24 (m, 4H), 7.13 – 6.93 (m, 4H), 5.77 (d, J = 12.9 Hz, 2H), 3.97 (q, J = 7.2 Hz, 4H), 3.46 (s, 
3H), 2.66 – 2.45 (m, 4H), 1.93 – 1.79 (m, 2H), 1.65 (s, 12H), 1.32 (q, J = 6.4, 5.2 Hz, 6H). 13C 
NMR (101 MHz, methanol-d4) δ 172.89, 171.61, 167.66, 144.00, 141.27, 138.32, 129.31, 
123.56, 123.01, 109.50, 94.51, 61.49, 35.75, 29.06, 26.92, 22.51, 20.90, 14.48, 11.66. ESI-MS: 
for C35H44N3+: expected m/z = 506.3530 [M]+; found m/z = 506.3531 [M]+; 0.20 ppm error. 
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